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 Part one of this dissertation describes the synthesis of novel polycyclic natural product-
like compounds from dicyclopropylmethylamine starting materials. Using methodology 
previously developed in our group, products from the initial one-pot multicomponent reaction 
via the rearrangement of a bicyclo[1.1.0]butane intermediate were successfully transformed into 
polycyclic systems. These small, medium and large heterocycles mimic complex alkaloids found 
in nature, and were further elaborated to incorporate additional functionalities. 
Part two describes our investigation into the parvistemonine class of Stemona alkaloids. 
We developed a unified strategy to target several related Stemona natural products. A [3,3]-
sigmatropic rearrangement was used to relay key stereochemical information across the 
characteristic pyrrolo[1,2-a]azepine core of these molecules and install contiguous stereocenters 
in a controlled fashion. This approach produced advanced intermediates towards the syntheses of 
parvistemonine and sessilifoliamides B and D, and culminated in the first enantioselective total 
syntheses of sessilifoliamide C and 8-epi-stemoamide. 
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1.0  SYNTHESIS OF NON-NATURAL POLYCYCLIC ALKALOIDS 
1.1 INTRODUCTION 
1.1.1 Preparation and Reactions of Alkenylzirconocenes 
Organozirconium compounds are useful reactive intermediates in organic synthesis and have 
been under significant investigation over the last 20 years following the synthesis of Cp2Zr(H)Cl 
by Wailes and Weigold in the 1970’s.1 Previously, the most common zirconium complexes, 
Cp2ZrCl2 and Cp2ZrBr2, had been used mainly in Friedel-Crafts and Ziegler-Natta 
polymerization reactions.2
1
 The discovery of zirconocene hydrochloride, Cp2Zr(H)Cl, and its 
reactivity with organic substrates dramatically increased the utility of zirconium in small 
molecule synthesis. Schwartz and co-workers systematically investigated the reactivity of this 
complex, now commonly referred to as “Schwartz’s reagent,” with alkenes  and alkynes3. 
Typically, the reagent is formed by addition of a metal-hydride species such as LiAlH4,4
3
 
LiAlH(Ot-Bu)3,  or NaAlH2(OCH2CH2OCH3)2) to a zirconocene salt.5
3
 Although isolable and air-
stable, the resulting zirconocenes are often contaminated with metal salts and over-reduced 
products. a An improved protocol developed by Buchwald and co-workers in 1987 involves a 
CH2Cl2 wash to convert the dihydride species to the desired monochloride, proving a cleaner 
isolate this versatile reagent.6 Most recently in situ generation of “a convenient and genuine 
 2 
equivalent to HZrCp2Cl” was reported where the active species is formed by reaction between 
Cp2ZrCl2 and DIBAL-H in THF to circumvent the problem of reagent degradation upon storage, 
which displays similar activity to the isolated complex in alkyne hydrozirconations.7
The scope of hydrozirconation reactions using Schwartz’s reagent has been investigated 
extensively.
 
2 Whereas the formation of many organometallic compounds such as organolithiums 
and organomagnesiums suffers from poor functional group compatability, the hydrozirconation 
of alkynes has shown to be tolerant of ethers, bulky esters (e.g., TIPS, tert-butyl), acyl silanes, 
and alkenes (with ≤ 1 equivalent of Cp2Zr(H)Cl),8
2
 however ketone, aldehyde, amide, and nitrile 
groups are generally still reactive. In the hydrozirconation of alkenes, zirconium migrates to the 
least hindered position via a β−hydride elimination/hydrometalation processes (Scheme 1a). 
Hydrozirconation of internal alkynes under thermodynamic conditions positions the zirconium 
atom at the less sterically demanding site (Scheme 1-1b).  
 
R n
Cp2Zr(H)Cl
R
H
ZrClCp2
n R
H
n
R
H
H
ZrClCp2
n R
ZrClCp2
n
H
H
-Cp2Zr(H)Cl
+Cp2Zr(H)Cl
R1 R2
R1 > R2
Cp2ClZr
R1 R2
H H
R1 R2
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a.
b.
Cp2Zr(H)Cl
1-1 1-2 1-3
1-4 1-5
1-6
1-7 1-8
 
Scheme 1-1. Hydrozirconation of a. alkenes and b. internal alkynes. 
 
Despite the inherent polarization of the zirconium-carbon bond, organozirconium 
compounds react selectively and are easily handled due to the steric shielding of the polar 
 3 
covalent bond by the two bulky cyclopentadienyl ligands. Small electrophiles such as proton, 
halogens, CO, and dioxygen may be directly inserted into the Zr-C bond. Z-Alkenes may be 
accessed via hydrozirconation of stannylacetylenes and appropriate functionalization thereof 
(e.g., Stille cross-coupling).9 Hanzawa and co-workers have showed that acylzirconocenes 
derived from insertion of CO into the Zr-C bond add directly to aldehydes10 and imines,11 and 
participate in Pd-catalyzed cross-coupling reactions12 as well as Pd-catalyzed 1,2- or 1,4-
additions to α,β−unsaturated ketones (Scheme 1-2a).13 Along with acylzirconocenes, 
allylzirconocenes are the only organozirconium reagents that will react directly with organic 
electrophiles such as aldehydes and imines in the absence of an added catalyst. Suzuki and co-
workers showed that these reagents, generated from allene hydrozirconation, react readily with 
aldehydes to provide allylic alcohols in high diastereoselectivities (Scheme 1-2b).14
 
 
R
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Cl CO
R
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R
O
R
O
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b.
• R
H
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H
R'
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Cl
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H
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R
 
Scheme 1-2. Formation and aldehyde additions of a. acylzirconocenes and b. allylzirconocenes. 
 
 4 
One method that has proven to increase the reactivity of organozirconium compounds has 
been to relieve the steric shielding around the Zr-C bond, while simultaneously increasing the 
cationic character of the metal center, via chloride abstraction from the intermediate complex.15
15
 
The resulting cationic zirconium species have been shown by Suzuki and co-workers to generate 
allylic alcohols from the addition to aldehydes in a direct sequence.  For example, treatment of 
the intermediate alkenylzirconium species (1-18) with 5 mol% of AgClO4 in the presence of the 
aldehyde electrophile yields addition product 1-20 in 90% yield after 10 min (only 17% of the 
product was isolated after 2 h in the absence of Ag(I) salts) (Scheme 1-3).  Wipf and Xu showed 
that cationic alkenylzirconium intermediates also promote rearrangements of terminal epoxides 
to the corresponding aldehydes that undergo subsequent vinylation to afford secondary allylic 
alcohols in moderate yields.16
 
 
C4H9
Cp2Zr(H)Cl
CH2Cl2,
rt, 10 min
Zr
Bu
Cl
Cp
Cp
Ph H
O
cat. AgClO4 Ph Bu
OH
90%
1-17 1-18
1-19
1-20
 
Scheme 1-3. Cationic zirconocene addition to hydrocinnamaldehyde. 
 
The most commonly used method to increase the reactivity of organozirconocenes is 
transmetallation to another, more highly reactive element. Alkyl- and alkenylzirconocenes can be 
effectively transmetallated to a multitude of elements including B,17 Al,18 Ni,19 Cu,20 Pd,21 Hg,22 
Sn23 and Zn.24 Correspondingly, zirconocenes have been used to affect a wide variety of 
transformations including (i) trapping with an electrophilic halogen to afford vinyl halides,1 (ii) 
cross-coupling reactions to yield trisubstituted olefins,25 (iii) formation of cationic zirconocenes 
that add to aldehydes to produce allylic alcohols,26 (iv) reaction with isonitriles followed by 
 5 
treatment with mild acid to produce enals,27 and (v) additions to acid chlorides resulting in 
unsaturated enones (Scheme 1-4).28
 
 
R2
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ZrClCp2
R2
X2 or 
NXSi
R1
X
R2 R1
R2
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H3O+
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Pd(0),
R3-X
ii
iii
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1-6 1-7
1-21
1-22
1-23
1-24
1-25  
Scheme 1-4. General transformations of alkenylzirconocenes. 
 
While the aforementioned processes have been well established in the literature and 
remain attractive options for the use of organozirconium compounds in organic synthesis, 
transmetallation to zinc remains the most studied transformation of organozirconium reagents 
due to the functional group tolerance and general scope of the resulting reactions.24 Early uses of 
zinc halides in organozirconium reactions by Negishi revealed that palladium-mediated cross 
coupling reactions were greatly accelerated when using ZnCl2 as an additive.29 The increased 
reactivity is likely attributed to transmetallation of the vinylzirconocene species to the zinc salt, 
which facilitates the subsequent transmetallation to palladium and accelerates the palladium 
cross-coupling catalytic cycle. The Negishi protocol has since held a prominent place in 
palladium coupling reactions and has been used extensively in natural product synthesis.30 It is 
nicely showcased in Panek’s total synthesis of callystatin A (Scheme 1.5):31 a Zn-assisted sp2-sp2 
 6 
coupling between iodide 1-28, resulting from the hydrozirconation of alkyne 1-26 allows for a 
bromine-selective Negishi coupling to form the corresponding trisubstituted olefin in 
intermediate 1-29. A final coupling reaction between the iodide and organozirconocene 1-32 
yields the natural product after deprotection and oxidation steps. 
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Scheme 1-5. Panek’s synthesis of callystatin A. 
 
In 1994, Wipf and Xu reported that vinylzinc reagents prepared from the 
hydrozirconation of alkynes followed by transmetallation with dimethylzinc add to aldehydes to 
afford racemic allylic alcohols in good yields.32 Further investigations found that the reaction 
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requires only a catalytic amount of ZnMe2, and that zirconium plays a pivotal role in activation 
of the carbonyl unit, as alkyl- and alkenylzinc reagents do not react in the absence of Lewis acids 
or bases.15b This procedure facilitated access to a critical intermediate in Wipf’s synthesis of 
curacin A,33 and this approach was also applied to the syntheses of other complex natural 
products such as asukamycin,34 nisamycin,35 ratjadone,36 laulimalide,37 sphingosine,38 and 
fostriecin,39
 
 showing good diastereoselectivities in the addition event in some cases (Figure 1.1). 
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O
O
H
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H
H
O H
H
HO
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O O
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O
OH
H H
Ratjadone
(Williams 2001)  
Figure 1-1. Total syntheses using Zr→Zn aldehyde additions to assemble allylic alcohol intermediates. 
 
In their initial Zr∏Zn aldehyde addition report, Wipf and Xu observed that the addition 
of 8 mol% of proline-based catalyst 1-34 at –20 oC afforded enantiomerically enriched allylic 
alcohols in (low) 38% ee.33 Later, Wipf and Ribe showed that novel amino-thiol ligand 1-36 
increased the enantioselectivity of the alkenylzinc addition to 95% after a 60 min incubation time 
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at –30 °C, which was necessary to completely equilibrate the chiral ligand and achieve 
reproducible selectivities (Scheme 1-6).40 Catalytic asymmetric Zr∏Zn 
transmetallation/aldehyde additions have since been used to prepare allylic alcohol segments in 
the syntheses of halichlorine (Danishefsky),41 leucascandrolide (Wipf, Williams)42,43 and 
lobatamine C (Porco)44 33 as well as those previously shown in Figure 1-1. ,35,36,37,39,45
 
 
C4H9
1. Cp2Zr(H)Cl, CH2Cl2
2. ZnMe2, –65 °C
3.
N
CH3
Ph
Ph
HO
4. PhCHO, –20 °C, 8 h
C4H9 (S)
OH
Ph
38% ee
1-17 1-34 1-35
NH2
SH
1-36
1-35: 98% ee
 
Scheme 1-6. Enantioselective alkenylzinc additions to aldehydes. 
 
While enantioselective additions of organozinc reagents to aldehydes represent a highly 
utilized method to create synthetically useful intermediates,46 the aldimine variant of this process 
remains relatively undeveloped. The reactivity of aldimines suffers due to lower electrophilicity 
and softer Lewis base character of the C=N double bond as compared to the corresponding 
carbonyl unit. Successful enantioselective additions to imines include Soai et al.’s use of the 
diphenylphosphinoyl group to activate aldimines towards the addition of dialkylzinc reagents in 
the presence of stoichiometric amounts of N,N-dialkylnorephedrines.47
43
  Other chiral amino 
alcohols have been used to afford the same transformation with comparable results.  This 
process is also amenable to other activated imines such as N-tosylamines,48 N-arylamines,49 
nitrones,50 and N-(amidobenzyl)benzotriazoles.51 
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1.1.2 Synthesis of C-Cyclopropylalkylamines 
Wipf, Kendall and Stephenson applied the Zr∏Zn transmetallation strategy to add alkenylzinc 
species to N-diphenylphosphinoyl and N-tosyl aldimines.8 A variety of alkynes were 
hydrozirconated using Schwartz’s reagent in dichloromethane, then transmetallated with 
dimethylzinc in toluene and added to aromatic aldimines at room temperature to yield the 
corresponding allylic amines in modest to good yields in the one-pot procedure (Scheme 1-7). 
Later, this strategy was successfully applied to the hydrozirconation of allenes and addition of 
the resulting allyl zirconocenes to imines to generate homoallylic amines. 
 
R1
1. Cp2Zr(H)Cl
2. ZnMe2 R
1MeZn
R2
N
H
R3
R2
HNR3
R11-37 1-38
1-39
1-40  
Scheme 1-7. One-pot hydrozironation/transmetallation allylic amine synthesis. 
 
During their studies an unexpected observation was made where a solvent switch from 
dichloromethane to toluene or THF prior to imine introduction was found to be essential to 
generate the desired products, and that performing the entire reaction sequence in CH2Cl2 led to 
the formation of cyclopropylalkyl amines (Scheme 1-8). The addition of CH2I2 or CH2Cl2 to the 
zinc-amide facilitated the formation of these products (Scheme 1-8, pathway a). Furthermore, it 
was discovered that the order of addition of the reaction components influences the reaction 
pathway, and addition of the dihalomethane reagent prior to the imine afforded homoallylic 
amines (Scheme 1-8, pathway b). 
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2. ZnMe2
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4. CH2I2
1. Cp2Zr(H)Cl
2. ZnMe2
3. CH2I2
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R1
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HNR3
R1 R2
HNR3
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R1
R2
HNR3
R1
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1-37
1-41 1-42
1-43 1-44
 
Scheme 1-8. Product dependence on order of addition. 
 
The one-pot cyclopropylalkyl amine formation was found to be tolerant of silyl ethers, 
TIPS esters, carbamates, and internal alkynes. The cyclopropanated products were formed in 
greater than 95:5 diastereoselectivities in most cases. It is proposed that the stereochemical 
preference is due to a chelated transition state incorporating both zinc and the zirconocene 
complex (Scheme 1-9). Following hydrozirconation, transmetallation, and imine addition, 
intermediate 1-46 was treated with dihalomethane (CH2Cl2 or CH2I2) the halomethylzinc species 
1-47 was formed. The zirconocene complex obtained in the transmetallation event then served as 
a Lewis acid activator for zinc carbeneoid formation by complexation to the halogen atom of the 
halomethylene intermediate in 1-48. The carbene was delivered to the proximal olefin by one of 
the two feasible transition states, 1-49 or 1-50. Large destabilizing steric interactions between the 
N-diphenylphosphinoyl group and the alkene moiety disfavored conformer 1-49, whereas 
transition state 1-50 relieved this steric congestion. However it was itself subjected to a 1,3-
allylic strain interaction that usually leads to a preference for syn selectivity, but in this case the 
allylic interaction was less demanding, which explained the diastereomeric ratios of the product 
cyclopropylalkyl amines.  
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Scheme 1-9. Proposed mechanism and cyclopropanation transition states. 
 
1.1.3 Simmons-Smith Cyclopropanation and Applications 
Whereas the Wipf cyclopropylalkyl amine methodology was the first report of a one-pot Zr→Zn 
transmetallation, imine addition and cyclopropanation sequence, cyclopropanation reactions with 
zinc carbenoids have been well investigated.52 This is due in large part to the efforts of Simmons 
and Smith who, three decades after Emschwiller first reported the preparation of IZnCH2I,53 
reported that the same reagent was effective at achieving stereospecific formations of 
cyclopropanes from alkenes.54 The zinc carbenoid, which is now commonly known as the 
Simmons-Smith reagent, was initially formed via oxidative addition across the X-CH2X bond 
using a zinc-copper couple in an ethereal solvent (THF, Et2O, DME). Due to inconsistent reagent 
formation in the presence of an excess of metal salts, the reagent has since been prepared in a 
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number of alternative ways. An early protocol reported by Wittig described treating 
diazomethane with ZnI2 to generate IZnCH2I or Zn(CH2I)2 via nucleophilic displacement, 
however nowadays this protocol is rarely used.55 The most popular method for generating the 
Simmons-Smith reagent, developed by Furukawa in 1966,56 is through alkyl exchange between 
ZnEt2 and CH2X2 to give the active species EtZnCH2I or Zn(CH2I)2. This process is accelerated 
by catalytic amounts of oxygen in the solvent, leading to zinc reagents that afford the highest 
diastereoselectivities in directed Simmons-Smith reactions. The major advantages of the 
Furukawa method are that coordinating solvents are not required, starting materials are 
commercially available and can be used without extensive purification, and the reagents are more 
reactive, although their stabilities are significantly lower. Notably, in a report by Charette, the 
preparation of Simmons-Smith reagent in CH2Cl2 on large scale (8 mmol, ~1 g of ZnEt2) resulted 
in an explosion.57
While zinc remains the preferred metal for use in cyclopropanation reactions, a number 
of other metal reagents have proven effective in promoting the same transformation exhibiting 
several differences in terms of chemoselectivity.
 To avoid this dangerous situation, a stoichiometric amount of DME can be 
added to a solution of diethylzinc prior to CH2I2 introduction to sufficiently stabilize the reagent 
towards exothermic decomposition to allow for safe large-scale usage. 
58 Samarium and zinc are highly selective for 
reacting with allylic alcohols in the presence of other alkenes whereas aluminum preferentially 
reacts with isolated olefins in identical systems.59
53
 The most reactive cyclopropanating reagent, 
CF3CO2ZnCH2I (Shi reagent), affords a mixture of products when more than one reactive site is 
present.  
Not surprisingly, the Simmons-Smith reaction has been used with neighboring group 
participation to install allylic cyclopropane moieties in natural product synthesis. Oppolzer nicely 
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applied this directivity in the synthesis of (R)-muscone where the allylic alcohol 1-54 (installed 
via an intramolecular coupling using Noyori’s DIAB ligand) was subjected to Denmark’s 
cyclopropanation conditions60 to give the syn-cylopropylcarbinol as a single diastereomer 
(Scheme 1-10).61 Johnson and Barbachyn used a similar approach in their synthesis of both 
enantiomers of thujopsene where the α− and β−allylic alcohols 1-57 and 1-58 directed a 
cyclopropanation under the Simmons-Smith protocol (Scheme 1-11).62
 
  
H O
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HO
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HO
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Scheme 1-10. Oppolzer’s synthesis of (R)-muscone. 
 
O
S
NMe
O
Ph CH3
n-BuLi,
THF, 89%
OH
S
NMe
Ph
O
OH
S
NMe
Ph
O
CH2I2, Zn(Ag)
Et2O, 80%
CH2I2, Zn(Ag)
Et2O, 78%
OH
S
NMe
Ph
O
OH
S
NMe
Ph
O
(+)-thujopsene
(-)-thujopsene
1-56
1-57
1-58
1-59
1-60
 
Scheme 1-11. Johnson’s synthesis of (+)- and (–)-thujopsene. 
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While directed cyclopropanation reactions in cyclic systems are biased by ring 
conformations and axial vs. equatorial positioning, acyclic systems follow different trends. The 
cyclopropanation of chiral allylic alcohols tends to favor the syn-diastereomer while chiral allylic 
ethers favor the anti-diastereomer.63
63
 It is not only the substrate that controls stereoselectivity in 
these reactions, but the choice of the appropriate reagent can have profound effects on the 
reaction outcome. Whereas the traditional Simmons-Smith reagent provides a roughly 1:1 
mixture of syn- and anti-diastereomers, the Furukawa reagent often affords a much higher 
selectivity.  The substitution pattern around the allylic alcohol or ether changes the observed 
facial selectvitiy of the reaction as well.64
 
 As the steric bulk of R4 increases, the syn-diastereomer 
becomes favored since the minimization of allylic strain dominates the conformational 
preferences in the transition state (Scheme 1-12). 
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Scheme 1-12. Diastereoselective transition state models of allylic cyclopropanations. 
 
The directing effect of an amide function in cyclopropanation reactions has not been as 
widely investigated, although some reports exist in the literature.65 Marquez et al. performed a 
study comparing the directing capabilities of an amide versus a hydroxyl group on a 
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cyclopropene skeleton (Scheme 1-13).65b Methylene attack occurs syn- to the amide (anti- to the 
hydroxyl function) when an N-H bond is present, and syn- to the hydroxyl group when the amide 
nitrogen is protected as the benzoate. Based on these results, the secondary amide emerges as the 
stronger directing group; however N-substitution appears to significantly suppress the directing 
capability of this group to the point that the diastereofacial selectivity is reversed. It is important 
to note that this comparison has not been reproduced on acyclic systems, so any conformational 
effects of the ring cannot be completely discounted. 
 
BnO
HO
NH
Ac
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HO
NH
Ac
BnO
HO
N
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N
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1-66 1-67
1-68 1-69  
Scheme 1-13. Marquez cyclopropanation study. 
 
1.1.4 Synthesis of C, C-Dicyclopropylmethylamines 
During the course of our group’s study of the one-pot Zr→Zn transmetallation, imine addition 
and cyclopropanation sequence, another interesting observation was made.66 Serendipitously, 
when alkynylimine 1-71 was used in the presence of excess Zn(CH2I)2, an unexpected polycyclic 
product, later identified to be dicyclopropylmethylamine 1-77, was isolated in lieu of the 
expected cycloproylalkynylamide (1-72, Scheme 1-14). Alkynes and alkynylimines with 
substituents including silyl ethers, carbamates, sulfonamides, silyl esters and orthoesters were 
tolerated in the multicomponent process. Strikingly, when internal alkynes were used the rare 
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bicyclo[1.1.0]butane scaffold could be successfully isolated, giving a clue into potential reaction 
intermediates. Mechanistically, a cascade reaction where 10 C-C bonds are formed and 2 C-C 
bonds are broken was proposed, with a key intermediate in the process being 
bicyclo[1.1.0]butane 1-74 (Scheme 1-14). In fact, resubjection of isolated 1-72 to the reaction 
conditions yields the rearranged product and provides support to the hypothesized mechanistic 
pathway: hydrozirconation, transmetallation and addition to the alkynylimine forms intermediate 
1-72, which undergoes alkyl group exchange and triple cyclopropanation to generate 
bicyclobutane 1-74. It has been shown that these intermediates undergo double σ-bond insertions 
with carbenes67
 
 to form skipped dienes, and a final cyclopropanation of the allylic π-bond yields 
the isolated product 1-77 in 43-66% yields (94-96% yield per C-C bond formed). This 
multicomponent organometallic reaction represents the first synthetically useful example of a 
double C,C-σ-bond insertion, and can be performed from readily available starting materials. 
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Scheme 1-14. Proposed reaction mechanism for the formation of dicyclopropylmethyl amines. 
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1.1.5 Synthesis and Applications of Bicyclo[1.1.0]butanes 
Historically the bicyclobutane functionality has remained under investigated for its reactive 
potential. Understandably this is an effect of the technologies known to form the bicycle, which 
involve lengthy routes and harsh conditions that are incompatible with many common functional 
groups. Therefore to exploit the intriguing reactivity of the bicyclobutane group an easier method 
of synthesis needed to be developed. In 2006 Wipf and Walczak discovered a key result towards 
this goal in that di-lithiation of 1-78 affords, in situ, bicyclo[1.1.0]butyllithium 1-79, which can 
be added to aldehydes and imines (Scheme 1-15). The resulting bicyclobutane adducts were 
allylated and subjected to a formal Alder-ene reaction to produce the novel bicyclic products 1-
88 and 1-91 (Scheme 1-16).  
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Scheme 1-15. Bicyclo[1.1.0]butyllithium formation and addition to imines. 
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Scheme 1-16. Spontaneous formal Alder-ene rearrangements of N-allyl bicyclobutanes. 
 
Transition metal-catalyzed reactions of the bicyclobutylamines were investigated and it 
was found that rhodium inserts into the central Csp3-Csp3 σ-bond of bicyclobutane, which has 
been likened to a Csp2=Csp2 π-bond to explain the reactivity of bicyclobutanes.68
 
 Rh-insertion is 
benefited by the release of ~65 kcal/mol in strain energy in forming the rhodium carbene which 
performs a cyclization/cyclopropanation to form pyrrolidine or azepine products, depending on 
the phosphine ligand present (Scheme 1-17). Allyl ether 1-95 provides a mixture of 5- and 7-
membered heterocycles and sequential isomerization followed by ring-closing metathesis of 1-98 
provides the interesting tricyclic scaffold 1-100 in a handsome sequence. 
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Scheme 1-17. Rh(I)-catalyzed isomerizations of bicyclo[1.1.0]butanes. 
 
More recent uses of bicyclobutanes include the application towards natural product 
synthesis. Wipf and Ueda have reported the use of the Alder-ene sequence to generate the 
tricyclic core of the complex daphniglaucin alkaloids (Scheme 1-18).69
 
 Addition of 
bicyclo[1.1.0]butan-1-yllithium to imine precursor 1-01 gave the labile adduct 1-02 that was 
immediately subjected to alkylation with bromide 1-103. Deprotection and oxidation to the 
corresponding aldehyde followed by spontaneous rearrangement to afford the formal ene-product 
in 65% yield as a 6:1 mixture of diastereomers. Elaboration of the scaffold led to 1-107, which 
could be deprotected and cyclized, then oxidatively opened to afford diol 1-108. Mesylation and 
cyclization to form the ammonium salt completed the tricyclic core. Elaboration of this strategy 
into the completion of daphniglaucin A and related alkaloids is being pursued. 
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Scheme 1-18. Alder-ene approach to the daphniglaucin core. 
 
1.1.6 Synthesis of Azaspirocycles 
In 2004 Wipf, Stephenson and Walczak reported the use of the one-pot 
dicyclopropylmethylamine cascade reaction to form a libryary of azaspirocyclic compounds.70 
The diversity-oriented approach included metathesis (i), oxidation and reductive amination (ii), 
and epoxide ring opening (iii) strategies to produce azepine, piperidine and pyrrolidine 
azaspirocycles (Scheme 14).  The novel polycycles allowed for more meaningful biological 
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analysis of the dicyclopropyl amine functionality since linear chains are generally more rapidly 
metabolized than heterocyclic rings. 
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Scheme 1-19. Diversity-oriented synthesis of azaspirocycles. 
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 As shown in Scheme 1-19, the epoxidation and intramolecular ring-opening sequence 
(iii) afforded two distinctly different products in equal amounts. Mechanistically, this 
observation was rationalized by the preference of a 5-exo vs. 6-endo cyclization of the two 
epoxide diastereomers (Figure 1-2). As anions 1-116 and 1-117 are formed in the reaction the 
preference for the 5-exo cyclization is demonstrated by the formation of 1-118 from 1-116. In the 
case of 1-117, however, the transition state leading to the 5-exo ring closure develops a 
destabilizing steric interaction between the phenyl and diphenylphosphinoyl groups as shown in 
B. Instead, the epoxide moiety can rotate and present the homo-benzylic carbon for attack in a 6-
endo manner to produce piperidine 1-120 possessing geminal phenyl and hydroxy substituents. 
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Scheme 1-20. Unexpected 11-membered ring formation during ring-closing metathesis. 
 
An additional unexpected observation was made in the course of the library synthesis: 
during the formation of azepines (Scheme 1-19, pathway i) under ring-closing metathesis (RCM) 
conditions, exposure of tosyl-protected carbamate 1-121 to the allylation conditions resulted in 
carbamate cleavage (presumeably due to sodium hydroxide present in the mixture) and bis-
allylation to provide triene 1-122 (Scheme 1-20). Upon treatment with Grubbs 2nd generation 
metathesis catalyst (1-123) in refluxing CH2Cl2 under an ethylene atmosphere a chemoselective 
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cyclization to provide the 11-membered ring, and not the 7-membered azepine, in 84% yield and 
in a ~1:1 E/Z ratio. This result is especially intriguing as nitrogen-containing macrocycles are a 
common structural motif in many biologically active natural products (Figure 1-3). 
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Figure 1-3. Examples of nitrogen-containing macrocycles in natural products. 
 
1.2 RESULTS AND DISCUSSION 
1.2.1 Initial Investigations 
As part of our continued study of novel polycyclic heterocycles, we wished to expand the unique 
products derived from our initial one-pot dicyclopropylmethylamine synthesis into polycyclic 
natural product-like compounds containing a macrocyclic ring system within their polycyclic 
structures. Natural products containing similar moieties are of considerable relevance both in 
terms of their molecular complexity and scientific advances made in pursuit of their syntheses as 
 24 
well as their profound biological activities and modes of action. Our initial goal was to combine 
the macrocyclic  ring system with a smaller ring as shown in Scheme 1-21. 
 
HN NTs
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N NTs
Ph
nm
N NTs
nm
Ph
1-125 1-126 1-127  
Scheme 1-21. Generic target structures and strategy. 
 
To synthesize the necessary cyclopropyl building blocks, we followed our established 
procedure for the synthesis of substituted dicyclopropylmethylamines.66 Alkyne 1-128 was 
prepared in a straightforward manner in 2 steps from commercially available materials, and the 
requisite imine (1-129) was generated by TiCl4-mediated condensation of 
diphenylphosphinoylamide and phenylpropargyl aldehyde. Following the general rearrangement 
protocol, 1-128 was treated successively with Cp2Zr(H)Cl, ZnMe2 and imine 1-129 (Scheme 1). 
Introduction of 4 equivalents of the Furukawa-modified Simmons-Smith reagent formed the 
bicyclo[1.1.0]butane intermediate and following insertion, rearrangement to the skipped diene, 
and final cyclopropanation of the proximal olefin produced dicyclopropylmethylamine 1-121 in 
60% yield (95% yield per C-C bond formed). 
Simultaneous carbamate removal and allylation of the diphenylphosphinoylamide and 
tosylamide groups occurred in 68% yield using NaH and allyl iodide with HMPA as an additive 
(to promote nucleophilic substitution and, presumeably, to provide an adventitious amount of 
water to hydrolyze the carbamate) in THF at reflux to provide 1-122. This compound, when 
subjected to the same metathesis conditions as reported in the previous azepine studies (10 mol% 
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of Grubbs 2nd generation catalyst in CH2Cl2 at reflux under ethylene gas), cyclized to afford the 
macrocyclic product in 96% yield (Scheme 1-22). 
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Scheme 1-22. Synthesis of macroyclic compound 1-124. 
 
After successful formation of the macrocycle, our attention turned towards the annulation 
of the smaller ring. Removal of the diphenylphosphinoyl group to accommodate further reactions 
of the free amine proved successful under standard acidic methanol deprotection conditions;72
 
 
however, these conditions also led to the problematic addition of HCl across the styrenyl double 
bond, thereby destroying one of the olefin moieties we envisioned using in the final ring-closing 
step. Other methods for removing this protecting group, for example BF3·OEt2 in MeOH, 
returned starting material or quickly led to complete decomposition (TFA in dichloromethane) 
(Scheme 1-23). 
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Scheme 1-23. Attempted removal of the N-diphenylphosphinoyl protecting group. 
 
Due to the difficulties associated with removing the diphenylphosphinoyl group from key 
intermediate 1-124, we concluded that a second metathesis reaction would not be a feasible 
approach to generate our desired polycylic core. Instead, we planned to reduce the macrocyclic 
olefin selectively using diimide conditions to leave the more polarized styrene double bond 
intact, and form a pyrrolidine ring using a similar oxidation/reductive amination protocol as 
previously employed in the azaspirocycle studies.70 Diimide reduction using 1 equivalent of 
TsNHNH2 led to the formation of the desired product (1-127) in only 33% yield accompanied 
with over-reduced 1-126 and starting material (Scheme 1-24). The osmium-mediated Johnson-
Lemieux oxidation of 1-127 led to phenylketone 1-128 in 50% yield, however deprotection did 
not provide any cyclized product (only starting material was isolated in <5 mg scale reactions). 
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Scheme 1-24. Reduction and cyclization attempts. 
 
1.2.2 Revised Approach to Polycyclic Structures 
From our inability to cyclize the pyrrolidine ring following macrocycle formation we reasoned 
that the conformational preference of the large ring likely prevented pyrrolidine ring formation. 
Hence, we once again reevaluated our strategy and surmised that macrocycle formation after 
cyclization of the smaller ring would be an energetically more favorable process and have a 
greater chance for success (Scheme 1-25). 
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Scheme 1-25. Revised cyclization strategy. 
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In our revised route (Scheme 1-26), Johnson-Lemieux oxidation of rearrangement 
product 1-121 provided ketone 1-131 in 66% yield, and it was later discovered that the yield 
could be improved to 75% by performing the two-step Upjohn dihydroxylation followed by 
Criegee elimination sequence. Deprotection of the diphenylphosphinoyl group with HCl in 
MeOH and reductive amination of the crude amine using sodium cyanoborohydride afforded 
pyrrolidines 1-132a and 1-132b, which were immediately subjected to allylation conditions 
without further purification. Simultaneous bis-allylation and carbamate removal using allyl 
iodide, sodium hydride, and HMPA had proven to be irreproducible and routinely gave mixtures 
of mono- and bis-allylated products.73 As an alternative, phase-transfer conditions using tetra-n-
butylammonium hydrogensulfate and allylbromide partitioned between toluene and saturated 
aqueous sodium hydroxide (1:1 v/v) were found to be superior in terms of reproducibility and 
scalability. The addition of ~5% v/v of methanol served to efficiently cleave any remaining 
carbamate (a byproduct in early attempts), and the desired bis-allylated pyrrolidines 1-133a and 
1-133b were the only products isolated from the reaction mixture in 71% yield over 3 steps as a 
1.1:1 mixture of diastereomers separable by column chromatography.74
 
 The major and minor 
diastereomers were tentatively assigned by 3J coupling constant analysis and comparison to 
analogous pyrrolidine rings formed by reductive aminations during our group’s diversity-
oriented synthesis of azaspirocycles (Scheme 1-18). Our assignement was confirmed by the X-
ray structure of 1-136 a later stage. 
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Scheme 1-26. Pyrrolidine formation from 1-121. 
 
1.2.3 Improvement of Cyclization Diastereoselectivity 
Attempts to increase the diastereoselectivity of the reduction event using borohydride reagents of 
varying steric and electronic properties led to similarly unselective ratios of pyrrolidine products, 
with the best result occurring when NaBH(OPiv)3 was used (1.6:1 d.r., Table 1-1). As an 
alternative strategy, we turned to a cyclodehydration/reduction method initiated by BF3·OEt2 and 
proceeding though cyclic imine 1-135 (Scheme 1-28). Screening various reductants revealed that 
trichlorosilane possesses the optimal balance between reactivity and steric properties and 
provided an improved ratio of 1-132a to 1-132b (4.6:1). In each case, the crude mixture of syn- 
and anti-pyrrolidines was allylated under phase transfer conditions to provide more easily 
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handled and separable 1-133a and 1-133b, which, upon isolation, revealed the selectivity of the 
reduction step. 
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Scheme 1-27. Reductive amination approach. 
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Scheme 1-28. Cyclodehydration/reduction approach. 
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Table 1-1. Reagent screening for the a. reductive amination and b. cyclodehydration/reduction approaches. 
a. Reductive amination of 1-134 in Scheme 1-27 1-133a : 1-133bi 
NaBH3CN, MeOH 1.1 : 1 
NaBH3CN, AcOH, MeOH 1.5 : 1 
NaBH(OPiv)3 1.6 : 1 
NaBH(OAc)3 1.1 : 1 
b. Reduction of 1-135 in Scheme 1-28 1-133a : 1-133bi 
Ph3SiH SMii 
Ph2SiH2 SMii 
PhSiH3 1.1 : 1 
Cl3SiH 4.6 : 1 
RhCl(PPh3)3, H2, MeOH SMii 
Raney Ni, H2, EtOH 2 : 1 
DIBAL-H, CH2Cl2 1 : 1.3iii 
iratios of isolated products. iino reduction products observed and 1-135 was recovered from the reaction. 
iiicarbamate function was removed during the reaction. 
 
1.2.4 RCM and Completion of the Polycylic Core 
Gratifyingly, exposure of the major diastereomer resulting from the cyclization/allylation 
sequence to the 2nd generation Grubbs metathesis catalyst under ethylene in CH2Cl2 at reflux for 
4 h led to an efficient formation (90% yield) of our target macrocyclic compound as a single 
olefin isomer (Scheme 1-29). Unfortunately assignment of the newly formed double-bond was 
not possible using 1H NMR coupling constant analysis due to the overlap of the olefin peaks, 
despite solvent changes and high-field instruments. Fortunately the polycyclic product 
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crystallized from hexanes/EtOAc and the (E)-olefin was unambiguously identified by X-ray 
crystallography, interestingly as a 3:1 ratio of conformational isomers in the solid state as 
evidenced by static disorder of the unit crystal in the alkene chain linking the two nitrogen atoms 
(Figure 1-4).75,76
 
 Ethylene was essential in this transformation in order to avoid a deleterious 
polymerization of the starting material that occurred under an N2 atmosphere. Notably, exposure 
of anti-pyrrolidine 1-133b to identical RCM conditions led to polymerization of the diene, 
presumably due to the increased spatial distance of the reacting olefins. 
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Scheme 1-29. Ring-closing metathesis of 1-133a. 
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Figure 1-4. a. X-ray crystal structure of 1-136, b. orientation of butene unit (3:1 solid:dashed ratio), and c. overlaid 
crystal and calculated lowest energy structures (calculated using MOE; MMFF94x basis set). 
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 Functionalization of the metathesis product proved to be more difficult than originally 
anticipated. The olefin was resistant towards hydrogenolysis in the presence of a number of 
catalysts, including Pd-, Ru-, and Pt- complexes, which appeared to open the pyrrolidine ring 
under hydrogenation conditions due to the benzylic character of the amine. After several trials it 
was discovered that the use of 20 mol% Pd(OH)2 in THF under 1 atm of H2 for 10 h saturated the 
macrocyclic double bond in 24-62% yield (Scheme 1-30). Attempts to epoxidize the olefin under 
Sharpless and Shi conditions were unsuccessful, and exposure of 1-136 to m-CPBA led to 
formation of the N-oxide on the pyrrolidine ring. 
 Modification of 1-136 was accomplished by dihydroxylation under Upjohn conditions to 
produce a 2.3:1 ratio of separable diols (Scheme 1-30). The ratio of diastereomers was found to 
be related to the catalyst loading: 10 mol% of OsO4 produced a 1:1 mixture after 12 h (100% 
conversion by TLC) and 5 mol% of OsO4 afforded a 2.3:1 ratio after 24 h (100% conversion by 
TLC). The minor isomer (1-138b) was converted into its corresponding cyclic sulfate by 
treatment with sulfuryl diimidazole. 2D-NOESY spectroscopy of the rigidified heterocycle 
established the relative stereochemical arrangement of the diol portion of 1-139, and, by relation, 
of 1-138a and 1-138b. The N-tosyl group of 1-138a was successfully removed using SmI2 with 
notable tolerance towards the cyclopropane moieties to reveal the unprotected secondary 
amine.77
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Scheme 1-30. Elaboration of metathesis product 1-136. 
 
1.2.5  Incorporation of Indole Moiety 
Having developed a route to access these polycyclic alkaloid skeletons, we sought to incorporate 
a heterocyclic unit commonly found in biologically active natural products into the scaffold, and 
we chose indole as a target structure to accomplish this goal. N-Tosylindole imine 1-145 was 
successfully synthesized through a Sonogashira coupling of propargyl alcohol with readily 
available iodide 1-142, followed by MnO2 oxidation and TiCl4-mediated imine formation 
(Scheme 1-31). It should be noted that the best results regarding the isolation of 1-145 came 
when oven-dried, non-deactivated (i.e. no Et3N in the eluent) silica gel was used in 
chromatographic purification. Remarkably, the stability of 26 was greatly improved compared to 
other alkynyl imines, likely owing to the presence of the strongly electron-withdrawing tosyl 
group. This behavior is consistent with our lab’s observations in preparing various electron-rich 
and electron-deficient aryl substituted alkynyl imines. 
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Scheme 1-31. Sonogashira cross-coupling route to 1-145. 
 
The cascade bicyclobutane insertion/rearrangement sequence using 1-145 proceeded to 
afford 1-146 in 47% yield (Scheme 5). Similar to what was previously developed for the phenyl-
containing substrate, 2-step oxidation, deprotection and cyclodehydration produced isolable 
cyclic imine 1-148. Applying our previously identified optimal reduction conditions (excess 
Cl3SiH in CH2Cl2) yielded an improved 7.5:1 syn:anti selectivity of pyrrolidines. Molecular 
modeling of 1-148 (MMFF basis set) suggests that pyramidalization of the sulfur atom of the 
indole N-tosyl group and the resulting facial bias is likely responsible for the increased 
diastereoselectivity of this reduction compared to phenyl-substituted imine 1-135.  
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Scheme 1-32. Cascade rearrangment using N-tosylindole imine 1-145 and cyclization of 1-147. 
 
For the allylation of 1-149a, we foresaw that the phase-transfer allylation conditions that 
had worked well for our previous system would be incompatible with 1-149 due to the lability of 
the indole tosyl group towards the basic conditions needed for in situ carbamate deprotection. In 
fact, when uncyclized 1-146 was subjected to the alkylation conditions, the tri-allylated 
compound 1-150 containing 4 olefins was isolated (Scheme 1-33). Treatment of this material to 
metathesis conditions produced a number of products, with azepine 1-151 appearing to be the 
major constituent (smallest ring formation).  
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Scheme 1-33. Allylation of 1-146 under phase-transfter conditions and metathesis of 1-150. 
 
For a solution to the allylation problem we turned to the Pd-catalyzed conversion of allyl 
carbamates into their N-allyl derivatives to prepare our metathesis precursor. The ethyl 
carbamates of the crude pyrrolidine products from the Cl3SiH reduction of 1-148 were removed 
using 3 equivalents of DIBAL-H (which had been observed as a byproduct in the 
diastereoselective cyclic imine reduction studies, Table 1-1), as opposed to alkoxide conditions. 
The resulting amines were protected with AllocCl to afford 1-152a and 1-152b in 33% isolated 
yield from 1-148. The inseparable mixture of bis-Alloc carbamates was exposed to catalytic 
Pd(PPh3)4 under microwave heating to provide bis-allylated 1-153a and 1-153b, separable by 
column chromatography, which confirmed the diastereoselectivity of the reduction step.  
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Scheme 1-34. Imine reduction and carbamate cleavage followed by two-step allylation. 
 
In a similar manner as before, RCM of diene 1-153a under ethylene and 10 mol% of 1-
123 provided 1-154 as a single isomer that was dihydroxylated to furnish the polycyclic diols 1-
155a and 1-155b in a 1.7:1 ratio. Exposure of diol 1-155a to SmI2 for bis-tosyl deprotection led 
to a complex mixture of compounds by 1H NMR analysis.  
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Scheme 1-35. RCM to complete 1-154 and subsequent dihydroxylation. 
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Having successfully constructed the polycyclic indole-containing scaffold, we were 
intrigued by the possibility of using the indole unit as a handle to perform a final ring closure 
between the macrocyclic olefin of 1-154 or the diol of 1-155a. Initially, we attempted to activate 
the system using Brønsted- (TfOH, MsOH) and Lewis-acid (Sc(OTf)3) catalysis but with no 
success. Photochemical conditions did not affect any bond formation between indole and the E-
olefin either. Deprotonation of the indole proton using n-BuLi appeared to be promising with 1-
154 exhibiting remarkable stability in the presence of the strong base, however trapping of the 
anion with a halogen source to perform a Heck-coupling was not successful, returning starting 
material from the reaction mixture. Finally we decided to reverse our approach to use the 
macrocyclic functionality as the nucleophile. However activation of the indole ring of diol 1-
155a using NBS did not initiate the desired cyclization. Removal of the indole tosyl group would 
provide the most likely chance of successful cyclization, perhaps by bis-acylation of the diol and 
indole. However, we found that once the macrocyclic ring had been closed the sulfonamide was 
surprisingly resistant to conventional deprotection conditions (K2CO3, MeOH, heat).  
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Scheme 1-36. Attempts to connect indole ring and macrocycle. 
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1.3 CONCLUSION 
Organozirconium compounds and their derivatives possess a rich history in organic synthesis due 
to their versatility, ease of preparation and diversity of transformations.  Impressively, the future 
of these reactive intermediates is not outshined by their past. The ability to access novel 
functionalities, such as the bicyclo[1.1.0]butane scaffold, and catalyze novel transformations78
In our own studies we successfully synthesized natural product-like compounds 
possessing 3-, 5- and 11-membered rings within their polycyclic frameworks, originating from 
the carbene insertion/rearrangement of a bicyclo[1.1.0]butane intermediate. We demonstrated 
that elaboration of these advanced structures is possible under dihydroxylation, reductive 
desulfonylation and sulfate formation conditions. Additionally we have expanded the scope of 
our multicomponent one-pot dicyclopropylmethylamine synthesis through the use of indole 
imine 1-145 in the cascade sequence. Finally, we have contributed to the intrigue of the products 
derived from this methodology by demonstrating the types of complex molecules that can be 
accessed. 
 
leaves the exciting world of organozirconium chemistry open for deeper exploration. 
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2.0  STUDIES ON STEMONA ALKALOIDS: PARVISTEMOLINE, STEMOAMIDE 
AND SESSILIFOLIAMIDES 
2.1 INTRODUCTION 
2.1.1 Introduction to Stemona Alkaloids 
Extracts of the tuberous roots of the Stemonacae family of flowering plants have been used for 
centuries in Asia for their anti-cough and anti-parasitic (anthelmintic) properties.79 Unbeknownst 
to the ancient pharmacist was the intense molecular complexity and diversity, yet surprising 
similarity, of the chemical products these plants produce. Modern methods of extraction, 
separation and characterization have revealed well over 80 distinct alkaloids from the 3 genera 
(Stemona, Croomia and Stichoneuron) of Stemonaceae. While debate exists over the exact 
classification of the Stemona alkaloids (8 structural classes in 199480 79 vs. 5 in 2000 a vs. 3 in 
200681
In general, the Stemona alkaloids are classified by a conserved, pyrrolo[1,2-a]azepine 
core functionalized with carbon chains mostly forming terminal lactone rings.
), it is safe to say the lines between classification groups are becoming increasingly blurry 
with the isolation of each new alkaloid and the evidence that they contain hinting at biosynthetic 
relationships with other Stemona members. 
81 Interestingly, 
prior to 1980 almost all the structural determined of newly isolated Stemona alkaloids could only 
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be performed by X-ray crystallography due to their structural complexity and general instability. 
It is this same molecular complexity that has led to a considerable amount of synthetic interest in 
the scientific community. The pursuit of synthesizing these alkaloids has led to the development 
of new strategies for the construction of the skeleton along diverse routes including alkylations, 
acylations, cycloadditions, transition-metal mediated reactions, and radical ring closures.82
 
 With 
such a breadth of research existing in the literature regarding the total syntheses of Stemona 
alkaloids only examples and approaches relevant to the material contained in this dissertation 
will be presented. 
2.1.2 Approaches to Stemona Alkaloids 
In 1989 Williams and co-workers published the enantioselective total synthesis of (+)-croomine, 
which was the first reported total synthesis of a Stemona alkaloid (Scheme 2-1).83
 
 In their 
pioneering work, 2-1 was completed in a 24-step linear route from (S)-Roche ester (2-2) 
featuring a Sharpless epoxidation (>80% de) on allylic alcohol 2-4 followed by regioselective 
epoxide opening to form the key vicinal stereocenters in 2-7. The pyrrolo[1,2-a]azepine ring 
system was completed by performing a Staudinger-aza-Wittig reaction on azido-aldehyde 2-9 
followed immediately by an iodo-amination on the proximal cis-olefin. Interestingly the final 
cyclization to form the “eastern” lactone proceeded with retention of configuration, suggesting 
anchimeric assistance of the pyrrolidine nitrogen and formation of an aziridinium intermediate 
that was subsequently opened by the methyl ester to afford the observed stereochemical 
configuration. 
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Scheme 2-1. Williams’ total synthesis of (+)-croomine. 
 
The Staudinger-aza-Wittig/iodoamination sequence became a hallmark of Williams’ 
studies on Stemona alkaloids and he also applied this strategy to the syntheses of (–)-stemonine84 
and (–)-stemospironine.85 The Staudinger methodology was applied to the total synthesis of the 
smaller Stemona alkaloid, (–)-stemoamide as shown in Scheme 2-2.86 For the synthesis of the 
pyrrolo[1,2-a]azepine core, Williams used established aldol methodology to set the C(8) and 
C(9) stereocenters of lactone 2-13. Homoallylation and reduction of the ketone provided alcohol 
2-14 that was inverted via the mesylate to afford the key Staudinger substrate (2-15). Closure of 
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the azepine ring under nucleophilic alkylation conditions followed by deprotection and oxidation 
to the lactone completed the first total synthesis of (–)-stemoamide. 
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Scheme 2-2. Williams’ approach to (–)-stemoamide. 
 
In the years since Williams’ publication, stemoamide has become one of the most highly 
targeted of the Stemona alkaloids. Its popularity is likely due to its manageable functionality, 
intriguing contiguous stereochemical pattern, and amenability of the ring system towards 
synthetic creativity, as evidenced by the number of diverse approaches towards the alkaloid. 
Examples of the major strategies- radical cyclizations, cycloadditions, and ring-closing 
metathesis reactions- are presented below. 
Recent syntheses of (–)-9,10-bis-epi-stemoamide and (+/-)-9,10-bis-epi-stemoamide 
reported by Khim (2004)87 and by Cossy (2006),88 respectively, feature a key 7-exo-trig radical 
cyclization perfomed in the final steps of each synthesis to complete the azepine ring (Scheme 2-
3). In the Khim synthesis, an enantioselective Birch reduction and methylation provides 2-19 
possessing a chiral auxiliary, which is removed in the subsequent iodolactonization to afford 2-
20. Lithium hydroxide-mediated fragmentation provides butenolide 2-22, which after coupling 
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with succinimide is converted into radical precursor 2-23. Treatment of the sulfide with n-
Bu3SnH and AIBN generates the radical species that cyclizes in a 7-exo-trig fashion to form syn-
fused (–)-9,10-bis-epi-stemoamide (2-24). 
In Cossy’s synthesis, a more direct route is taken to the identical sulfide, albeit in racemic 
fashion. Alkylation of succinimide with diol 2-25 followed by acylation provides 2-26. Ring-
closing metathesis forms butenolide 2-23 which undergoes an identical 7-exo-trig radical 
cyclization to furnish the racemic bis-epimer of 2-24. 
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Scheme 2-3. Radical cyclization approaches to stemoamide core. 
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A unique approach by Narasaka features the single electron transfer reaction of α-stannyl 
amides to form N-acyl imines, which can be subsequently intercepted with various nucleophiles 
(Scheme 2-4).89
 
 The oxidation of 2-28 to radical cation 2-29 followed by elimination of 
tributylstannyl radical generates imine 2-30 that is trapped by silyl enol ether 2-31 to afford 
ketone 2-33 in 86% yield. Various functional group conversions led to 2-34 and an 
intramolecular cyclization onto the unprotected pyrrolidone ring furnished the 5,7-core and 
allowed for the completion of (±)-2-17. 
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Scheme 2-4. Intermolecular oxidative coupling approach to (±)-stemoamide by Narasaka. 
 
In a recent synthesis reported by Bates and Sridhar,90 the azepine ring was formed by an 
inramolecular propargylic Barbier cyclization (Scheme 2-5). Elaboration of succimimide into 
aminal 2-35 followed by alkylation of the amide, alkynylation, and functional group 
manipulations provided bromide 2-36 in a 10-step sequence. Screening of various metals to 
initiate the Barbier cyclization revealed indium to be superior, affording allene 2-37 in 82% yield 
and a 16:1 ratio of diastereomers. Cyclocarbonylation of the allene formed advanced butenolide 
2-38, which was subsequently reduced to afford the racemate of the target alkaloid. 
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Scheme 2-5. Intramolecular propargylic Barbier cyclization to synthesize (±)-stemoamide by Bates. 
 
In 1997, Jacobi and co-workers reported a 7-step synthesis of (±)-stemoamide featuring a 
key Diels-Alder/retro-Diels-Alder process to set the entire skeleton of target molecule.91 Later 
introduction of the requisite stereochemical elements in the starting material allowed for the key 
[4+2] sequence to operate in an enantioselective manner and provide (–)-stemoamide in ~20% 
overall yield for the 9-step enantioselective route.92
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Scheme 2-6. Diels-Alder/retro-Diels-Alder approach used by Jacobi to form the (–)-stemoamide ring system. 
 
In another example for cycloaddition reactions to access the core of Stemona alkaloids, 
Figueredo and co-workers have reported the intermolecular [3+2] cyclization of nitrone 2-43 
with α,β-unsaturated esters (2-44 and 2-47, Scheme 2-7).93 Following the initial cyclization, the 
mesylate in 2-44 was displaced to provide the polycyclic salt, which was successfully opened 
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using zinc to deliver the Stemona pyrrolo[1,2-a]azepine core. Alternatively, using α,β-
unsaturated lactone 2-47 in the dipolar cycloaddition step provided tricycle 2-48, which when 
opened under identical conditions provided 2-50 as the C(9) epimer, which is a useful 
intermediate for the synthesis of other Stemona alkaloids.82 
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Scheme 2-7. Intermolecular nitrone [3+2] cycloadditions by Alibés and Figueredo to access the pyrrolo[1,2-
a]azepine core of Stemona alkaloids. 
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Scheme 2-8. Ring-closing metathesis approaches to (–)-stemoamide. 
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Given the polycyclic nature of the Stemona alkaloids, it is not surprising that a large 
number of groups targeting the stemoamide ring system have used ring-closing metathesis to 
form the azepine moiety (Scheme 2-8). Mori and Kinoshita are credited with the first application 
of RCM to the synthesis of (–)-stemoamide in their 1996 report.94
88
 Enyne metathesis of 2-52 
(synthesized from (S)-pyroglutamic acid and alkyl bromide 2-51) possessing the conjugated 
alkyne was successful despite potential complications. Gurjar and Reddy published a formal 
synthesis of 2-17 using a carbohydrate-based approach. Borrowing from Williams’ (and, later, 
Cossy’s)  Staudinger approach to form the pyrrolidone ring, Gurjar synthesized diene 2-57, 
which was subjected to Grubbs’ 1st generation ruthenium metathesis catalyst to close the C(6)-
C(7) bond of the azepine ring. Cleavage of the acetonide and deoxygenation provided common 
intermediate 2-59 to complete the formal synthesis. 
In 2004 Sibi and Subramanian used olefin metathesis to close the C(7)-C(8) bond of the 
azepine from diene 2-61 formed by a substrate-directed conjugate addition.95 Lactonization, 
methylation and inversion of the C(9) center completed the synthesis. Olivio and co-workers 
have used an anti-aldol reaction to set the C(9) and C(8) stereocenters prior to azepine and 
lactone formation.96
 
 Oxidation of 2-67 to the lactone allowed for metathesis of the two 1,2-
disubstituted olefins to complete the pyrroloazepine system. Somfai’s group applied RCM in a 
manner reminiscent of Sibi’s cyclization starting from a molecule reminiscent of Mori’s 
approach (2-52). In Somfai’s synthesis, a 1,1-disubstituted olefin was used as a metathesis 
partner for the formation of the C(8)-C(9) bond. The C(9) stereocenter was later installed by a 
nickel hydride reduction of 2-73 prior to α-methylation in a manner similar to Mori and Jacobi. 
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2.1.3 Stemona Alkaloid Synthesis in the Wipf Group 
The Wipf group has maintained an active program in the total synthesis of Stemona alkaloids 
since the discovery and development of the oxidative cyclization of tyrosine to hydroindolines.97
 
 
Wipf and co-workers used stenine and tuberostemonine to showcase the versatility of these 
cyclization products in scaffold-driven total synthesis approaches.  
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Figure 2-1. Conserved hydroindole core found in stenine and tuberostemonine. 
 
2.1.3.1 Total Synthesis of Stenine 
The stenine subfamily of the Stemona alkaloids, characterized by the presence of a 
tetracyclic 5,6,7,5-ring core containing lactone, azepine, and hydroindoline rings, is comprised of 
seven members, with stenine and tuberostemonine representing the most common derivatives. 
The absolute configuration of tuberostemonine was unambiguously established by X-ray analysis 
in 1967 and relayed to other members in this group by simple analogy as well as chemical 
degradations.98 Stenine was originally isolated from Stemona tuberosa in 1967.99 This polycyclic 
alkaloid has attracted a significant amount of synthetic attention, culminating in a number of 
racemic100 and enantioselective101 syntheses starting in 1990 with a pioneering Diels-Alder based 
synthesis by the Hart group at Ohio State University, and most recently complemented by the 
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Aubé group at the University of Kansas, who also accomplished the synthesis of neostenine and 
13-epineostenine by the aza-Schmidt approach.79a,82 As stated previously, the Wipf group used 
stenine and tuberostemonine to showcase the utility of a scaffold-driven total synthesis approach, 
taking advantage of the versatile oxidative tyrosine cyclization to hydroindolines previously 
developed by Wipf and co-workers as outlined in Figure 2-1.97 
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Scheme 2-9. Oxidative cyclization of Cbz-L-tyrosine and optimized conditions. 
 
Following their established protocol,97,102 hydroindoline 2-74 was accessed in one-pot 
from Cbz-protected L-tyrosine (Scheme 2-9). This fragment possesses the 5-6 system conserved 
in 2-75 and fortuitously offers synthetic handles that would allow for the elaboration of this 
privileged structure into the Stemona target. Unlike the hydroindoline system in the natural 
product, 2-74 is oxygenated at C(3a) in a cis-ring fusion that would need to be inverted for the 
synthesis of stenine. Fortunately, the convex nature of 2-74 could be exploited, and 1,2-reduction 
of the benzoyl-protected enone under Luche conditions proceeded by axial attack to provide 
chemical access to the α-face of the molecule, presumably via oxygen chelation to set the 
necessary hydrogen-substituted trans-ring fusion at C(3a). It was hypothesized that reduction of 
the π-allylpalladium complex had the highest chance of success. Not surprisingly, extensive 
optimization was needed to selectively reduce the palladium intermediate at the more hindered 
tertiary carbon. Fortunately the use of catalytic tris(benzylideneacetone)dipalladium(0) 
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chloroform complex (2 mol%), the crystalline and less oxygen-sensitive tribenzylphosphine (8 
mol%), with triethylamine and formic acid in THF at reflux proved to maximize the yield of the 
desired 2-79. 
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Scheme 2-10. Allylic deoxygenation and C(3a) inversion. 
 
Elaboration of 2-79 through oxidation and alkylation steps provided enone 2-80. Luche 
reduction of 2-80 reformed the α-alcohol and allowed for an elegant relay of stereochemistry 
from C(6) to C(4) via an Eschenmoser-Claisen rearrangement, which had been applied by Hart et 
al. in their synthesis of (±)-stenine a few years earlier (Scheme 2-11).100a,100b Following the 
radical decarboxylation of the methyl ester and elaboration of the alkyl side chain, 
iodolactonization of the dimethylamide arising from the Eschenmoser-Claisen rearrangement 
was successful, with specific care being taken to avoid hydrolysis of the acid-sensitive silyl 
ether. Keck allylation of the resulting iodide provided the alkyl functionality present in the 
natural product with retention of stereochemistry, albeit as the propenyl appendage. Following 
the installation of the methyl group on the γ-lactone that proceeded smoothly using lithium 
diisopropylamide and methyl iodide in a 23% HMPA/THF mixture to provide a single 
diastereomer, the carbon-shortened ethenyl moiety (2-85) was revealed following oxidation, 
reduction and Grieco elimination steps. 
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Scheme 2-11. Eschenmoser-Claisen rearrangment and subsequent iodolactonization and methylation to form the α-
methyl-γ-lactone in 2-85. 
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Scheme 2-12. Cyclization and completion of (–)-stenine (2-75). 
 
The remaining challenge in the synthesis was the closure of the azepine ring. Initial 
studies of the endgame strategy where Mitsunobu conditions were used to provide the azepine 
ring by amine displacement of the activated alcohol were unsuccessful when applied to 2-85. 
Thus an amidation approach was used to form the corresponding lactam. Dess-Martin and 
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sodium chlorite oxidations provided the carboxylic acid that, following tandem Cbz-deprotection 
and saturation of the ethenyl chain under hydrogenation conditions, was activated with 
pentafluorophenyl diphenylphosphinate (FDPP)103
 
 and successfully cyclized to afford lactam 2-
87. Conversion of the amide to the thioamide and desulfurization with Raney nickel provided 2-
75 in 73% yield, concluding the first enantioselective synth sesis of (–)-stenine in 25 steps and an 
overall yield of 2% starting from bicycle 2-74. 
2.1.3.2 Total Synthesis of Tuberostemonine 
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Scheme 2-13. Tuberostemonine retrosynthesis and proposed γ–butyrolactone formation. 
 
Using the stenine synthesis as a template, Wipf and co-workers began the campaign 
towards tuberostemonine, confident that the chiral ester moiety of bicycle 2-74 would provide a 
chemical opportunity to elaborate the route. The distinctive γ-butyrolactone moiety in 2-76 
remained the key structural feature that was unaddressed in the stenine synthesis, and synthesis 
of the lactone could be achieved by converting the methyl ester into the Weinreb amide and 
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performing an addition with lithiated orthoester 2-89, containing the requisite methyl-bearing 
stereocenter present in the 5-membered ring. The orthoester could be accessed in a 
straightforward fashion from the bromide of commercially available methyl-(S)-(+)-3-hydroxy-
2-methylpropionate (Scheme 2-13). Diastereoselective reduction of the resulting ketone (2-90) 
followed by acid-mediated cyclization between the newly formed alcohol and orthoester would 
provide the butyrolactone stereospecifically. Several aspects of the stenine synthesis remained 
laborious and required multiple steps to accomplish “one” chemical transformation; for example 
the appendage of the ethyl chain and azepine ring formation were targeted for improvement.  
 In lieu of forming the azepine ring via an amidation-thionation-reduction sequence in the 
final stages of the synthesis as in the case of stenine, the possibility of using an initial ring-
closing metathesis to form the 7-membered ring was pursued (Scheme 2-14). Cyclization of 2-94 
was successful, providing 2-96 in 92% yield using Grubbs’ 2nd generation metathesis catalyst (2-
95; however, differentiation of the two resulting olefins in 2-96 using traditionally selective 
reducing reagents (diimide, borohydride, Wilkinson’s catalyst, etc.) was surprisingly 
unsuccessful. Selective reduction of the azepine ring was finally accomplished by treating the 
enone with thiophenol to temporarily protect the electrophilic alkene, and reducing the azepine 
double-bond using Wilkinson’s catalyst before treatment with DBU to eliminate thiophenol and 
reveal the enone.  
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Scheme 2-14. RCM and reduction to form tricycle 2-98. 
 
Exposure of Weinreb amide 2-99, accessed from ester 2-98 with in situ generated 
organolithium 2-89, provided 2-99 in 76% yield. Treatment of the ketone with L-Selectride led 
to a chelate-controlled reduction to yield a 6-7:1 diastereomeric mixture of alcohols that was 
subjected to TsOH-mediated orthoester hydrolysis in MeOH to afford the butyrolactone and 
deprotect the silyl ether in 70%. Gratifyingly, the lactone was tolerant of the elevated 
temperatures required to initate the [3,3]-rearrangement and 2-101 was isolated, setting the stage 
for selenolactonization to produce 2-102 in 67% yield.  
Following the Keck allylation of selenide 2-102 using AIBN and performing the reaction 
in neat allyltriphenyltin, it was found that achieving selective alkylation of the core lactone over 
the eastern γ-butyrolactone was delicate and small changes to the amount of HMPA/LDA 
complex used in the reaction (i.e. ± 0.1 equivalents) had drastic consequences on the 
composition of the product mixture.  Nonetheless, 59% of the desired material could be isolated 
using the optimal conditions (1.1 equiv. HMPA/LDA) along with 11% of the dimethylated 
material and 22% of recovered starting material. Fortunately, exo-methyl alkylation resulting in 
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the (S)-stereocenter was confirmed by NOESY and 1H coupling constant analysis. Ruthenium-
mediated isomerization using Grubbs’ 2nd generation catalyst and cross-metathesis using 
Hoveyda-Grubbs catalyst (2-104) proceeded well, and final hydrogenation with catyalytic 
palladium on carbon afforded 2-76 in 97%, thus concluding the first enantioselective synthesis of 
tuberostemonine in 27 steps and ca. 1% overall yield from Cbz-L-tyrosine. 
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Scheme 2-15. Completion of tuberostemonine (2-76). 
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2.1.3.3 Hypothetical Biosynthetic Relationship of the Tuberosteminone Family 
Given the structural similarities between many Stemona alkaloids, it is not surprising that 
biosynthetic relationships between the members of several families have been proposed.104 Wipf 
and Li hypothesized on the origins of the tuberostemonine family,105 citing that upon air- or 
Hg(II)-oxidation of tuberostemonine, oxotuberostemonine (2-105) can be isolated (Scheme 2-
16).106
 
 Additional hypothetical but straightforward C,C-bond fragmentation reactions provide 
access to tuberostemonone as well as key intermediate 2-107. Strategic oxidations of 2-107 
followed by intramolecular condensation reactions result in the formation of stemoninine and 
parvistemonine. In practice, if selective cleavage of the hydroindoline group resulting from the 
oxidative cyclization of tyrosine could be realized as outlined in Figure 2-2, this concept could 
prove fruitful for the total syntheses of this family of alkaloids and provide strong support for the 
existence of common biosynthetic intermediates for many Stemona alkaloids. 
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Scheme 2-16. Proposed biosynthetic origins of Stemona alkaloids by Wipf. 
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Figure 2-2. Differential fragmentation concept of hydroindoline 2-74 leading to Stemona alkaloids. 
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2.1.3.4 Hydroindoline Fragmentation Approach to Tuberostemonone 
To test their hypothesis, Wipf and Li investigated the alkoxy radical fragmentations of 
hydroindoline model systems targeting the 9-membered lactam ring of tuberostemonone (2-
106).105 By using the Suárez reagent (PhI(OAc)2, I2),107  hydroindoline 2-110 was converted into 
aminal 2-114 in 73% yield following trapping of the proposed α-aza-radical intermediate (2-
112) and displacement with acetate (Scheme 2-17). Conversion of the acetate to furnish the 
requisite keto-lactam in 2-115 was achieved by oxidation of the in situ-generated iminium ion by 
m-CPBA and pyridine.108
 
 The successful and modest-yielding selective hydroindoline 
fragmentation and subsequent conversion to the 9-membered keto-lactam provided validation for 
the initial synthetic hypothesis and warranted application towards the total synthesis of 
tuberostemonone. 
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Scheme 2-17. Model system for the radical fragmentation of hydroindolines to the 9-membered lactam. 
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Scheme 2-18. Retrosynthetic analysis of tuberostemonone (2-106). 
 
Retrosynthetically, tuberostemonone was simplified to indoline 2-116, identified to be a 
key precursor to the featured fragmentation reaction. Using the C(3a)-hydroxyl unit as a key 
stereochemical directing element, an intramolecular 1,4-conjugate addition was proposed to form 
lactone 2-117. This polycycle could be accessed following enolate alkylation and acylation of the 
hydroindoline arising from the oxidative cyclization of tyrosine. 
Wipf and Pierce tested a wide range of substrates for the efficient and selective alkylation 
of 2-74 and found that the two-step palladium-catalyzed allylic alkylation worked best (Scheme 
2-19).109 Coupling of 2-bromopropionic acid using DCC provided 2-122, which smoothly 
participated in a 1,4-addition under radical conditions to afford advanced intermediate 2-123. To 
complete the requisite functionalization for the completion of the synthesis, appendage of the 
side-chain protected as the benzyl ether can be accomplished using cross-metathesis, and enol 
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triflate formation and coupling will provide the ethyl alkene, on which hydroboration and 
oxidation can be used to install the final hydroxyl group. 
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Scheme 2-19. Wipf and Pierce’s approach towards tuberostemonone. 
 
2.1.3.5 Hydroindoline Fragmentation Approach to Parvistemonine 
Consistent with the hypothesized biosynthetic origins of the Stemona alkaloids (Scheme 
2-16), the Wipf group investigated the selective fragmentation of the C(3a)-C(4) bond in 2-74 for 
the synthesis of parvistemonine as outlined in Figure 2-2. After considerable and unfortunately 
unsuccessful investigation into many model systems for the fragmentation of an azido radical 
species,110 Wipf and Joo attempted to exploit the β-stabilizing effect of silicon to promote a more 
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efficient fragmentation process. In fact, the Posner group had earlier reported the successful 
application of the β-silicon effect in related radical ring expansions of conjugated cycloalkenones 
into homoallylic lactones.111
 
 The requisite model system was synthesized starting from indoline 
2-74 via a conjugate addition of the TMS-methylene side chain (Scheme 2-20). Protection of the 
ketone as the acetal and exposure to the Suárez reagent afforded the desired fragmentation 
product, trapped as the acetate in 50% yield. 
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Scheme 2-20. Radical fragmentation on unstubstituted model system. 
 
Pleased with the vast improvement in selectivity and efficiency using silicon to stabilize 
the radical, the requisite side chain for the subsequent azepine formation was appended to the 
fragmentation precursor via enolate alkylation and functional group manipulations (Scheme 2-
21). Quite interestingly, the internally fragmented product (2-131) was isolated as the major 
product in 23% with only 10% of the desired ketone 2-130 produced. Clearly, incorporation of 
the side-chain had a dramatic effect on the success and selectivity of the fragmentation event, 
possibly due to conformational effects and differences in orbital overlap of the reacting bonds. 
As a last resort, the azepine ring was closed by RCM of 2-132 prior to fragmentation. Once 
again, exposure of 2-132 to the Suárez reagent led to a mixtures of products, with optimized 
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conditions providing a 25% yield of the desired bicycle along with 23% of unreacted starting 
material. Likely, the instability of the C(4) ketone of 2-134 plays a major role in the limited 
success of this process and thus hampers efforts to synthesize parvistemonine via this 
fragmentation route. However, it should be noted that the fragmentation is possible, and 
therefore the hypothesized differential fragmentation of oxotuberostemonine (2-105) to afford 
tuberostemonone and parvistemonine in a biosynthetic context cannot be discounted. 
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Scheme 2-21. Fragmentation reactions of substituted hydroindolines. 
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2.2 RESULTS AND DISCUSSION 
2.2.1 Retrosynthetic Analysis of Parvistemoline 
Having experienced mild but ultimately insufficient success in affecting the selective radical 
fragmentation of indolines for the synthesis of the parvistemonone ring system, our attention 
turned to the related alkaloid parvistemoline (2-135) and the synthesis of the intriguing 5,5-
tetrahydrofuranolactone moiety characteristic of this Stemona sub-family. 
Retrosynthetically, we envisioned forming this unprecedented ring system by performing 
a Michael addition of the furan oxygen into the corresponding butenolide and protonation to set 
the requisite stereocenters (Scheme 2-22). The butenolide unit could be accessed via a known 
method from aldehyde 2-137,112
40
 which would be revealed following a stereoselective aldol 
addition of acetaldehyde to generate the furan precursor fragment in 2-136. To set the adjacent 
stereocenters on the azepine ring we imagined using a [3,3]-sigmatropic rearrangement to relay 
stereochemical information on the α-face of the molecule, in a novel approach to the 5,7-
pyrrolo[1,2-a]azepine of the Stemona alkaloids that is reminiscent of the Eschenmoser-Claisen 
rearrangement in the stenine and tuberostemonine syntheses from our lab. The [3,3]-
rearrangment precursor could be formed by RCM of the azepine ring, and the key stereocenter 
can be set by application of our group’s methodology for the hydrozirconation of alkynes, 
transmetallation to zinc and chiral ligand-directed addition to aldehydes.  The requisite diene 
could be synthesized in a straightforward fashion from the alkylation of known pyrrolidone 2-
141 with commercially available bromoethyl dioxolane (2-142), accessible from ethyl 
pyroglutamate. 
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Scheme 2-22. Initial retrosynthetic analysis of parvistemoline (2-135). 
 
Prior to embarking on the synthesis we decided to study the formation of the 
furanolactone ring by our proposed endgame Michael addition sequence. Therefore, we first 
looked to complete the heterocycle on model system 2-144 using an isopropyl group to mimic 
the azepine ring junction (Scheme 2-23). Butenolide 2-145 could be synthesized from aldehyde 
2-146 which we envisioned arising from an auxiliary-controlled syn-aldol addition with 2-147. 
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Scheme 2-23. Retrosynthesis of model system 2-144. 
 
2.2.2 Model System Study 
Acylation of Evans’ auxiliary with isovaleryl chloride proceeded in good yield and the aldol 
addition under Bu2BOTf conditions with freshly distilled acetaldehyde provided 2-147 in high 
yield and excellent diastereoselectivity (Scheme 2-24). The newly generated hydroxyl group was 
subsequently protected as the TIPS and PMB ethers. At the same time, the oxazolidinethione, 
known for its increased chelation and lability during deprotection,113
 
 was also used in the aldol 
sequence to afford 2-154, albeit in lower yield diastereoselectivity under the titanium conditions. 
TBS protection of the aldol product afforded silyl ether 2-155 in 93% yield. 
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Scheme 2-24. Diastereoselective aldol additions using a. oxazolidinone and b. oxazolidinethione auxiliaries and 
protection of the resulting alcohols. 
 
With the variety of aldol adducts in hand we attempted to remove the chiral auxiliary; 
however, we were not successful despite exploring a wide range of conditions (Scheme 2-25). In 
practice we found that reagents preferred to react with the carbonyl/thiocarbonyl function of the 
hererocyclic ring to provide ring-opened products exclusively. Opening of the oxazolidinone ring 
with sodium methoxide in methanol cleanly provided 2-161, which we imagined could perform a 
transesterification under acidic conditions. In fact, heating the primary alcohol in acidic methanol 
in the microwave initiated the rearrangment (presumably driven by protonation of the more basic 
nitrogen atom). To our surprise, attempts to reduce ester 2-162 using LAH failed, which we 
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attributed to formation of the aluminum amide and metal-assisted transamidation prior to ester 
reduction. 
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Scheme 2-25. Difficulty removing the oxazolidinone/oxazolidinethione auxiliary. 
 
With the removal of the auxiliary proving to be problematic, we abandoned the 
enantioselective approach to 2-144 and focused on forming the correct bond connectivity in a 
racemic fashion. In a straightforward manner, ethyl acetoacetate was alkylated with isopropyl 
iodide in 65% yield to afford 2-166. Chelated reduction using freshly prepared Zn(BH4)2 
afforded a 6:1 mixture of syn:anti products. Protection of the newly formed alcohol as the TES 
ether and reduction gave 2-168. Surprisingly, when the alcohol was exposed to mild oxidative 
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conditions (Swern, TPAP/NMO, Parikh-Doering) the carboxylic acid was the only product 
observed by 1H NMR and IR spectroscopy. We rationalized this overoxidation by the activation 
of the generated aldehyde by the neighboring, mildly coordinative TES group (2-171) to 
facilitate further oxidation from the +2 oxidation state to the +3 state of the carboxylate. 
Revising the protective group strategy to the MOM ether (2-172) allowed for the successful 
formation of aldehyde 2-173 under previously unsuccessful conditions. 
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Scheme 2-26. Synthesis of aldehyde 2-173 of the racemic model system. 
 
Vinyl Grignard addition to 2-173 proved to be rather unselective, providing a mixture of 
allylic alcohols that were acylated using methacryloyl chloride to afford 2-175. RCM by periodic 
addition of Grubbs 2nd generation catalyst formed the butenolide ring in 2-176 in 82% yield. 
Smooth MOM deprotection was followed by a base-induced Michael addition of 2-177 to afford 
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a mixture of cyclized diastereomers. Gratifyingly, the major isomer (2-178, assigned by 1H NMR 
coupling constant analysis) could be separated by MPLC purification. 
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Scheme 2-27. Completion of the racemic model system by RCM and Michael addition. 
 
2.2.3 Synthesis of the 5,7-Pyrrolo[1,2-a]azepine Core 
Confident that our endgame strategy had a reasonable chance of success, we began the 
synthesis of parvistemoline from (S)-ethyl pyroglutamate (2-143, Scheme 2-28). Reduction to 
the alcohol followed by protection as the TBS-ether set the stage for alkylation with 2-142 and 
deprotection to unmask the primary alcohol in 2-182. Oxidation to the aldehyde followed by 
Wittig olefination gave the precursor to the aliphatic aldehyde, which was revealed by p-TsOH 
in THF/H2O under microwave heating. The low yields in this sequence reflect a surprisingly 
high water solubility of the intermediates and associated difficulties in purification. 
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Scheme 2-28. Synthesis of aldehyde 2-184 from ethyl pyroglutamate. 
 
In 1998, Wipf and Ribe reported the successful use of amino-thiol ligand 2-185 in 
affecting asymmetric additions of vinylzinc reagents, generated from the corresponding 
vinylzirconocenes via transmetallation, to aliphatic and aromatic aldehydes.40 Having 
synthesized aldehyde 2-184 we sought to apply the same conditions to our system; however upon 
multiple attempts both in the presence and absence of ligand no addition product was observed. 
It is possible that in situ oligomerization of the aldehyde unit or intramolecular cyclization of the 
amide into the aldehyde could account for the observed behavior. While we have no empirical 
data to support such a claim, 2-184 was similarly unreactive towards the addition of 
vinylmagnesium chloride indicating the nucleophile in the former reaction was not solely 
responsible for the lack of conversion. 
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Scheme 2-29. Addition attempts to aldehyde 2-184. 
 
Upon failing to achieve the desired aldehyde addition, we revised our approach in favor 
of a convergent route that would incorporate the C(7) stereocenter as a pre-set fixture in one of 
the fragments. As shown in Scheme 2-30, our revised plan involved the alkylation of vinyl 
pyrrolidone with iodide 2-188 containing the chiral allylic alcohol. RCM and acylation would 
provide our [3,3]-rearrangment precursor as we had planned before, however, due to the 
difficulty of affecting a stereoselective aldol addition on our model system, we decided to 
investigate whether incorporating substitution in the [3,3]-reaction to form 2-191 from 2-190 
would be feasible. 
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Scheme 2-30. Revised, convergent approach to parvistemoline. 
 
Discouraged by the inefficiency and low yields of our initial route to pyrrolidone 2-141, 
we decided to pursue an alternate strategy. Known methods of constructing 2-141 involve 
laborious purifications, redox processes, or low-yielding eliminations.114 We believed we could 
take advantage of the known reduction of the thioamide group under palladium catalysis to the 
aldehyde, the Fukuyama reduction,115 which would allow for a Wittig olefination to install the 
requisite alkene. Along these lines, the carbodiimide-mediated coupling of (S)-pyroglutamic acid 
and ethanethiol proceeded on large scale to afford the corresponding thioester in 71% yield 
following purification (Scheme 2-31). Quite surprisingly given the well-documented substrate 
tolerance of the Fukuyama conditions, thioamide 2-192 did not react in the presence of catalytic 
palladium and triethylsilane. It was found that protection of the amide was necessary to affect the 
desired reduction, which, once it did proceed, was complete in under 10 minutes. Isolation of the 
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crude aldehyde (2-193) and immediate exposure to Wittig conditions to minimize racemization 
of the aminoaldehyde provided the target compound in 91% yield over the two-step sequence. 
The N-Boc group initially installed for the Fukuyama reduction was in fact necessary for the 
preservation of the vinyl pyrrolidone product which, when unprotected, decomposed in a matter 
of hours. With the carbamate in place, 2-195 was benchtop stable for months with no noticeable 
decomposition by 1H NMR analysis. Overall, this sequence provided our desired vinyl 
pyrrolidone in 4 steps (3 purifications) on multigram (>10 g) scale and was a considerable 
improvement over known literature methods. 
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Scheme 2-31. Improved route to pyrrolidone 2-195 featuring a Fukuyama reduction/Wittig olefination sequence. 
 
Next, we had the task of preparing the known iodide 2-188. Following a literature 
protocol, PMB-protected 3-butyn-1-ol was homologated using paraformaldehyde, followed by 
conversion to the trans-olefin using Red-Al (Scheme 2-32, route A). Sharpless asymmetric 
epoxidation of 2-197 provided the allylic epoxide that was converted to the primary iodide for 
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epoxide opening and formation of chiral allylic alcohol 2-199 under zinc conditions. Protection 
of the newly formed alcohol as the TBS-ether and removal of the PMB group allowed for 
primary iodide formation to complete 2-188. While the desired material was accessible, the route 
was step intensive (8 steps from commercial materials) which hindered material throughput. 
Unfortunately the asymmetric epoxidation step proved to be particularly sensitive to reaction 
conditions, reagent quality and scale, making it a poor choice for introducing the chiral element 
into our substrate. Ultimately, we opted for a shorter route that would provide optically pure 
material in a more direct sequence. 
In 2002, Pu and co-workers reported the Ti-BINOL-mediated addition of alkynylzinc 
reagents to aldehydes.116 The Wipf group applied these addition conditions to the synthesis of 
disorazole C1 using TMS-acetylene and aldehyde 2-200 in 2004.117
Finally, we decided to pursue a chiral resolution route to access the allylic alcohol 
following a route developed by De Risi, Polliini and co-workers in for their studies on the 
Geissman-Waiss lactone
 Following the 2004 protocol, 
aldehyde 2-200, obtained on large scale in 2 steps from commercial materials, was subjected to 
the addition conditions to afford propargyl alcohol 2-201 in 75% yield and good 
enantioselectivity by comparison of optical rotation data (Scheme 2-32, route B). Removal of the 
TMS group and reduction to the alkene using Schwartz reagent furnished the allylic alcohol 
moiety. TBS protection and selective cleavage of the primary silyl ether using acidic methanol at 
low temperature followed by iodination successfully provided 2-188. While route B proved to be 
shorter than the epoxidation route, it suffered from the need to use neat diethylzinc in the 
enantioselectivity-defining step, which limited the scalability for obvious safety concerns. 
118 and later applied by Ghosh and co-workers in their synthesis of 
largazole.119 Alcohol 2-202, prepared in one-step from tert-butyl acetate,120 could be selectively 
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acylated by PS Amano lipase in the presence of vinyl acetate in refluxing pentane. The resulting 
products could be separated and the desired enantiomer (2-203) was hydrolyzed and re-protected 
as the TBS-ether (2-205). Direct reduction of the tert-butyl ester to the alcohol using 3 
equivalents of DIBAL-H or other metal hydride reagents led to the formation of unidentifiable 
side products and a decreased yield of the isolated product. We found the best strategy was to 
reduce 2-205 to the aldehyde using DIBAL-H (no side products detected) and treat the crude 
aldehyde with sodium borohydride in methanol. In a similar manner to the previous two routes, 
iodination of the alcohol provided our desired material on multigram scale. The chiral resolution 
route proved to be superior for our purposes given the scalability of the enzymatic resolution 
(perfomed on ~40g scale without complication) and the ability to recycle batches of enzyme in 
successive reactions. A large amount of chiral material could be produced in a facile process at 
the beginning of the synthetic sequence, thus minimizing resources bringing racemic material 
forward to the resolution step. 
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Scheme 2-32. Routes used to synthesize iodide 2-188. 
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Scheme 2-33. Pyrrolo[1,2-a]azepine core completed by alkylation and RCM. 
 
With our alkylation components in hand, we were ready for segment condensation 
following the deprotection of the N-Boc group of 2-195, taking care to avoid loss of the volatile 
material upon workup. Initially, the alkylation was performed with sodium hydride and TBAI in 
DMF; however, the yields were irreproducible (40-76%) and extended reaction times were 
required. Fortunately, phase-transfer conditions proved to be superior in terms of reproducibility 
and rate as well as scalability to allow for the production of 2-189 on multigram scale. RCM of 
the diene using Grubbs 2nd generation catalyst (2-95) and completion of the pyrrolo[1,2-
a]azepine core proceeded in 98% yield. Deprotection of the unstable TBS-ether under acidic 
conditions afforded our key allylic alcohol (2-208), which was found to be sensitive to oxygen 
(oxidation at C(9a) of the homoallylic amide), water soluble, and quite hygroscopic. 
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2.2.5 [3,3]-Sigmatropic Rearrangement Strategy 
At this point, we transformed 2-208 into the β-keto ester in anticipation of performing a Carroll 
rearrangement that would furnish the desired oxidation state at C(16) needed to form the 
furanolactone ring system as demonstrated in our model system. Acylation of 2-208 using the 
acetone adduct of diketene (2-209) proceeded in 53% yield (Scheme 2-34). However, prior to 
performing the [3,3]-rearrangement, we observed a dynamic keto-enol tautomerism, evident in 
the 1H NMR spectrum of 2-210 (δ 11.9 ppm, Scheme 2-34), and we foresaw certain 
epimerization of the product β-keto acid 2-211, thereby sabotaging our efforts to install the 
correct configuration at C(10). 
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Scheme 2-34. Synthesis and 1H NMR spectrum of β-keto ester 2-210. 
 
Rethinking our rearrangement strategy, we believed the most convergent pathway to our 
desired product would be to use ester 2-214 containing the requisite chiral secondary alcohol pre-
installed, which would not participate in tautomerizaiton to racemize the α-stereocenter (Scheme 
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2-35). However, under the strongly basic conditions required to form the silyl ketene acetal 
intermediate of the Ireland-Claisen reaction the β-oxygenation would certainly lead to 
elimination. Our solution was to make the substrate containing a dimethylphenylsilyl group (2-
216) that would act as a non-eliminating placeholder for later introduction of the required 
oxygenation through a late-stage Tamao-Fleming oxidation. These reactions occur with retention 
of configuration so no additional redox steps would be needed, and the remaining functionality 
should be tolerant of the selective transformation of the silane. 
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Scheme 2-35. [3,3]-Sigmatropic rearrangment strategy revisited. 
 
2.2.6 Eschenmoser-Claisen Rearrangement and Synthesis of epi-Stemoamide 
What still remained unknown to us was whether any [3,3]-sigmatropic reaction could 
take place on the concave face of the pyrroloazepine core at the sp2-hybridized C(8)-carbon 
adjacent to the C(9)-stereocenter responsible for the concavity of the bicyclic system. We 
decided to attempt the Eschenmoser-Claisen rearrangement to probe the reactivity, both due to 
its prior successful use in our stenine and tuberostemonine syntheses as well as the increased 
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nucleophilicity of the enamine intermediate to facilitate the rearrangement. Gratifyingly, 
treatment of 2-208 to the rearrangement conditions (excess dimethylacetamide dimethylacetal in 
diglyme at 180 °C under microwave heating for 15 min) afforded dimethylamide 2-219 (Scheme 
2-36). 
While analyzing the structure of 2-219, we were struck by the relation of the product to 
the stemoamide core and the resemblance of this intermediate to those found in prior syntheses 
of the tricyclic alkaloid (Section 2.1.2, Scheme 2-8). Once again using conditions from our 
stenine and tuberostemonine work, dimethylamide 2-219 was subjected to iodolactonization 
using a buffered solvent system to provide the corresponding lactone in excellent yield. Radical 
de-iodination of 2-220 proceeded smoothly to afford the unsubstituted ring system of 
stemoamide, and we were able to install the methyl group using conditions reported by Sibi to 
complete the first total synthesis of (–)-8-epi-stemoamide in a total of 12 steps and 14.3% overall 
yield from pyroglutamic acid. It is worth noting the originality of our approach to the 
stemoamide core compared to those outlined in section 2.1.2. While we employ an RCM strategy 
for the construction of the pyrroloazepine core as other groups have previously done, we 
successfully relay the stereochemical information from C(7) to C(9) in what is a novel 
transformation for this class of Stemona alkaloids.  
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Scheme 2-36. Successful Eschenmoser-Claisen rearrangement and synthesis of 8-epi-stemoamide. 
 
Interestingly, iodide 2-220 was labile towards basic conditions and the elimination 
product (2-223) could be formed upon treatment with DBU. Enolate alkylation of this 
intermediate provided 2-224, possessing the vinyl lactone handle which could be of potential use 
in future studies of related alkaloids. 
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Scheme 2-37. Iodide elimination and alkylation of lactone 2-223. 
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2.2.7 Sessilifoliamides and Hypothetical Biosynthetic Relationship to Parvistemoline 
Having demonstrated the success of the [3,3]-rearrangement and the opportunistic use of the 
product for the synthesis of the stemoamide epimer, we now investigated whether alkyl 
substitution on the rearranging fragment would be tolerated and what the stereochemical 
consequences would be. Initially, we were hesitant to investigate the substitution pattern 
containing the proposed bulky silane moiety (2-216, Scheme 2-35) for fear of hindering 
reactivity, and a more gradual investigation (i.e. saturated alkyl chain) into tolerated substitution 
was encouraged by the 2003 isolation of the sessilifoliamde family of Stemona alkaloids and 
their striking similarities to parvistemoline (Scheme 2-38).121
 
 Sessilifoliamides A-D were 
isolated from the roots of Stemona sessilifolia along with five known alkaloids including stenine 
(2-75), 2-oxostenine and tuberostemonone (2-106). The structures of 2-225-2-228 were 
unambiguously determined by X-ray crystallography and chemical derivatization. In a similar 
manner to our proposed biosynthetic relationship between tuberostemonine, tuberostemonone 
and parvistemonone (Scheme 2-16), parvistemoline and the individual sessilifoliamides can be 
related through oxidation and cyclization events as shown in Scheme 2-38. Developing a strategy 
to take advantage of these structural similarities for a total synthesis would be highly desirable 
and would lend support to the idea of common biosynthetic precursors. In our case, the common 
strategy would begin with the successful [3,3]-rearrangement and the ethyl substitution pattern 
conserved throughout the sessilifoliamides. 
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Scheme 2-38. Hypothesized biosynthetic relationship between the sessilifoliamides and parvistemoline. 
 
We initially opted to attempt the Johnson orthoester Claisen conditions for the alkyl-
substituted [3,3]-sigmatropic rearrangement in lieu of the Eschenmoser-Claisen protocol due to 
the commercial availability of a variety of orthoesters and the ease of functionalizing the 
resulting compounds (i.e. methyl/ethyl ester vs. dimethylamide/morpholine amide). Alcohol 2-
208 was treated with excess triethylorthobutyrate (2-229) and catalytic acid in o-dichlorobenzene 
for 2 days at 130 °C to provide a 42% yield of ethyl esters 2-230a and 2-230b in a 2.5:1 mixture 
of diastereomers, which could be successfully separated by MPLC purification. Varying the acid 
source, reaction temperature, solvent, heating method and the time of the reaction did not appear 
to have dramatic effects on the outcome of the reaction (Table 3-1). Interestingly, entries 5 and 6 
indicate that acid is not necessary for the rearrangement to occur, however the overall yield 
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suffers. In regards to stereoselectivity, there was a mild increase in the d.r. of the reaction 
products when o-DCB was used as a solvent instead of xylenes. In many reactions at elevated 
temperatures the remaining mass balance was the corresponding ketone of the starting material, 
indicating an acid-mediated oxidation of the allylic alcohol was operative under the reaction 
conditions. 
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Scheme 2-39. Orthoester Johnson-Claisen  rearrangement to produce 2-230a and 2-230b. 
 
Table 2-1. Conditions screened for the Johnson-Claisen rearrangement in Scheme 3-39. 
Reaction Solvent Acid (10 mol% ) Temperature Time Yield d.r. 
1 Xylenes Propionic acid 130 °C 2 h n/a - 
2 Xylenes CSA 130 °C 2 h n/a - 
3 Xylenes 2,4,6-trichlorophenol 130 °C 2 h 37% 1.3:1 
4 Xylenes HCl/dioxane 130 °C 2 h 52% 1.6:1 
5 Xylenes - 130 °C 4 h 39% 1.6:1 
6 o-DCB - 200 °C (µW) 40 min 30% 2:1 
7 o-DCB HCl/dioxane 240 °C (µW) 40 min 36% 2.1:1 
8 THF HCl/dioxane rt 4 days n/a - 
9 o-DCB HCl/dioxane 130 °C 2 days 42% 2.5:1 
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We concluded that increasing the diastereoselectivity of the orthoester Claisen 
rearrangement by varying the reaction conditions was not likely to be successful. Therefore, we 
wanted to assess the feasibility of using steric effects to accomplish our goal, and we proposed 
that increasing the bulk of the alkyl groups on the orthoester carbon would affect the transition 
state of the reacting ketene acetal. There are few literature reports of acyclic, bulky orthoesters, 
and certainly none have been used in a [3,3]-rearrangement. Reported methods of forming 
acyclic orthoesters are extremely few, essentially falling into two categories: 1) Pinner reaction 
of nitriles to amidates and alcoholysis to the corresponding orthoester and 2) Brønsted acid-
mediated thermal displacement using LeChatelier’s principle.122 The Pinner method for 
orthoester formation requires lengthy reaction times to fully convert the amidate intermediate 
into the orthoester, and was shown to be extremely sensitive to steric factors.123
 
 The 
displacement method proved to be optimal for the formation of β-branched orthoesters with the 
sole condition being a significant boiling point difference between the alcohol to be incorporated 
and that which is departing form the orthoester- in our case, ethanol. Attempting to incorporate 
α-branching into the orthoester was unsuccessful, providing incomplete conversion and several 
side products (hydrolysis of the orthoester to the ethyl ester being the major constituent) by 13C 
NMR spectroscopy of the crude reaction mixture. 
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Scheme 2-40. Branched orthoesters produced by trans-orthoesterification. 
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Scheme 2-41. Johnson-Claisen rearrangement on a model system using substituted orthoesters. 
 
Table 2-2. Screening various orthoesters in the Johnson-Claisen rearrangement of 2-238 shown in Scheme 2-41. 
orthoester d.r. 
2-229 1.5-2 : 1 
2-231 2 : 1 
2-232 2 : 1 
2-233 2 : 1 
2-234 NR 
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To assess the capacity of the substituted orthoesters to increase the diastereoselectivity of 
the [3,3]-rearrangement, we used allylic alcohol 2-238 as a model system possessing the geminal 
dimethyl substitution pattern to mimic the ring junction of the Stemona molecules and thus 
sufficiently increase the steric environment at the reacting sp2-hybridized carbon. Exposure of 2-
238 to the thermal reaction conditions using 2-229-2-234 proved to us that β-branched 
orthoesters did not sufficiently increase the diastereoselectivity of the rearrangement. Since we 
were unsuccessful in forming any α-branched orthoesters that would increase the steric 
environment closer to the reacting atoms we turned our attention elsewhere. 
Concurrent to the orthoester study, we were investigating the feasibility of performing the 
[3,3]-sigmatropic rearrangement possessing the β-silane moiety in a one-pot, Eschenmoser-
Claisen-like process. To set the silicon-bearing stereocenter, we followed methodology reported 
by Fleming and co-workers describing the conjugate addition of dimethylphenylsilyllithium to 
enones directed by Koga’s lactam auxiliary (Scheme 2-42).124 The auxiliary was smoothly 
removed using lithium methoxide to provide ethyl ester 2-241, and the lactam would be easily 
recovered following chromatography of the reaction mixture on SiO2 to isolate 2-242 by flushing 
the column with dichloromethane. Reduction of the ester to the alcohol using LAH followed by 
Swern oxidation afforded aldehyde 2-242. Conversion of the aldehyde into the nitrile using 
NH4OH and I2125
 
 provided the precursor for orthoester formation. Unfortunately, the silane 
proved too labile for the harsh conditions required for the Pinner reaction and decomposition of 
the nitrile occurred rapidly. 
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Scheme 2-42. Diastereoselective silane addition and attempt to form orthoester via the Pinner route. 
 
Alternatively, we succeeded in synthesizing the cyclic OBO-orthoester derivative (2-247) 
through saponification of ester 2-241 and carbodiimide coupling of oxetane 2-245 to provide 2-
246, which upon treatment with BF3·OEt2 cyclized to form the orthoester in 78% yield. 
However, attempts to perform an intermolecular trans-orthoesterification were unsuccessful, as 
was performing a Johnson-Claisen rearrangement with 2-247 in the presence of methanol, 
hoping to intercept the intermediate oxocarbenium ion and affect irreversible C-C bond 
formation. 
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Scheme 2-43. Synthesis of OBO orthoester 2-247. 
 
As a final effort, we imagined a way to access the adduct of alcohol 2-208 with the β-
silane fragment and we hypothesized that an activated amide (or imidate) similar to that which is 
generated under the Eschenmoser-Claisen conditions could have a chance at success. Towards 
this goal, EDC-coupling of acid 2-244 and dimethylamine provided the corresponding dimethyl 
amide (2-248, Scheme 2-44). Activation of the amide with dimethylsulfate provided our target 
compound, imidate 2-249. Once again, the desired transformation remained elusive with reaction 
between the lithium alkoxide of 2-208 and 2-249 only supplying methylated material, indicating 
a polarized O-Me bond and consequent facile methyl transfer compared to addition to the C-N π-
bond. Attempts to convert 2-249 into the corresponding dimethylacetal under basic and acidic 
conditions were not fruitful. To combat the methyl transfer problem, we synthesized the 
corresponding thio-analog (2-252); presumably a less polarized S-Me bond could suppress 
methyl transfer to the alkoxide in the rearrangement step. Thioamide 2-251, formed using 
Lawesson’s reagent from 2-248, was alkylated using Meerwein’s salt to provide 2-252. Using 
this reagent in the alkoxide addition pathway did not produce any detectable methylated product 
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2-250, however no rearrangement product could be observed either. 1H NMR monitoring of the 
reaction in C6D6 did not reveal any conversion between the thioimidate and the lithium salt of 2-
208. 
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Scheme 2-44. Formation of a. imidate 2-249 and b. thioimidate 2-252 and attempted [3,3]-rearrangements. 
 
2.2.8 Ireland-Claisen Rearrangement and Application to Sessilifoliamides and 
Parvistemoline 
With our hopes of a facile one-pot [3,3]-rearrangement dwindling, we returned to our initial 
strategy of using an Ireland-Claisen reaction (Scheme 2-45), and we initially chose the ethyl 
substitution pattern of the sessilifoliamides to test our route. Esterification of 2-208 using butyric 
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acid and DCC afforded 2-253 in high yield. Using conditions reported by Kishi for silyl ketene 
acetal formation and rearrangement of glycal esters,126 the TBS-ketene acetal was isolated and 
subjected to heating in toluene to affect the rearrangement. To our pleasure the silyl ester was 
formed in the reaction and it was immediately subjected to deprotection with TBAF.127
 
 
Methylation of the crude acid allowed for straightforward isolation of 2-255a and 2-255b in 21% 
yield over the 4-step sequence. Unlike ethyl esters 2-230a and 2-230b, the methyl esters could 
not be separated by MPLC, although isolation of the mixture did confirm the diastereoselectivity 
of the rearrangement to be an unremarkable 2.2:1 ratio. 
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Scheme 2-45. Ireland-Claisen rearrangement of 2-253 and conversion to the corresponding methyl ester. 
 
Once again we were met with a less than desirable selectivity in the rearrangement event. 
From our initial studies on the Johnson-Claisen rearrangement we hypothesized modified steric 
parameters would have the greatest chance for increasing the diastereoselectivity in the 
rearrangement. Therefore, we attempted the Ireland-Claisen sequence using triisopropylsilyl 
chloride in place of TBSCl to bias the steric environment of the transition state further (Scheme 
2-46). As for the TBS-ketene acetal, heating the TIPS-ketene acetal in toluene for 2 hours 
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initiated the [3,3]-rearrangement to produce what appeared to be an increased ratio of silyl esters 
2-257a and 2-257b. Desilylation followed by methylation and purification by MPLC confirmed 
the increase in diastereoselectivity, and much to our delight 2-255a and 2-255b were obtained in 
34% yield as a 7.1:1 ratio of methyl esters. 
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Scheme 2-46. Effect of using the TIPS-ketene acetal (2-256) in the Ireland-Claisen rearrangement. 
 
We propose the nearly four-fold increase in diastereoselectivity to be a result of a 
significant destabilization of one of the two possible transition states for the rearrangement 
(Figure 2-3). As suggested by Ireland128 126 and more recently by Kishi,  Ireland-Claisen 
rearrangements on cyclic substrates proceed via chair-like or boat-like orientations of the 
reacting atoms. We hypothesize that by increasing the steric environment around silicon by 
going from TBS to TIPS, we are significantly destabilizing the chair transition state (TS) 
orienting the silicon atom underneath the 5,7-ring system, which favors the boat TS holding the 
silane away from any steric interaction with the azepine ring. It is worthwhile to note that 
although the TBS-ketene acetal does possess a tert-butyl group we imagine it would likely be 
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held in an axial orientation away from the ring system to minimize sterics, thereby orienting the 
two methyl groups on silicon towards the ring. Therefore, perhaps a more accurate comparison 
of the steric environments around silicon in the TS of the rearrangement would be TMS vs. 
TIPS. Although we have not performed this reaction we would expect the TMS ketene acetal to 
give similar diastereoselection as observed with TBS. Additionally, this TS analysis could 
explain the similar selectivity in the Johnson-Claisen and Ireland-Claisen reactions (ethyl ketene 
acetal vs. methyl silyl ketene acetal). 
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Figure 2-3. Proposed transition states for the Ireland-Claisen rearrangement. 
 
Having enjoyed success with the ethyl substitution pattern in the Ireland-Claisen 
rearrangement, we synthesized β-silyl ester 2-262 from 2-208 and 2-244 to determine whether 
our optimized [3,3]-rearrangement conditions could be successfully applied to the silyl-bearing 
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derivative. Treatment of 2-262 with TIPSCl and LiHMDS in a 23% THF/HMPA mixture at –78 
°C generated 2-263 and heating this material in distilled, degassed xylenes at reflux provided a 
mixture of products by 1H NMR, with a very small amount of the desired [3,3]-product 2-264 
present. We re-attempted the Ireland-Claisen protocol using TBSCl to determine if a less 
sterically demanding silyl ketene acetal was required for the [3,3]-rearrangement to occur in the 
presence of the bulky silane moiety in 2-262. While 2-265 formed without issue, the 
rearrangement conditions once again provided a mixture of compounds, although it did provide a 
better ratio of 2-266 to various side products than when 2-265 was used. From the crude reaction 
mixture silyl ester 2-266 could be isolated in 11% yield after chromatography on deactivated 
SiO2, although it remained contaminated with several unidentifiable compounds by 1H NMR 
analysis. After attempting several different rearrangement conditions (o-DCB, 240°C, µW, 30 
min; toluene, reflux, 2 h) and seeing no change in the ratio of products, we concluded that using 
the silane substitution as a placeholder for the necessary oxygenation at C(16) for the completion 
of parvistemoline would not be compatible with the Ireland-Claisen strategy due to steric effects. 
 
 100 
N OH
O
O
1. LiHMDS, R3SiCl,
THF/HMPA, 
–78 °C, 2 h
N OH
O
R3SiO
2. xylenes
reflux, 1 h N OH
HO
TIPSO
PhMe2Si
2-244,
EDC-HCl,
DMAP
CH2Cl2
93%
2-208
2-262
R = TIPS (2-263)
R = TBS (2-265)
R = TIPS (2-264)
R = TBS (2-266), <11%
PhMe2Si
PhMe2Si
H
N OH
H
O
O HH
H
O
Parvistemoline
(2-135)
steps
16
16
 
Scheme 2-47. Ireland-Claisen rearrangement attempts using 2-262. 
 
Despite failing to achieve the Ireland-Claisen reaction possessing the requisite silane 
substitution for the synthesis of parvistemoline, we had managed to increase the 
diastereoselectivity of the ethyl-substituted rearrangement products to a respectable level. 
Therefore, we forged onwards towards the sessilifoliamides. While methyl esters 2-255a and 2-
255b could not be separated by MPLC, the minor diastereomer arising from the C(9a) 
stereocenter of the pyrrolidone 2-195 as well as side products from the [3,3]-rearrangement could 
be removed at this stage (Scheme 2-47). Additionally, we discovered that the use of distilled, 
degassed xylenes to suppress oxidative decomposition of the silyl ketene acetal during heating 
provided the desired [3,3]-products in a much improved 51% yield over the sequence. 
Nucleophilic addition to the ester in 2-255a proved to be challenging as attempts to add Grignard 
and organolithium reagents were unsuccessful, returning unaltered starting material. 
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Additionally, attempts to convert the methyl ester to the corresponding Weinreb amide, even in 
refluxing toluene, were similarly unsuccessful in affecting any reaction with the ester. Therefore, 
we decided to generate a more flexible skeleton and lower the oxidation state to the aldehyde to 
affect reactivity. Hydrogenation of the endocyclic double-bond and conversion of the methyl 
ester to the aldehyde provided 2-267, which could be separated from its diastereomer at this 
stage. Gratifyingly, addition to the aldehyde using vinylmagnesium bromide provided a 2:1 
mixture of allylic alcohols that were acylated using methacryloyl chloride, as per our initial 
model studies on the furanolactone moiety, in a one-pot sequence. Direct subjection of unstable 
allylic esters 2-269a and 2-269b to RCM conditions closed the butenolide ring in 84% yield, and 
separation of the diastereomers by MPLC revealed the major isomer to be sessilifoliamide C by 
comparison of the natural and synthetic 1H and 13C NMR data (Tables 2-2, 2-3). Notably, there 
exists a discrepancy between the mangnitudes of our measured specific rotation ([a]D23 –84.6 (c 
0.25, CHCl3); –43.4 (c 5.0, EtOH) of 2-227 and that which has been reported for sessilifoliamide 
C ([a]D26 –140° (c 0.17, CHCl3).121 In summary, 2-227 was synthesized in 18 steps from (S)-
pyroglutamic acid and in 5.6% overall yield. 
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Scheme 2-48. Completion of sessilifoliamide C. 
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Table 2-3. 1H NMR comparison of synthetic and natural 2-227. 
C# Natural121 – 1H δ[ppm], mult (J) CDCl3, 
(500 MHz) 
Synthetic – 1H δ[ppm], mult (J) (600 
MHz) 
1 1.67, m 
1.95, m 
1.70-1.66, m 
1.98-1.92, m 
2 2.38, m 
2.38, m 
2.43-2.33, m 
2.43-2.33, m 
5 2.66 brt (12.3 Hz) 
4.04, brd (12.9 Hz) 
2.66, dt (1.3, 13.6 Hz) 
4.03, dt (3.2, 13.6 Hz) 
6 1.45, m 
1.72, m 
1.49-1.41, m 
1.74-1.72, bm 
7 1.34, m 
1.88, m 
1.40-1.30, m 
1.90-1.86, bm 
8 1.35, m 
1.68, m 
1.40-1.30, m 
1.70-1.66, m 
9 2.20, m 2.20, ddd (5.8, 8.3, 8.3 Hz) 
9a 3.93, m 3.93, ddd (5.9, 5.9, 10.7 Hz) 
10 1.67, m 1.70-1.66, m 
11 5.16, brd (1.9 Hz) 5.17, bm (2.1 Hz) 
12 7.02, d (1.4 Hz) 7.03, bm (1.6 Hz) 
15 1.94, d (1.5 Hz) 1.95, t (1.6 Hz) 
16 1.20, m 
1.36, m 
1.19, sept (7.3 Hz) 
1.40-1.30, m 
17 0.85, t (7.4 Hz) 0.84, t (7.6 Hz) 
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Table 2-4. 13C NMR comparison of synthetic and natural 2-227. 
C# Natural121 – 13C δ[ppm], CDCl3, (125 
MHz) 
Synthetic – 13C δ[ppm], (150 MHz) 
1 22.0 22.1 
2 30.8 31.0 
3 174.4 174.6 
5 40.6 40.7 
6 28.8 29.0 
7 29.4 29.5 
8 24.5 24.6 
9 43.3 43.3 
9a 60.8 60.9 
10 44.2 44.2 
11 82.1 82.3 
12 148.3 148.2 
13 130.4 130.5 
14 174.3 174.5 
15 10.7 10.9 
16 19.1 19.1 
17 13.3 13.5 
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2.2.9 Future Directions 
To complete the syntheses of sessilifoliamides B and D, we propose using aldehyde 2-
262 as a key advanced intermediate (Scheme 2-48). Addition of the lithiated orthoester 2-89 used 
in our previous tuberostemonine work would provide 2-265, which following oxidation and 
orthoester cleavage in acidic methanol will complete sessilifoliamide D. Sessilifoliamide B can 
be accessed from sessilifoliamide D by reduction and cyclization steps or in a more direct 
fashion from 2-270 using acidic methanol and separating the C(11) diastereomers. 
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Scheme 2-49. Proposed route for the completion of sessilifoliamides B and D. 
 
Future directions towards the completion of parvistemoline are summarized in Scheme 2-
50. Possible approaches include an aldol reaction between acetaldehyde and tricyclic 
intermediate 2-221, which we accessed from alcohol 2-208 via the Eschenmoser-Claisen 
rearrangement as shown in Scheme 2-36. We have demonstrated that stereospecific alkylation of 
the enolate of the lactone ring is possible, and the approach of the incoming electrophile would 
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be substrate directed to install the C(10) and C(16) stereocenters of aldol product 2-271. 
Protection of the alcohol and opening of the lactone in 2-271 will allow for deoxygenation at 
C(8), followed by formation of butenolide in 2-273 according to our sessilifoliamide C synthesis 
(Scheme 2-48). MOM-ether deprotection and Michael addition steps should furnish 
parvistemoline, similar to our initial model system. 
Alternatively, we propose re-visiting our Carroll rearrangement strategy (Scheme 2-34) 
to assess the viability of performing a Noyori reduction on rearrangement product 2-211. The 
keto-enol tautomerization should not effect the facial selectivity in the hydrogenation event, and 
the C(10) and C(16) stereocenters should be set in a catalyst-controlled manner. Elaboration of 
2-274 into 2-273 would mirror our sessilifoliamide C sequence, and completion of the target 
alkaloid could be achieved from this common intermediate as described for approach a. 
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Scheme 2-50. Proposed routes to parvistemoline involving a. aldol addition and b. Noyori reduction steps. 
 
2.3 CONCLUSION 
The Stemona alkaloids possess a rich history in organic synthesis and the number of 
creative approaches that have been reported for the total syntheses of these molecules is a 
testament to their complexity and intrigue. Our group has maintained a fascination with these 
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molecules, resulting in the syntheses of stenine and tuberostemonine as well as the development 
of key hydroindoline fragmentation methodology as outlined in section 2.1.3. 
In our current investigation, we successfully developed a novel, convergent route to the 
characteristic pyrrolo[1,2-a]azepine core of the Stemona alkaloids, featuring a Fukuyama 
reduction, intermolecular alkylation of two chiral fragments and ring-closing metathesis to 
complete the azepine ring. Careful design of our synthetic strategy allowed for the relay of 
stereochemical information across the 7-membered ring in a [3,3]-sigmatropic rearrangement. 
Performing an Eschenmoser-Claisen rearrangement allowed for the straightforward completion 
of 8-epi-stemoamide. 
We also developed an Ireland-Claisen approach for the relay of stereochemical 
information, which we discovered had the advantage of tolerating substitution on the 
intermediate silyl ketene acetal to install 3 contiguous stereocenters in a controlled fashion. 
Optimization of the reaction conditions to bias the transition state on steric grounds provided 
good levels of diastereoselection and we were successful in using the rearrangement products to 
complete the first total synthesis of sessilifoliamide C, as well as synthesize key intermediates 
for the completion of related sessilifoliamides. 
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3.0  EXPERIMENTAL 
3.1 GENERAL  
All moisture-sensitive reactions were performed using syringe-septum cap techniques under an 
inert atmosphere of N2. All glassware was flame dried or dried in an oven (140 °C) for at least 2 
h prior to use. THF and Et2O were dried by distillation over Na/benzophenone ketyl or LiAlH4. 
CH2Cl2 and toluene were dried by passage through alumina columns in a solvent purification 
system. NEt3 and DME were distilled from CaH2. Me2Zn and Et2Zn were purchased from the 
Aldrich Chemical Company and Cp2Zr(H)Cl was prepared according to a literature protocol.129 
Unless otherwise stated, solvents and reagents were used as received. Analytical thin layer 
chromatography was performed on pre-coated silica gel 60 F-254 plates (particle size 0.040-
0.055 mm, 230-400 mesh) and visualized with a 254 nm UV light or by staining with a solution 
of p-anisaldehyde (7.5 mL p-anisaldehyde, 25 mL concentrated H2SO4 and 7.5 mL glacial acetic 
acid in 675 mL of 95% ethanol), KMnO4 (1.5 g of KMnO4, 10 g of potassium carbonate and 2.5 
mL of 5 % aqueous NaOH in 150 mL H2O), or Vaughn’s reagent (4.8 g of (NH4)6Mo7O24·4 H2O 
and 0.2 g of Ce(SO4)2 in 100 mL of a 3.5 N H2SO4 solution). NMR spectra were recorded at 300 
MHz/75 MHz (1H NMR/13C NMR) on a Bruker Avance instrument or 600 MHz/150 MHz (1H 
NMR/13C NMR) on a cryoprobe-equipped Bruker Avance instrument at 21 °C unless otherwise 
noted. CDCl3 was filtered through dried basic alumina prior to sample preparation. Chemical 
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shifts are reported in parts per million with the residual solvent peak as an internal standard. 1H 
NMR spectra are tabulated as follows: chemical shift, multiplicity (s=singlet, d=doublet, 
t=triplet, q=quartet, dd=doublet of doublets, ddd= doublet of doublet of doublets, dddd= doublet 
of doublet of doublet of doublets, dt= doublet of triplets, m=multiplet, b=broad) coupling 
constant and integration. 13C spectra are tabulated by observed peak. Melting points were 
determined using a Laboratory Devices Mel-Temp II. Infrared spectra were measured on a 
Nicolet AVATAR 160 FT-IR E.S.P. spectrometer or a Perkin-Elmer Spectrum 100 FT-IR/ATR 
spectrometer. Mass spectra were obtained on a Micromass Autospec double focusing instrument. 
Optical rotations were recorded on a Perkin-Elmer 242 polarimeter at 23 °C; CHCl3 was filtered 
through dried basic alumina prior to sample preparation. 
3.2 EXPERIMENTAL PROCEDURES 
 
Ts
N
CO2Et
1-128  
O-Ethyl-N-but-3-ynyl-N-[(4-methylphenyl)sulfonyl]carbamate (1-128). According to 
a literature procedure, 130
130
 3-butyn-1-ol (1.78 mL, 23.5 mmol) was added to a cooled (0 °C) 
solution of TsNHCO2Et (8.56 g, 35.2 mmol) and PPh3 (18.5 g, 70.4 mmol) in THF (300 mL). 
The solution became cloudy after 10 min and the suspension was stirred for 18 h, and 
concentrated in vacuo. The residue was purified by chromatography on SiO2 (20% EtOAc/Hex) 
to yield 1-128 (6.19 g, 60%) as a colorless oil that solidified upon standing. Analytical data 
matched previously reported data for 1-128:  mp 60.2 - 61.7 °C; 1H NMR δ (CDCl3) 7.83 (d, J 
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= 8.4 Hz, 2 H), 7.30 (d, J = 8.1 Hz, 2 H), 4.13 (q, J = 6.9 Hz, 2 H), 4.01 (t, J = 7.2 Hz, 2 H), 2.64 
(dt, J = 7.5, 2.7 Hz, 2 H), 2.43 (s, 3 H), 2.02 (t, J = 2.7 Hz, 1 H), 1.19 (t, J = 7.2 Hz, 3 H); 13C 
NMR δ (CDCl3) 152.0, 144.6, 136.4, 129.3, 128.3, 80.1, 70.5, 63.5, 45.2, 21.9, 21.6, 19.9, 13.9. 
 
Ph
NP(O)Ph2
H
1-129  
N-(3-Phenylprop-2-ynylidene)-P,P-diphenylphosphinamide (1-129). According to a 
known procedure,131,132 66, ,70,8 to a mixture of Ph2(O)PNH2 (7.25g, 33.4 mmol), NEt3 (13.3 mL, 
100 mmol), and phenylpropargyl aldehyde (4.35 g, 33.4 mmol) in CH2Cl2 (260 mL) at 0 °C was 
added with a solution of TiCl4 (2.58 mL, 23.4 mmol) in CH2Cl2 (45.0 mL) using a syringe pump 
over 1 h. The reaction was stirred for 2 h and diluted with dry Et2O (500 mL). The slurry was 
filtered through a 1:1 Celite/florisil mixture and concentrated in vacuo. The residue was purified 
through a pad of dry, deactivated SiO2 (80% EtOAc/Hex with 1% NEt3 v/v) to yield 1-129 (3.80 
g, 35%) as a 10:1 mixture of imine and aldehyde. Analytical data matched previously reported 
datat for 1-129:131 1H NMR  (CDCl3) δ (characteristic signals) 9.38 (s, 1 H), 8.71 (d, J = 31.2 Hz, 
1 H), 7.92 (dd, J = 7.8, 1.5 Hz, 2 H), 7.88 (dd J = 8.1, 1.5 Hz, 2 H), 7.58 (dd, J = 7.8, 1.2 Hz, 2 
H), 7.46-7.33 (m, 9 H). 
 
Ph
Ph2(O)PNH
Ts
N
CO2Et
1-121  
(S*)-[(1R*,2S*)-2-(2-{P,P-Diphenylphosphinoylamino-[1-(2-phenylallyl) 
cyclopropyl]methyl}cyclopropyl)ethyl]-(4-methylphenylsulfonyl)carbamic acid ethyl ester 
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(1-121). According to a literature procedure,66 a suspension of Cp2Zr(H)Cl (3.77 g, 14.6 mmol) 
in CH2Cl2 (65.0 mL) at 0 °C was treated with 1-128 (3.74 g, 12.7 mmol) in CH2Cl2 (10.0 mL). 
The slurry was stirred for 15 min during which time the reaction became a pale yellow solution. 
The reaction mixture was then cooled to –78 °C and ZnMe2 (6.35 mL of a 2.0 M solution in 
toluene) was added. The resulting solution was warmed to 0 °C over 15 min. A solution of 1-129 
(2.09 g, 6.35 mmol) in CH2Cl2 (20.0 mL) was added and the reaction mixture was allowed to 
warm to room temperature and stirred for 4 h. In a separate flask, diethylzinc (3.13 g, 25.4 
mmol) was diluted in CH2Cl2 (22.0 mL) and treated with freshly distilled DME (2.64 mL, 25.4 
mmol) followed by dropwise introduction of CH2I2 (4.09 mL, 50.8 mmol) at –20 °C. The 
mixture was stirred for 15 min and cannulated into the reaction flask at –20 °C. The solution was 
allowed to warm to room temperature while stirring overnight. The reaction mixture was 
quenched with sat. NH4Cl (aq.), filtered through a 1:1 mixture of Celite/Florisil, extracted with 
EtOAc (3 x 20 mL), dried (MgSO4), and concentrated in vacuo. The crude product was purified 
by chromatography on deactivated SiO2 (20% EtOAc/Hex, then 50% EtOAc/Hex then 80% 
EtOAc/Hex containing 1% v/v NEt3) to yield 1-121 (2.64 g, 60%) as a colorless foam: 1H NMR 
δ (CDCl3) 7.93-7.75 (m, 8 H), 7.53-7.44 (m, 4 H), 7.40-7.24 (m, 7 H), 5.28 (d, J = 1.2 Hz, 1 H), 
5.13 (s, 1 H), 4.09 (q, J = 6.9 Hz, 2 H), 3.83 (t, J = 7.8 Hz, 2 H), 3.13 (app t, J = 6.6 Hz, 2 H), 
2.54 (d, J = 14.7 Hz, 1 H), 2.43 (s, 3 H), 2.25 (q, J = 9 Hz, 1 H), 1.85 (m, 1 H), 1.34-1.24 (m, 2 
H), 1.15 (t, J = 7.2 Hz, 3 H), 0.80-0.70 (m, 1 H), 0.49-0.33 (m, 8 H); 13C NMR δ (CDCl3) 
152.04, 145.70, 145.11, 144.15, 141.63, 136.64, 134.33, 133.56, 132.62, 132.12, 131.99, 131.83, 
131.71, 131.49, 129.05, 128.31, 128.24, 128.14, 128.08, 128.03, 127.22, 126.02, 115.06, 62.94, 
61.03, 46.85, 37.79, 33.96, 24.19, 24.11, 22.69, 22.64, 21.40, 15.10, 13.81, 10.93, 10.50, 10.03. 
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Ph
Ph2(O)PN
N
Ts
1-122  
N-Allyl-[2-((1R*,2S*)-2-{((S*)-N-allyl-N-diphenylphosphinoylamino)-[1-(2-
phenylallyl)cyclopropyl]methyl}cyclopropyl)ethyl]-4-methylphenylsulfonamide (1-122). 
Following a literature procedure,70 a solution of 1-121 (43.0 mg, 0.062 mmol) in THF (800 L) 
was treated with NaH (10.0 mg, 0.42 mmol) followed by HMPA (53.0 L, 0.304 mmol) and 
allyl iodide (60.0 L, 0.657 mmol). The reaction mixture was heated to 70 °C for 2 h, then 
cooled to room temperature and quenched with sat. aq. NaHCO3. The aqueous phase was 
extracted with EtOAc (3 x 5 mL), dried (MgSO4), filtered, and concentrated. The resulting 
residue was purified by chromatography on deactivated SiO2 (50% EtOAc/Hex with 1% v/v 
NEt3) to yield 1-122 (28.7 mg, 68%) as a pale yellow foam: IR (neat) 3058, 2990, 2921, 2359, 
2342, 2219, 1438, 1341, 1198, 1156, 1108, 1046, 912, 724 cm-1; 1H NMR (CDCl3) δ 7.85-7.78 
(m, 4 H), 7.70 (d, J = 8.1 Hz, 2 H), 7.48-7.37 (m, 7 H), 7.32-7.2 (m, 6 H), 5.95-5.82 (m, 1 H), 
5.63 (dddd, J = 16.5, 10.2, 6.3, 6.3 Hz, 1 H), 5.33-5.12 (m, 3 H), 4.99-4.82 (m, 3 H), 3.99-3.71 
(m, 4 H), 3.19-3.02 (m, 3 H), 2.46 (d, J = 12.6 Hz, 1 H), 2.42 (s, 3 H), 2.08-2.04 (m, 1 H), 1.64 
(s, 2 H), 0.97-0.59 (m, 5 H), 0.39-0.17 (m, 4 H); 13C NMR δ 144.91, 143.08, 142.04, 138.83, 
138.68, 137.11, 133.34, 132.73, 132.61, 132.49, 131.57, 129.63, 128.39, 128.27, 128.22, 127.29, 
127.21, 125.97, 118.71, 115.59, 114.48, 63.14, 51.01, 47.13, 46.97, 39.03, 33.14, 21.49, 19.75, 
19.48, 14.73, 9.45, 6.97; MS (ESI) m/z (rel. intensity) 727 [M+Na]+ (100), 705 [M+H]+ (55), 413 
(23), 212 (14). 
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N NTs
Ph
Ph2(O)P
1-124  
(2S*,11S*,12R*)-3-(N-Diphenylphosphinoyl)-2-[1-(2-phenylallyl)cyclopropyl]-8-(4-
methylphenylsulfonyl)-3,8-diazabicyclo[9.1.0]dodec-5-ene (1-124). A flask containing 1-122 
(185 mg, 0.263 mmol) and 1-123 (22.3 mg, 0.0263 mmol) in dry CH2Cl2 (50.0 mL) was purged 
under aspirator vacuum and filled with ethylene gas (5 times), then heated to reflux under a 
balloon of ethylene for 4 h. The reaction mixture was cooled to room temperature, filtered 
through Celite, concentrated, and purified by chromatography on deactivated SiO2 (50% 
EtOAc/Hex containing 1% v/v NEt3) to yield 1-124 (172 mg, 96%) as a colorless foam: IR (neat) 
3055, 2925, 2855, 1732, 1438, 1335, 1265, 1184, 1104, 738 cm-1; 1H NMR (CDCl3) δ 8.08 (t, J 
= 8.1 Hz, 2 H), 7.89 (t, J = 7.8 Hz, 2 H), 7.77 (d, J = 7.8 Hz, 2 H), 7.59-7.40 (m, 13 H) 5.99 (bm, 
1 H), 5.69 (bm, 1 H), 5.45 (bs, 1 H), 5.02 (bs, 1 H), 4.20 (bm, 1 H), 3.85 (bm, 1 H), 3.43 (bm, 1 
H), 3.26 (bd, J = 14.7 Hz, 1 H), 3.03 (bd, J = 14.4 Hz, 1 H), 2.86 (bd, J = 14.4 Hz, 1 H), 2.62 (bt, 
J = 12 Hz, 1 H), 2.54 (s, 3 H), 1.38 (bs, 1 H), 1.09 (bt, J = 11.4 Hz, 1 H), 0.93 (bs, 2 H), 0.73 
(bm, 1 H), 0.56 (bm, 1 H), 0.43 (bs, 1 H), 0.30-0.23 (bm, 2 H); 13C NMR (CDCl3) δ 143.75, 
143.08, 141.25, 136.51, 134.92, 133.03, 132.92, 132.67, 132.55, 131.68, 131.29, 129.52, 128.63, 
128.47, 128.25, 128.08, 127.35, 127.27, 126.89, 125.54, 114.61, 65.25, 52.00, 45.96, 44.75, 
38.48, 36.60, 21.68, 21.38, 20.94, 16.35, 15.78, 9.63, 6.62; MS (ESI) m/z (rel. intensity) 699 
([M+Na]+, 100) 677 ([M+H]+, 37); HRMS (ESI) m/z calculated for C41H45N2O3SPNa [M+Na]+ 
699.2786, found 699.2798. 
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Ph
O
HNP(O)Ph2
Ts
N
CO2Et
1-131  
Ethyl [2-(2-(1R*, 2S*)-{(S*)-(N-dipenylphosphinoylamino)-[1-(2-oxo-2-phenylethyl)-
cyclopropyl]methyl}cyclopropyl)ethyl]-N-(4-methylphenylsulfonyl)carbamate (1-131). To a 
stirred solution of 1-121 (2.71 g, 3.90 mmol) in acetone (36 mL) and H2O (9 mL) was added N-
methylmorpholine N-oxide (564 mg, 4.66 mmol) followed by OsO4 (590 µL, 0.194 mmol, 0.33 
M solution in toluene). After 4 h additional OsO4 was added (260 µL, 0.095 mmol) and the 
reaction mixture was allowed to stir overnight at room temperature. The black slurry was 
quenched by addition of H2O (20 mL) and sat. aq. Na2S2O3 solution (20 mL). The aqueous phase 
was extracted with EtOAc (3 x 20 mL), and the combined organic layers were washed with 
brine, dried (MgSO4), filtered, and concentrated to provide a brown foam. 
The mixture of diastereomeric diols was taken up in CH2Cl2 (75 mL) and treated with 
K2CO3 (1.07 g, 7.78 mmol) followed by Pb(OAc)4 (2.15 g, 4.67 mmol) at room temperature. 
After 30 min the reaction volume was reduced to one-third under reduced pressure and the 
resulting slurry was diluted with sat. aq. NH4Cl, brine, and the aqueous layer was extracted with 
CH2Cl2 (3 x 20 mL). The combined organic extracts were dried (MgSO4), filtered, concentrated, 
and purified by chromatography on SiO2 (50% EtOAc/Hex, then 60% EtOAc/Hex) to afford 1-
131 (2.05 g, 2.93 mmol, 75%) as a colorless, lustrous foam: IR (neat) 3296, 3058, 2993, 2928, 
2359, 2340, 1729, 1675, 1652, 1596, 1448, 1370, 1266, 1171, 1088, 1019, 977, 813 cm-1; 1H 
NMR (600 MHz, CDCl3) δ 7.19 (d, J = 7.2 Hz, 2 H), 7.89-7.84 (m, 4 H), 7.77 (d, J = 8.3 Hz, 2 
H), 7.57 (t, J = 7.4 Hz, 1 H), 7.48-7.39 (m, 8 H), 7.28 (d, J = 8.3 Hz, 2 H), 4.65 (t, J = 8.8 Hz, 1 
H), 4.10-4.05 (m, 2 H), 3.95 (d, J = 17.7 Hz, 1 H), 3.76 (t, J = 7.9 Hz, 2 H), 2.69 (d, J = 17.8 Hz, 
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1 H), 2.42 (s, 3 H), 2.22 (q, J = 9.0 Hz, 1 H), 1.86-1.81 (m, 1 H), 1.19-1.14 (m, 1 H), 1.14 (t, J = 
7.2 Hz, 3 H), 0.94-0.91 (m, 1 H), 0.66 (dddd, J = 5.1, 5.1, 8.8, 8.8, 1 H), 0.57-0.43 (m, 4 H) 0.38-
0.33 (m, 2 H); 13C NMR (150 MHz, CDCl3) δ 201.1, 152.4, 144.5, 137.3, 137.0, 134.4, 134.2, 
133.6, 133.41, 133.37, 132.35, 132.28, 132.1, 132.0, 131.7, 129.4, 128.8, 128.6, 128.5, 128.41, 
128.40, 128.3, 63.3, 61.3, 47.1, 44.5, 34.2, 23.30, 23.27, 22.42, 22.38, 21.8, 15.7, 14.1, 13.8, 
11.2, 10.4; HRMS (ESI) m/z calculated for C39H43N2O6PSNa [M+Na]+ 721.2477, found 
721.2473. 
 
NPh H
Ts
N
H N
Ph
H
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N
H
1-133a 1-133b
 
N-Allyl-N-{2-[2-(1R*,2S*)-((6S*,4S*)-5-allyl-6-phenyl-5-azaspiro[2.4]hept-4-
yl)cyclopropyl]ethyl}-4-methylbenzenesulfonamide (1-133a) and N-Allyl-N-{2-[2-(1R*,2S*)-
((6R*,4S*)-5-allyl-6-phenyl-5-azaspiro[2.4]hept-4-yl)cyclopropyl]ethyl}-4-
methylbenzenesulfonamide (1-133b). To a solution of 1-131 (2.05 g, 2.93 mmol) in MeOH (5 
mL) was added a solution of HCl in MeOH (acetyl chloride (1.34 mL, 18.5 mmol) added 
dropwise to MeOH (5 mL) at 0 ºC, stirred for 30 min) and this mixture was allowed to stir 
overnight at room temperature. The volatiles were removed under reduced pressure to afford the 
deprotected primary amine as a brown foam.  
The crude amine was taken up in MeOH (17 mL) and treated with NaBH3CN (970 mg, 
14.7 mmol), and the orange slurry was stirred for 5 h at room temperature. The volatiles were 
removed under reduced pressure and the orange residue was partitioned between toluene (57 
mL) and sat. aq. NaOH (57 mL), and Bu4NHSO4 (862 mg, 3.52 mmol) was added followed by 
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allyl bromide (2.57 mL, 29.3 mmol). This biphasic mixture was stirred vigorously for 12 h at 
which point additional PhMe (25 mL), sat. aq. NaOH (25 mL), and allyl bromide (2.57 mL, 29.3 
mmol) were added. The emulsion was stirred for another 24 h and the mixture was diluted with 
EtOAc (50 mL) and H2O (50 mL), and the aqueous phase was extracted with EtOAc (3 x 30 
mL). The combine organic layers were dried (MgSO4), filtered, concentrated, and purified by 
chromatography on SiO2 (10% EtOAc/Hex) to afford 1-133a (537 mg, 1.09 mmol, 37%) and 1-
133b (496 mg, 1.01 mmol, 34%) as yellow syrups, (1.1:1 ratio of diastereomers): 1-133a: IR 
(neat) 3068, 2994, 2924, 2858, 1726, 1599, 1454, 1344, 1160, 1091, 923, 815 cm-1; 1H NMR 
(600 MHz, CDCl3) δ 7.69 (d, J = 8.2 Hz, 2 H), 7.38 (d, J = 7.9 Hz, 2 H), 7.30 (t, J = 7.4 Hz, 2 
H), 7.27 (d, J = 7.9 Hz, 2 H), 7.23 (dt, J = 1.3, 7.3 Hz, 1 H), 5.80 (dddd, J = 6.6, 6.6, 10.2, 16.9 
Hz, 1 H), 5.65 (dddd, J = 6.4, 6.4, 10.1, 16.6 Hz, 1 H), 5.17 (dd, J = 1.4, 17.1 Hz, 1 H), 5.13 (dd, 
J = 1.2, 10.1 Hz, 1 H), 5.03 (dd, J = 1.9, 10.2 Hz, 1 H), 4.96 (dd, J = 1.7, 17.1 Hz, 1 H), 3.88 (dd, 
J = 6.8, 9.3 Hz, 1 H), 3.80, 3.77 (ddAB, J = 6.4, 15.4 Hz, 2H), 3.33 (dd, J = 6.5, 15.1 Hz, 1 H), 
3.26 (ddd, J = 5.7, 10.5, 13.9 Hz, 1 H), 3.18-3.13 (m, 2 H), 2.40 (s, 3 H), 2.06 (d, J = 8.2 Hz, 1 
H), 1.89 (dd, J = 9.4, 12.2 Hz, 1 H), 1.79 (dd, J = 6.8, 12.2 Hz, 1 H), 1.71 (dddd, J = 5.7, 5.7, 
10.9, 13.5 Hz, 1 H), 1.29-1.22 (m, 1 H), 0.97 (ddd, J = 4.3, 5.5, 9.6 Hz, 1 H), 0.51-0.46 (m, 3 H), 
0.41 (ddd, J = 4.0, 6.1, 9.9 Hz, 1 H), 0.36 (ddd, J = 4.2, 6.1, 9.6 Hz, 1 H), 0.15 (ddddd, J = 4.8, 
4.8, 7.9, 10.4 14.2 Hz, 2 H); 13C NMR (150 MHz, CDCl3) δ 144.2, 143.2, 137.2, 134.3, 133.5, 
129.8, 128.3, 127.7, 127.2, 126.9, 118.8, 117.2, 69.7, 65.7, 53.1, 50.9, 47.4, 45.7, 32.9, 25.2, 
21.6, 21.5, 13.4, 12.9, 8.9, 7.0; HRMS (ESI) m/z calculated for C30H39N2O2S [M+H]+ 491.2732, 
found 491.2725. 1-133b: IR (neat) 2065, 2992, 2923, 2866, 1641, 1598, 1493, 1455, 1343, 1159, 
1091, 921, 814, 741 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.68 (d, J = 8.3 Hz, 2 H), 7.37 (d, J = 
7.2 Hz, 2 H), 7.31-7.26 (m, 4 H), 7.22 (t, J = 7.2 Hz, 1 H), 5.76 (dddd, J = 4.3, 7.3, 10.4, 11.5 
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Hz, 1 H), 5.63 (dddd, J = 6.4, 6.4, 10.1, 16.6 Hz, 1 H), 5.15 (dd, J = 1.3, 17.1 Hz, 1 H), 5.12 (dd, 
J = 1.3, 10.1 Hz, 1 H), 5.07 (dd, J = 1.1, 17.3 Hz, 1 H), 5.00 (dd, J = 1.0, 10.3 Hz, 1 H), 4.12 (dd, 
J = 4.4, 8.2 Hz, 1 H), 3.80, 3.77 (ddAB, J = 6.4, 15.4 Hz, 2 H), 3.25 (dddd, J = 2.1, 2.1, 4.2, 14.9 
Hz, 1 H), 3.22-3.12 (m, 2 H), 3.03 (dd, J = 7.3, 14.9 Hz, 1 H), 2.45 (dd, J = 8.3, 12.7 Hz, 1 H), 
2.41 (s, 3 H), 2.09 (d, J = 9.8 Hz, 1 H), 1.84-1.89 (m, 1 H), 1.61 (dd, J = 4.4, 12.7 Hz, 1 H), 1.11-
1.02 (m, 2 H), 0.60-0.56 (m, 2 H), 0.52-0.47 (m, 1 H), 0.45-0.38 (m, 2 H), 0.20 (ddd, J = 4.9, 
4.9, 8.4 Hz, 1 H), 0.07 (ddd, J = 4.9, 4.9, 8.9 Hz, 1 H); 13C NMR (150 MHz, CDCl3) δ 143.9, 
143.2, 137.3, 137.1, 133.4, 129.7, 128.2, 128.1, 127.2, 126.9, 118.8, 115.5, 70.3, 65.5, 50.9, 50.8, 
47.2, 43.6, 32.6, 25.6, 21.6, 18.7, 14.7, 14.2, 9.4, 7.4; HRMS (ESI) m/z calculated for 
C30H39N2O2S [M+H]+ 491.2732, found 491.2722. 
 
N H
Ph
N
Ts
CO2Et
1-135  
Ethyl {2-[(1R*,2S*)-2-((1S*)-6-phenyl-5-azaspiro[2.4]hept-5-en-4-yl)cyclopropyl]-
ethyl}-(N-4-methylphenylsulfonyl)carbamate (1-135). To a stirred solution of 1-131 (724 mg, 
1.04 mmol) in MeOH (1 mL) was added HCl in MeOH (acetyl chloride (800 µL, 11.3 mmol) 
added dropwise to MeOH (5 mL) at 0 ºC, stirred for 30 min) and the reaction mixture was stirred 
overnight at room temperature and the volatiles were removed under reduced pressure to give 1-
134 as a brown foam. 
The crude amine was taken up in CH2Cl2 (12 mL), cooled to –78 ºC and treated with 
BF3·OEt2 (156 µL, 1.24 mmol). The reaction mixture was allowed to warm to room temperature 
and was stirred for 3 h. The volatiles were removed under reduced pressure and the resulting 
residue was purified by chromatography on SiO2 (20% EtOAc/Hex containing 1% v/v NEt3) to 
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afford 1-135 (417 mg, 0.869 mmol, 84%) as a colorless foam: IR (neat) 3067, 2992, 2925, 1732, 
1448, 1370, 1266, 1169, 1089, 761, 739, 674 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.82-7.78 (m, 
4 H), 7.39-7.37 (m, 3 H), 7.25 (d, J = 8.5 Hz,  2 H), 4.08 (q, J = 7.1 Hz, 2 H), 3.94 (app t, J = 7.5 
Hz, 2 H), 3.40 (d, J = 8.2 Hz, 1 H), 3.05, 2.98 (dAB, J = 18.9 Hz, 2 H), 2.38 (s, 3 H), 1.86-1.74 
(m, 1 H), 1.68-1.55 (m, 1 H), 1.13 (t, J = 7.1 Hz, 3 H), 1.08-1.02 (m, 1 H), 0.82-0.66 (m, 2 H), 
0.61-0.46 (m, 4 H), 0.38 (ddd, J = 4.7, 4.7, 9.2 Hz, 1 H); 13C NMR (75 MHz, CDCl3) δ 171.8, 
152.3, 144.3, 136.8, 134.8, 130.3, 129.2, 128.3, 128.2, 127.5, 79.9, 63.0, 47.1, 45.5, 34.3, 24.0, 
21.5, 21.1, 14.0, 12.7, 12.7, 9.8, 9.5; HRMS (EI+) m/z calculated for C27H32N2O4S (M•+) 
480.2082, found 480.2079. 
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CO2Et
1. HCl, MeOH
2. BF3·OEt2, CH2Cl2
3. Cl3SiH, CH2Cl2
4. Allyl bromide,
    Bu4NHSO4, PhMe,
    NaOH (aq.)
62%, 4.6:1 d.r.
1-131
1-133a
1-133b
 
Cyclodehydration/Reduction procedure: To a stirred solution of 1-131 (3.1 g, 4.41 
mmol) in MeOH (20 mL) was added a solution of HCl in MeOH (acetyl chloride (4.25 mL, 59.8 
mmol) added to MeOH (25 mL) at 0 °C, stirred for 30 min). The reaction mixture was allowed to 
stir overnight at which point the volatiles were removed under reduced pressure. 
The crude amine 1-134 was taken up in dry CH2Cl2 (55 mL), cooled to –78 °C, and 
treated with BF3·OEt2 (669 µL, 5.33 mmol). The reaction mixture was allowed to warm to room 
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temperature and was stirred for 3 h at which point the volatiles were removed under reduced 
pressure. 
To a solution of crude 1-135 in CH2Cl2 (25 mL) was added Cl3SiH (25 mL) and the 
reaction was allowed to stir at room temperature for 72 h. Upon consumption of the starting 
material by MS analysis, the reaction was carefully quenched at 0 °C by dropwise addition of 
sat. aq. NaHCO3 (100 mL). The slurry was extracted with EtOAc (3 x 50 mL) and the combined 
organic layers were dried (MgSO4), filtered, and concentrated under reduce pressure. 
The crude residue of 1-132a and 1-132b was partitioned between PhMe (88 mL) and sat. 
aq. NaOH (88 mL) and treated with Bu4NHSO4 (1.50 g, 4.43 mmol) and allyl bromide (3.80 mL, 
44.3 mmol), and the resulting gemulsion was stirred vigorously for 24 h. The aqueous phase was 
extracted with EtOAc (3 x 100 mL) and the combined organic layers were dried (MgSO4), 
filtered, concentrated, and the crude residue was purified by chromatography on SiO2 (10% 
EtOAc/Hex) to afford 1-133a (1.10 g, 2.24 mmol, 51%) followed by 1-133b (225 mg, 0.459 
mmol, 11%). Analytical data of material obtained by this method was identical to the 
aforementioned procedure. 
 
N
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1-136  
{1-[(13S*)-13-Phenyl-7-(4-methylphenylsulfonyl)-(1S*,2S*,4R*)-7,12-diazatetracyclo 
[109.1.54.2](15-spiro[2.4]heptane)]cyclopropyl}hept-9-ene (1-136). To a solution of 1-133a 
(380 mg, 0.775 mmol) in dry CH2Cl2 (165 mL) was added 1-123 (69.2 mg, 0.078 mmol). The 
reaction vessel was purged under aspirator vacuum and refilled with ethylene gas (5 times) and 
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kept under a balloon of ethylene while the reaction was heated to reflux for 4 h. The brown 
solution was cooled to room temperature and filtered through a pad of Celite/florisil (1:1 v/v) 
and concentrated. The crude material was purified by chromatography on SiO2 (10% 
EtOAc/Hex) to afford 1-136 (320 mg, 0.492 mmol, 90%) as a colorless solid: m.p. 155.5-160.3 
(decomp.); IR (neat) 3060, 2991, 2919, 2855, 2359, 1599, 1492, 1453, 1341, 1161, 1091, 1006, 
968, 903, 731 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.68 (d, J = 8.1 Hz, 2 H), 7.41 (d, J = 7.2 Hz, 
2 H), 7.32-7.26 (m, 4 H), 7.21 (t, J = 7.2 Hz, 1 H), 5.61-5.53 (m, 2 H), 4.09 (d, J = 11.0 Hz, 1 H), 
3.73 (dd, J = 5.7, 10.7 Hz, 1 H), 3.36 (d, J = 13.7 Hz, 1 H), 3.25 (d, J = 14.6 Hz, 1 H), 2.84-2.79 
(m, 2 H), 2.72-2.68 (m, 1 H), 2.43 (s, 3 H), 2.45-2.40 (m, 1 H), 2.00 (app t, J = 11.4 Hz, 1 H), 
1.74 (d, J = 9.5 Hz, 1 H), 1.57 (dd, J = 5.7, 12.0 Hz, 1 H), 1.11 (ddd, J = 5.0, 5.0, 9.7 Hz, 1 H), 
0.75-0.67 (m, 2 H), 0.56-0.53 (m, 2 H), 0.42-0.38 (m, 1 H), 0.34-0.30 (m, 1 H), 0.20 (ddd, J = 
4.3, 4.3, 8.6 H, 1 H), 0.14 (ddd, J = 4.7, 4.7, 8.3 Hz, 1 H); 13C NMR (75 MHz, CDCl3) δ 144.2, 
143.3, 138.7, 135.1, 129.7, 128.4, 127.5, 127.1, 124.7, 77.9, 70.0, 57.6, 52.3, 47.6, 46.5, 36.9, 
26.3, 23.8, 21.6, 16.6, 15.2, 10.6, 8.8; HRMS (EI+) m/z calculated for C28H34N2O2S (M•+) 
462.2341, found 462.2344. 
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1-137  
(13S*)-13-Phenyl-7-(4-methylphenylsulfonyl)-(1R*,2S*,4R*)-7,12-diazatetracyclo 
[10.54.2.0.00.0](2-spiro[2.4]heptane)decane (1-137). To a vigorously stirred solution of 1-136 
(40.0 mg, 0.087 mmol) in THF (2 mL) was added Pd(OH)2 (12.2 mg, 0.017 mmol). The system 
was evacuated and filled with H2 (3 times) and stirred under a balloon atmosphere for 10 h. The 
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reaction mixture was filtered through Celite, concentrated under reduced pressure, and the 
residue was purified by chromatography on deactivated SiO2 (15% EtOAc/Hex with 1% v/v 
NEt3) to yield 1-137 (24.8 mg, 62%) contaminated with an unidentifiable byproduct as an impure 
colorless oil that solidified upon standing: IR (neat) 2922, 2854, 2359, 2342, 1733, 1456, 1342, 
1162, 1111, 711 cm-1; 1H NMR (C6D6) δ (characteristic signals) 7.65 (d, J = 8.1 Hz, 2 H), 7.46, 
(d, J = 8.4 Hz, 2 H), 7.26 (t, J = 7.5 Hz, 3 H), 6.81 (d, J = 8.1 Hz, 2 H), 3.71 (dd, J = 11.7, 7.2 
Hz, 1 H), 3.50 (dt, J = 15.3, 2.7 Hz, 1 H), 3.04 (tt, J = 12.9, 4.5 Hz, 1 H), 2.80-2.57 (m, 3 H), 
2.45 (dt, J = 11.7, 3.6 Hz, 1 H), 2.29-2.15 (m, 1 H), 2.12-2.05 (m, 2 H), 1.92 (s, 3 H), 1.86-1.81 
(m, 1 H), 1.38-1.30 (m, 1 H), 1.21-1.10 (m, 2 H), 0.94-0.82 (m, 2 H), 0.80-0.72 (m, 2 H), 0.67-
0.58 (m, 1 H), 0.45 (t, J = 10.8 Hz, 1 H), 0.33-0.28 (m, 2 H), 0.19-0.08 (m, 2 H); 13C NMR 
(C6D6) (characteristic signals) δ 145.8, 142.5, 134.9, 129.4, 128.1, 127.8, 127.1, 75.1, 71.1, 54.9, 
50.9, 46.8, 46.0, 34.8, 27.4, 26.8, 25.0, 22.9, 21.0, 14.7, 14.5, 10.2, 6.4; MS (ESI) m/z (rel. 
inensity) 465 [M+H]+. 
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(9R*, 10R*)-{1-[(13S*)-13-Phenyl-7-(4-methylphenylsulfonyl)-(1S*,2S*,4R*)-7,12-
diazatetracyclo[109.1.54.2](15-spiro[2.4]heptane)]cyclopropyl}heptane-9,10-diol (1-138a) and 
(9S*, 10S*)-{1-[(13S*)-13-Phenyl-7-(4-methylphenylsulfonyl)-(1S*,2S*,4R*)-7,12-
diazatetracyclo[109.1.54.2](15-spiro[2.4]heptane)]cyclopropyl}heptane-9,10-diol (1-138b). To 
a solution of 1-136 (36 mg, 0.077mmol) in THF (1.6 mL) and H2O (0.4 mL) at room temperature 
was added NMO  (12.6 mg, 0.093 mmol) followed by a solution of OsO4 in toluene (23.6 µL of 
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0.33 M, 0.008 mmol). The pale yellow reaction mixture was stirred at room temperature for 16 h, 
and the reaction mixture was quenched by addition of sat. aq. NH4Cl (2 mL), and sat. aq. 
Na2S2O3 (2 mL). The mixture was stirred for 30 min, and the aqueous phase was extracted with 
EtOAc (3 x 10mL) and the combined organic extracts were dried (MgSO4), filtered, and 
concentrated. MPLC purification of the residue yielded 1-138b (9.2 mg, 0.019 mmol, 24%) 
followed by 1-138a (20.9 mg, 0.042 mmol, 54%) as beige powders: 1-138a: IR (neat) 3486, 
3026, 2924, 2854, 1727, 1598, 1493, 1354, 1336, 1160, 1118, 1021, 730 cm-1; 1H NMR (300 
MHz, CDCl3) δ 7.65 (d, J = 8.3 Hz, 2 H), 7.42 (d, J = 8.4 Hz, 2 H), 7.35-7.30 (m, 4 H), 7.27-
7.22 (m, 1 H), 4.18 (bs, 1 H), 3.75-3.67 (m, 2 H), 3.59 (d, J = 13.0 Hz, 1 H) 3.38 (bs, 1 H), 3.10 
(bd, J = 8.2 Hz, 1 H), 2.93 (dd, J = 3.2, 13.9 Hz, 1 H), 2.81 (dd, J = 4.0, 12.7 Hz, 1 H), 2.80-2.67 
(m, 2 H), 2.44 (s, 3 H), 2.16 (dd, J = 7.7, 12.7 Hz, 1 H), 2.02 (d, J = 9.6 Hz, 1 H), 1.89 (dd, J = 
8.0, 12.6 Hz, 1 H), 1.30-1.22(m, 2 H), 1.15 (ddd, J = 5.0, 5.0, 9.6 Hz, 1 H), 0.77-0.68 (m, 1 H), 
0.62-0.46 (m, 3 H), 0.42-0.36 (m, 1 H), 0.28-0.23 (m, 2 H); 13C NMR (75 MHz, CDCl3) δ 144.1, 
144.0, 132.5, 130.0, 128.8, 128.0, 127.9, 127.8, 77.4, 74.9, 74.4, 72.4, 66.9, 60.9, 53.1, 52.0, 
45.2, 33.6, 24.5, 21.7, 13.8, 11.0, 10.5, 9.0; HRMS (ESI) m/z calculated for C28H37N2O4S 
[M+H]+ 497.2474, found 497.2447. 1-138b: IR (neat) 3436, 3307, 3057, 2953, 2924, 2852, 1729, 
1439, 1344, 1162, 1114, 1089, 728 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J = 8.2 Hz, 2 
H), 7.43 (d, J = 8.2 Hz, 2 H), 7.34-7.29 (m, 4 H), 7.25-7.20 (m, 1 H), 4.45-4.37 (bm, 1 H), 4.16 
(dd, J = 5.9, 10.9 Hz, 1 H), 3.90 (dd, J = 5.4, 10.7 Hz, 1 H), 3.55 (dd, J = 11.2, 12.9 Hz, 1 H), 
3.27 (ddd, J = 4.3, 14 Hz, 1 H), 2.89-2.75 (m, 2 H), 2.70-2.59 (m, 2 H), 2.50 (dd, J = 4.3, 13.0 
Hz, 1 H), 2.43 (s, 3 H), 2.21 (t, J = 11.6 Hz, 1 H), 1.69 (d, J= 9.6 Hz, 1 H), 1.48-1.39 (m, 2 H), 
0.97-0.90 (m, 3 H), 0.85-0.78 (m, 2 H), 0.54-0.44 (m, 3 H), 0.41-0.32 (m, 2 H); 13C NMR (75 
MHz, CDCl3) δ 144.4, 143.7, 134.1, 129.9, 128.6, 127.7, 127.6, 127.5, 76.3, 70.7, 67.5, 66.0, 
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56.0, 51.5, 49.3, 44.9, 34.1, 27.8, 25.6, 21.6, 15.3, 14.5, 11.0, 6.0; HRMS (ESI) m/z calculated 
for C28H37N2O4S [M+H]+ 497.2427, found 497.2439.  
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1-139  
{14-[(18S*)-18-Phenyl-7-(4-methylphenylsulfonyl)-(11R*,13S*,14S*)-4,6-dioxa-5-
thia-1,9-diazapentacyclo[109.1,9.3.54.2](15-spiro[2.4]heptane)]cyclopropyl}dodecane-5,5-
dioxide (1-139). To a stirred solution of 1-138b (9.00 mg, 0.017 mmol) and 1,8-
diazabicyclo[5.4.0]undec-7-ene (5.41 uL, 0.036 mmol) in dry THF (1 mL) at room temperature 
was added sulfuryl diimidazole (3.95 mg, 0.020 mmol) followed by NaH (1.81 mg, 0.045 mmol, 
60% disp. in oil). The colorless slurry quickly became pale yellow and the reaction mixture was 
stirred for 30 min at room temperature. The volatiles were removed under reduced pressure and 
the reaction mixture was filtered through a plug of SiO2 followed by chromatography on oven-
dried SiO2 (10% EtOAc/Hex) to afford 1-139 (8.0 mg, 0.014 mmol, 79%) as a colorless film 
contaminated with grease by NMR spectroscopy: IR (neat) 2953, 2922, 2853, 1734, 1597, 1458, 
1378, 1334, 1266, 1209, 1160, 1015, 815, 732, 700 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.68 (d, 
J = 8.3 Hz, 2 H), 7.42 (d, J = 7.5 Hz, 2 H), 7.36 (d, J = 8.5 Hz, 2 H), 7.33 (t, J = 7.5 Hz, 2 H), 
7.23 (t, J = 7.4 Hz, 1 H), 5.19 (ddd, J = 4.6, 4.6, 11.3 Hz, 1 H), 5.11 (ddd, J = 3.3, 5.0, 6.4 Hz, 1 
H), 3.90 (app t, J = 3.9 Hz, 1 H), 3.53 (app t, J = 13.1 Hz, 1 H), 3.38 (dd, J = 6.4, 14.7 Hz, 1 H), 
3.31 (dd, J = 3.1, 14.7 Hz, 1 H), 3.12 (dd, J = 3.1, 16.9 Hz, 1 H), 3.03-2.95 (m, 2 H), 2.49-2.46 
(m, 1 H), 2.45 (s, 3 H), 2.10 (dd, J = 7.2, 12.1 Hz, 1 H), 2.06 (d, J = 9.7 Hz, 1 H), 1.82 (dd, J = 
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6.1, 12.2 Hz), 1.03-0.99 (m, 1 H), 0.85-0.83 (m, 2 H), 0.81-0.78 (m, 1 H), 0.48 (ddd, J = 4.3, 4.3, 
6.6, 7.9, 7.9 Hz, 2 H), 0.37-0.30 (m, 3 H); 13C NMR (150 MHz, CDCl3) δ 144.7, 144.6, 132.5, 
130.2, 128.5, 128.0, 127.5, 127.0, 84.3, 78.9, 75.8, 71.1, 56.1, 53.1, 53.0, 44.5, 33.5, 32.1, 29.9, 
29.8, 29.5, 25.7, 22.9, 21.8, 14.3, 13.9, 9.0, 8.7. HRMS (ESI) m/z calculated for C28H35N2O6S2 
[M+H]+ 559.1937, found 559.1966. 
 
1-140
N
H
NH
Ph
H
HO OH
 
(9R*, 10R*)-{1-[(13S*)-13-Phenyl-(1S*,2S*,4R*)-7,12-diazatetracyclo[109.1.54.2](15-
spiro[2.4]heptane)]cyclopropyl}heptane-9,10-diol (1-140). A solution of 1-138a (10.0 mg, 
0.020 mmol, 1.0 equiv) in dry THF (1 mL) was added to a solution of freshly prepared SmI2 in 
THF (1.55 mL, 0.13 M, 0.20 mmol). The reaction mixture was allowed to stir for 15 min and 
was quenched with H2O (10 uL, 0.600 mmol) and pyrrolidine (34 uL, 0.402 mmol). The 
resulting white slurry was diluted with sat. aq. NaHCO3 (1 mL) and extracted with EtOAc (3 x 5 
mL). The combined organic extracts were dried (MgSO4), filtered, and concentrated. The crude 
mixture was purified by chromatography on SiO2 (30% acetone/CH2Cl2) to afford 1-140 (4.9 
mg, 0.014 mmol, 71%) containing an inseparable, unidentifiable impurity, as an orange film: IR 
(neat) 3345, 2924, 2853, 2453, 1726, 1601, 1454, 1260, 1079, 1038, 1014, 911, 729, 707 cm-1; 
1H NMR (600 MHz, CDCl3)  δ 7.56 (t, J = 7.7 Hz, 2 H), 7.51 (d, J = 7.2 Hz, 2 H), 7.34 (t, J = 7.4 
Hz, 1 H), 4.09 (dd, J = 6.3, 10.5 Hz, 1 H), 3.84 (t, J = 8.6 Hz, 1 H), 3.55 (t, J = 8.8 Hz, 1 H), 3.43 
(dd, J = 1.6, 13.2 Hz, 1 H), 3.33 (bd, J = 10.6 Hz, 1 H), 3.17 (s, 1 H), 3.11-3.06 (bm, 1 H), 3.06 
(dd, J = 10.1, 13.1 Hz, 1 H), 2.94 (d, J = 13.0 Hz, 1 H), 2.59 (dd, J = 10.7, 13.1 Hz, 1 H), 2.30-
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2.27 (m, 1 H), 2.03 (t, J = 11.0 Hz, 1 H), 1.97 (d, J = 10.7 Hz, 1 H), 1.81 (dd, J = 6.2, 13.2 Hz, 1 
H), 1.60 (bs, 1 H), 1.49-1.42 (m, 1 H), 1.03-0.98 (m, 1 H), 0.81 (d, J = 9.5 Hz, 1 H), 0.70 (ddd, J 
= 5.1, 5.1, 8.8 Hz, 1 H), 0.64-0.54 (m, 5 H); 13C NMR (150 MHz, CDCl3) δ   130.2, 128.7, 
127.9, 80.3, 73.6, 70.7, 69.5, 53.8, 48.6, 46.8, 44.1, 29.7, 29.3, 28.3, 25.1, 24.7, 14.8, 12.9, 9.2, 
5.1; HRMS (EI+) m/z calculated for C21H30N2O2 (M•+) 342.2307, found 342.2308. 
 
1-143
N
Ts
OH
 
3-[1-(4-Methylbenzenesulfonyl)-1H-indol-3-yl]prop-2-yn-1-ol (1-143). According to a 
literature procedure,133 indole (2.00 g, 17.1 mmol) was dissolved in dry DMF (30 mL) and 
treated with KOH (2.39 g, 42.7 mmol). After 10 min, I2 (4.38 g, 17.2 mmol) in dry DMF (30 
mL) was introduced gradually. The solution was stirred for 1 h and poured into H2O (400 mL) 
containing solid Na2S2O5 (800 mg) and aq. NH4OH (2 mL). The resulting slurry was filtered and 
the colorless filtrate was dissolved in Et2O (50 mL), dried (MgSO4), filtered, and concentrated to 
afford 3-iodoindole. The crude product was immediately dissolved in dry DMF (100 mL), cooled 
to 0 °C, and NaH (615 mg, 25.6 mmol) was introduced portionwise. After 30 min, p-
toluenesulfonyl chloride (4.89 g, 25.7 mmol) was added slowly and the reaction was stirred for 2 
h and quenched with sat. aq. NaHCO3 (100 mL). The aqueous phase was extracted with Et2O (3 
x 50 mL) and the combined organic layers were washed with H2O (50 mL), brine (100 mL), 
dried (MgSO4), filtered, and concentrated to afford 1-142 as a cream-colored solid that was used 
without further purification. 
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To a stirred solution of 1-142 (6.76 g, 17.1) in DME (50 mL) and H2O (25 mL) was 
added K2CO3 (5.89 g, 42.7 mmol), CuI (293 mg, 1.54 mmol), PPh3 (537 mg, 2.05 mmol), and 
10% Pd/C (544 mg, 0.512 mmol). The slurry was stirred for 15 min and propargyl alcohol (2.50 
mL, 42.9 mmol) was introduced. The reaction mixture was stirred at room temperature  for 48 h 
and was filtered through a pad of Celite, diluted with H2O (25 mL) and the aqueous phase was 
extracted with EtOAc (3 x 10 mL). The comnbined organic layers were dried (MgSO4), filtered, 
concentrated, and the crude product was purified by chromatography on SiO2 (20% EtOAc/Hex, 
then 50% EtOAc/Hex) to afford 1-143 (3.08 g, 9.47 mmol, 56% over 3 steps) as an orange 
crystalline solid: mp 163.2 - 165.1 °C; IR (neat) 3540, 3130, 2915, 2225, 1739, 1593, 1447, 
1378, 1362, 1280, 1228, 1174, 1163, 1132, 1102, 1031, 988, 965, 812, 748, 717, 661 cm-1; 1H 
NMR (600 MHz, CDCl3) δ 7.96 (d, J = 8.3 Hz, 1 H), 7.76 (d, J= 8.3 Hz, 2 H), 7.74 (s, 1 H), 7.62 
(d, J = 7.8 Hz, 1 H), 7.35 (t, J = 7.8 Hz, 1 H), 7.29 (t, J = 7.8 Hz, 1 H), 7.22 (d, J = 8.5 Hz, 2 H), 
4.55 (s, 2 H), 2.34 (s, 3 H), 1.74 (bs, 1 H); 13C NMR (150 MHz, CDCl3) δ 145.5, 134.9, 134.2, 
130.8, 130.2, 129.4, 127.1, 125.6, 123.9, 120.6, 113.7, 104.6, 91.6, 77.0, 51.9, 21.7; HRMS 
(ESI) m/z calculated for C18H15NO3SNa [M+Na]+ 348.0670, found 348.0684. 
 
1-144
N
Ts
O
H
 
[1-(4-Methylbenzenesulfonyl)-1H-indol-3-yl]propynal (1-144). To a vigorously stirred 
solution of 1-143 (20.0 g, 61.5 mmol) in CH2Cl2 (1 L) was added MnO2 (60.0 g, 586 mmol) in a 
single portion. The black slurry was stirred overnight and an additional portion of MnO2 (20.0 g, 
195 mmol) was added, and the reaction was complete after 6 h. The slurry was filtered through a 
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pad of Celite and concentrated to an orange sticky mass. Purification of the crude product by 
chromatography on SiO2 (25% EtOAc/Hex) afforded 1-144 (18.8 g, 58.1 mmol, 95%) as an 
orange-red oil: IR (neat) 2980, 2924, 2193, 1734, 1597, 1447, 1372, 1341, 1240, 1174, 1160, 
1089, 1044, 951, 814, 720 cm-1; 1H NMR (300 MHz, CDCl3) δ 9.45 (s, 1 H), 8.03 (s, 1 H), 7.98 
(d, J = 8.1 Hz, 1 H), 7.82 (d, J = 8.5 Hz, 2 H), 7.69 (d, J = 7.8 Hz, 1 H), 7.41 (dt, J = 1.4, 7.3 Hz, 
1 H), 7.35 (dt, J = 1.2, 7.7 Hz, 1 H), 7.28 (d, J = 8.6 Hz, 2 H), 2.37 (s, 3 H); 13C NMR (75 MHz, 
CDCl3) δ 176.3, 146.2, 134.6, 134.2, 133.6, 130.4, 130.0, 127.3, 126.3, 124.6, 120.7, 113.8, 
101.5, 93.5, 87.9, 21.8; HRMS (EI+) m/z calculated for C18H13NO3S (M•+) 323.0616, found 
323.0604. 
 
1-145
NP(O)Ph2
N
Ts
 
3-[1-(Methylphenylsulfonyl)indol-3-yl]-prop-2-ynyl-N-(P,P-diphenylphosphinoyl) 
imine (1-145). To a stirred solution of 1-144 (8.00 g, 24.7 mmol) and Ph2P(O)NH2 (6.66 g, 32.2 
mmol) in dry CH2Cl2 (450 mL) was added i-Pr2NEt (13.8 mL, 79.1 mmol). The yellow solution 
was cooled to –78 °C and a solution of TiCl4 (2.73 mL, 24.7 mmol) in dry CH2Cl2 (16 mL) was 
added dropwise over 5 minutes. The stirred reaction mixture was slowly allowed to warm to 
room temperature over 2 h. The solvent volume of the reaction was reduced to one-quarter 
volume under reduced pressure, and the resulting brown syrup was passed through a short 
column (~6”) of oven-dried SiO2 using 70% EtOAc/Hex as the eluent to yield 1-145 (7.68 g, 
14.7 mmol, 59%) as an orange foam: IR (neat) 3057, 2188, 1739, 1649, 1591, 1530, 1437, 1374, 
1284, 1232, 1173, 1125, 1101, 934, 826, 746, 725, 694, 664 cm-1; 1H NMR (300 MHz, CDCl3) δ 
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8.76 (d, J = 31.5 Hz, 1 H), 8.00 (s, 1 H), 7.97-7.88 (m, 5 H), 7.80 (d, J = 8.4 Hz, 2 H), 7.70 (d, J 
= 7.8 Hz, 1 H), 7.54-7.43 (m, 6 H), 7.39-7.30 (m, 2 H), 7.23 (d, J = 9.9 Hz, 2 H), 2.33 (s, 3 H); 
13C NMR (75 MHz, CDCl3) δ 157.73, 157.66, 145.0, 134.5, 134.4, 132.8, 132.7, 132.19, 132.15, 
131.8, 131.7, 131.1, 130.3, 130.0, 128.7, 128.6, 127.1, 126.1, 124.4, 120.7, 113.7, 102.6, 93.3, 
93.1, 93.0, 92.8, 21.7; HRMS (ESI) m/z calculated for C30H23N2O3SPNa [M+Na]+ 545.1065, 
found 545.1088. 
 
Ph2(O)PNHN
Ts
Ts
N
CO2Et
1-146  
(S*)-[(1R*,2S*)-2-(2-{P,P-Diphenylphosphinoylamino-[1-(2-{1-(Methylphenyl-
sulfonyl)indol-3-yl}allyl)cyclopropyl]methyl}cyclopropyl)ethyl]-(4-methylphenyl-
sulfonyl)carbamic acid ethyl ester (1-146). To a stirred solution of 1-128 (6.75 g, 22.9 mmol) 
in dry CH2Cl2 (125 mL) was added Cp2Zr(H)Cl (4.81 g, 23.9 mmol). The resulting slurry cleared 
after 5 min and the reaction mixture was cooled to –78 °C after 30 min. To the yellow solution 
was added ZnMe2 (11.4 mL, 22.9 mmol, 2 M solution in toluene) and the reaction mixture was 
stirred at –78 °C for 30 min, allowed to warm to 0 °C over 10 minutes, and a solution of 1-145 
(5.43 g, 10.4 mmol) in dry CH2Cl2 (90 mL) was added via cannula. The orange solution was 
warmed to room temperature and stirred for 3 h before being cooled to –30 °C. 
In a separate flask under an inert atmosphere, neat ZnEt2 (5.13 g, 41.6 mmol) was 
carefully diluted with dry CH2Cl2 (30 mL), cooled to –30 °C and treated with freshly distilled 
DME (4.40 mL, 41.6 mmol). The colorless solution was stirred for 10 min at –30 °C and CH2I2 
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(6.70 mL, 83.13 mmol) was introduced dropwise (CAUTION: EXPLOSION HAZARD).1
The reaction mixture was allowed to warm to room temperature and was stirred for 16 h, 
at which point the reaction was carefully quenched with the dropwise addition of sat. aq. NH4Cl 
(75 ml), and the mixture was diluted with EtOAc (100 mL). The resulting biphasic slurry was 
filtered through Celite, and the aqueous phase was extracted with EtOAc (3 x 150 mL). The 
combined organic layers were dried (MgSO4), filtered through Celite, and concentrated in vacuo. 
The crude reside was purified by chromatography on SiO2 (60% followed by 80% EtOAc/Hex) 
to afford 1-146 (4.30 g, 4.83 mmol, 47%) as a brown foam: IR (neat) 3352, 3206, 3060, 2992, 
2926, 1727, 1596, 1438, 1369, 1353, 1265, 1169, 1122, 1089, 735, 699, 670 cm-1; 1H NMR (600 
MHz, CDCl3) δ 8.01 (d, J = 8.3 Hz, 1 H), 7.86 (d, J = 11.8 Hz, 1 H), 7.85 (dd, J = 1.4, 11.9 Hz, 1 
H), 7.79 (d, J = 8.4 Hz, 2 H), 7.77 (m, 1 H), 7.76 (d, J = 8.4 Hz, 2 H), 7.63 (d, J = 8.0 Hz, 1 H), 
7.61 (s, 1 H), 7.50 (t, J = 7.6 Hz, 1 H), 7.46-7.43 (m, 2 H), 7.40 (t, J = 7.6 Hz, 1 H), 7.32-7.28 
(m, 5 H), 7.24-7.16 (m, 4 H), 5.47 (s, 1 H), 5.30 (s, 1 H), 4.13-4.07 (m, 2 H), 3.85 (t, J = 7.5 Hz, 
2 H), 3.19 (dd, J = 7.2, 8.9 Hz, 1 H), 3.07 (d, J = 14.9 Hz, 1 H), 2.55 (d, J = 14.8 Hz, 1 H), 2.43 
(m, 1 H), 2.41 (s, 3 H), 2.30 (s, 3 H), 1.85 (ddd, J = 7.1, 7.1, 13.5 Hz, 1 H), 1.34 (dddd, J = 8.1, 
8.1, 13.2, 16.4 Hz, 1 H), 1.15 (t, J = 7.1 Hz, 3 H), 0.76-0.71 (m, 1 H), 0.58-0.53 (m, 1 H), 0.48-
0.38 (m, 4 H), 0.35-0.30 (m, 2 H); 13C NMR (150 MHz, CDCl3) δ 152.4, 145.2, 144.5, 137.8, 
137.0, 135.6, 135.2, 132.5, 132.35, 132.28, 132.14, 132.08, 131.90, 131.88, 131.80, 130.1, 129.4, 
129.1, 128.7, 128.62, 128.55, 128.46, 128.42, 127.0, 125.0, 124.3, 123.70, 123.67, 121.1, 116.3, 
 The 
resulting solution was stirred at –30 °C for 30 min and cannulated into the imine addition pot at –
30 °C. 
                                                 
1 The preparation of the unstabilized zinc carbenoid reagent has been reported to be explosive on 
large scale. See Ref 57. 
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113.9, 63.3, 61.1, 47.2, 39.4, 34.3, 24.28, 24.24, 23.16, 23.1, 21.8, 21.7, 15.5, 14.2, 11.5, 10.9, 
10.0. HRMS (ESI) m/z calculated for C49H53N3O7PS2 [M+H]+ 890.3063, found 890.3073. 
 
1-147
O
Ph2(O)PNHN
Ts
Ts
N
CO2Et
 
(S*)-[(1R*,2S*)-2-(2-{P,P-Diphenylphosphinoylamino-[1-(2-{1-(Methylphenyl-
sulfonyl)indol-3-yl}-2-oxoethyl)cyclopropyl]methyl}cyclopropyl)ethyl]-(4-methylphenyl-
sulfonyl)carbamic acid ethyl ester (1-147). A solution of 1-146 (2.45 g, 2.75 mmol) and NMO 
(399 mg, 3.30 mmol) in acetone (27 mL) and H2O (6.75 mL) was treated with OsO4 (834 uL, 
0.275 mmol, 0.33 M solution in toluene). After 10 h the black slurry was quenched by the 
addition of H2O (10 mL) and sat. aq. Na2SO3 (10 mL), and diluted with EtOAc (50 mL). The 
aqueous phase was extracted with EtOAc (3 x 20 mL), and the combined organic layers were 
washed with brine (50 mL), dried (MgSO4), filtered, and concentrated in vacuo to afford the 
diastereomeric diols that were used without further purification. 
The crude brown foam was taken up in dry CH2Cl2 (39 mL) and to this solution was 
added K2CO3 (763 mg, 5.51 mmol) followed by Pb(OAc)4 (1.53 g, 3.30 mmol). After 2 h at 
room temperature the reaction was concentrated to one-third volume under reduced pressure and 
the mixture was purified by chromatography on SiO2 (50% EtOAc/Hex followed by 60% 
EtOAc/Hex) to afford 2-147 (1.81 g, 2.03 mmol, 74%) as a yellow foam: IR (neat) 3305, 3058, 
2993, 2360, 2218, 1730, 1659, 1596, 1596, 1440, 1378, 1286, 1172, 1138, 1019, 980, 910, 813, 
729 cm-1; 1H NMR (300 MHz, CDCl3) δ 8.30 (s, 1 H), 8.26 (dd, J = 1.2, 7.5 Hz, 1 H), 7.95 (dd, J 
= 1.2, 7.5 Hz, 1 H), 7.89-7.72 (m, 8 H),  7.48-7.29 (m, 11 H), 4.63 (app t, J = 8.7 Hz, 1 H), 4.09 
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(dq, J = 1.2, 7.2 Hz, 2 H), 4.07 (1, J = 6.9 Hz, 1 H), 3.81-3.75 (m, 3 H), 2.64 (d, J = 16.8 Hz, 1 
H), 2.42 (s, 3 H), 2.34 (s, 3 H), 2.21 (dd, J = 9, 17.7 Hz, 1 H), 1.89-1.78 (m, 1 H), 1.23-1.14 (m, 
1 H), 1.13 (t, J = 6.9 Hz, 3 H), 0.81 (bd, J = 16.2, 1H), 0.81-0.78 (m, 1H), 0.58-0.49 (m, 4 H), 
0.47-0.35 (m, 2 H); 13C NMR (75 MHz, CDCl3) δ 196.9, 152.4, 146.1, 144.4, 137.0, 135.04, 
134.99, 134.8, 134.6, 133.3, 133.1, 132.5, 132.4, 132.2, 132.1, 131.9, 131.64, 131.61, 131.59, 
131.55, 130.4, 129.4, 128.5, 128.41, 128.37, 113.3, 63.3, 61.6, 47.1, 45.4, 34.3, 23.4, 23.3, 22.9, 
22.8, 21.76, 21.75, 15.7, 14.2, 13.8, 11.3, 10.5; HRMS (ESI) m/z calculated for 
C48H50N3O8NaPS2 [M+Na]+ 914.2675, found 914.2702. 
 
1-148
N HN
Ts
Ts
N
CO2Et
 
Ethyl {2-[(1R*,2S*)-2-((1S*)-6-[1-(methylphenylsulfonyl)indol-3-yl]-5-azaspiro[2.4] 
hept-5-en-4-yl)cyclopropyl]ethyl}-(N-4-methylphenylsulfonyl)carbamate (1-148). To a 
stirred solution of 1-147 (1.68 g, 1.88 mmol) in MeOH (15 mL) was added a preformed solution 
of HCl in MeOH (acetyl chloride (3.45 mL) added to MeOH (13 mL) at 0 °C, stirred for 30 min) 
and the reaction mixture was stirred overnight at room temperature. The volatiles were removed 
under reduced pressure to afford the crude primary amine. 
The dark residue was taken up in dry CH2Cl2 (25 mL), cooled to –78 °C, and BF3·OEt2 
(286 µL, 2.26 mmol) was added. The reaction mixture was allowed to warm to room temperature 
and after 2 h the solution was concentrated under reduced pressure to afford 1-148 that was used 
without further purification. An analytical sample was purified by MPLC (20% EtOAc/Hex) to 
afford a beige foam: IR (neat) 3127, 3070, 2993, 2926, 2258, 1730, 1615, 1598, 1545, 1446, 
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1370, 1266, 1221, 1134, 1105, 1089, 1019, 911, 812, 734 cm-1; 1H NMR (300 MHz, CDCl3) δ 
8.45 (d, J = 7.2 Hz, 1 H), 7.97 (d, J = 8.1 Hz, 1 H), 7.78 (d, J = 8.4 Hz, 2 H), 7.77 (s, 1 H), 7.73 
(d, J = 8.4 Hz, 2 H), 7.36 (dt, J = 1.2, 7.5 Hz, 1 H), 7.30 (dt, J = 1.2, 7.8 Hz, 1 H), 7.22 (d, J = 
8.7 Hz, 2 H), 7.19 (d, J = 8.4 Hz, 2 H), 4.08 (q, J = 6.9 Hz, 2 H), 3.95 (t, J = 7.8 Hz, 2 H), 3.49 
(d, J = 7.5 Hz, 1 H), 3.05 (s, 2 H), 2.39 (s, 3 H), 2.32 (s, 3 H), 1.81-1.62 (m, 2 H), 1.13 (t, J = 7.2 
Hz, 3 H), 1.11-1.03 (m, 1 H), 0.79-0.73 (m, 2 H), 0.65-0.53 (m, 4 H), 0.45-0.38 (m, 1 H); 13C 
NMR (75 MHz, CDCl3) δ 166.7, 152.4, 145.5, 144.4, 136.9, 135.4, 135.0, 129.3, 128.6, 128.36, 
128.30, 127.0, 125.4, 124.4, 123.7, 118.8, 113.3, 80.0, 63.3, 47.4, 46.6, 34.5, 23.5, 21.7, 21.2, 
14.1, 12.8, 12.5, 10.0, 9.7; HRMS (ESI) m/z calculated for C36H40N3O6S2 [M+H]+ 674.2359, 
found 674.2346. 
 
1-152a, 1-152b
NH
Ts
N
H
O
ON
Ts O
O
 
N-Allyloxycarbonyl-N-{2-[2-(1R*,2S*)-((6S*,4S*)-5-allyloxycarbonyl-6-[1-
(methylphenylsulfonyl)indol-3-yl]-5-azaspiro[2.4]hept-4-yl)cyclopropyl]ethyl}-4-
methylbenzenesulfonamide (1-152a) and N-Allyloxycarbonyl-N-{2-[2-(1R*,2S*)-((6R*,4S*)-
5-allyloxycarbonyl-6-[1-(methylphenylsulfonyl)indol-3-yl]-5-azaspiro[2.4]hept-4-
yl)cyclopropyl]ethyl}-4-methylbenzenesulfonamide (1-152b). To crude 1-148 (1.81 g, 2.67 
mmol) dissolved in dry CH2Cl2 (15 mL) was added Cl3SiH (12.0 mL, 119 mmol) and the 
mixture was stirred at room temperature for 72 h until progress had stalled by MS analysis of 
quenched, filtered reaction aliquots (ca. 25 µL). The reaction mixture was cooled to 0 °C and 
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was carefully quenched by the dropwise addition of sat. aq. NaHCO3 (20 mL), and the resulting 
slurry was extracted with EtOAc (3 x 20 mL). The combined organic extracts were dried 
(MgSO4), filtered, concentrated, and the brown foamy reside was taken up in dry CH2Cl2 (15 
mL) and treated with Cl3SiH (12.0 mL, 119 mmol). The reaction mixture was stirred for 24 h and 
was cooled to 0 °C and was carefully quenched by the dropwise addition of sat. aq. NaHCO3 (20 
mL). The resulting slurry was extracted with EtOAc (3 x 20 mL) and the combined organics 
were dried (MgSO4), filtered, and concentrated to a brown foam that was used without further 
purification. 
 The crude pyrrolidines were separated into 4 batches134
The combined batches of deprotected material (659 mg, 1.09 mmol) were dissolved in a 
mixture of dry THF (10 mL) and CH2Cl2 (1 mL) and to this mixture was added DMAP (13.3 mg, 
0.109 mmol) and AllocCl (478 µL, 4.37 mmol) followed by NaH (131 mg, 5.46 mmol). The 
reaction mixture was stirred at room temperature for 14 h and was quenched with sat. aq. 
NaHCO3 (10 mL) and the aqueous phase was extracted with EtOAc (3 x 5 mL). The combined 
organic layers were dried (MgSO4), filtered, and concentrated to provide a mixture of starting 
material, mono- and bis-Alloc protected products. This complex mixture was resubjected to the 
 (100, 200, 250 and 278 mg) with 
the following procedure being representative for each: a solution of crude pyrrolidine (200 mg, 
0.37 mmol) in dry CH2Cl2 (5 mL) at room temperature was treated with DIBAL-H (813 µL, 
0.814 mmol), dropwise. The reaction mixture was stirred for 1 h and an additional amount of 
DIBAL-H (406 µL, 0.406 mmol) was added. After 30 min the reaction mixture was quenched 
with H2O (5 mL) and stirred for 30 min. The aqueous phase was extracted with EtOAc (3 x 5 
mL) and the combined organic layers were dried (MgSO4), filtered, and concentrated to a pale 
yellow foam (164 mg, 0.272 mmol, 92% theoretical) that was used without further purification. 
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initial reaction conditions [dissolved in dry THF (10 mL) and CH2Cl2 (1 mL) and to this mixture 
was added DMAP (13.3 mg, 0.109 mmol) and AllocCl (478 µL, 4.37 mmol) followed by NaH 
(131 mg, 5.46 mmol)] and was stirred for 18 h before being quenched with sat. aq. NaHCO3 (10 
mL) and extracted with EtOAc (3 x 5 mL). The combined organic extracts were dried (MgSO4), 
filtered, and concentrated to give a brown foam that was purified by chromatography on SiO2 
(30% EtOAc/Hex) to afford 1-152a, 1-152b (480 mg, 0.622 mmol, 57% theoretical, 33% from 
1-147) as a yellow sticky foam and an inseparable mixture of diastereomers and rotamers by 
NMR spectroscopy: 1H NMR (300 MHz, CDCl3) major peaks δ 7.98 (d, J = 8.6 Hz), 7.82 (t, J = 
8.2 Hz), 7.73 (d, J = 8.3 Hz), 7.54 (d, J= 7.9 Hz), 7.45 (s), 7.28 (d, J 8.3 Hz), 7.23-7.17 (m), 
5.84-5.69 (m), 5.30-5.14 (m), 4.56-4.52 (m), 3.96-3.87 (m), 3.1 (d, J = 9.3 Hz), 3.04 (d, J = 90.4 
Hz), 2.42 (s), 2.40 (s), 2.32 (s), 2.24 (dd, J = 7.4, 12.8 Hz), 2.10 (dd, J = 8.0, 12.8 Hz), 0.92-0.72 
(m), 0.60-0.35 (m), 0.11-0.04 (m); 13C NMR (75 MHz, CDCl3) major peaks δ 155.8, 152.1, 
144.8, 144.4, 136.8, 135.7, 135.4, 123.0, 131.2, 129.9, 129.8, 129.4, 128.44, 128.38, 126.8, 
126.7, 124.7, 123.2, 123.1, 122.5, 122.2, 119.8, 119.0, 114.0, 113.9, 77.4, 68.5, 67.6, 65.9, 65.4, 
54.8, 54.1, 47.2, 47.1, 41.6, 34.7, 34.4, 29.8, 26.0, 25.2, 23.1, 22.7, 21.7, 21.6, 15.8, 15.8, 13.6, 
12.9, 10.2, 9.2, 7.0, 3.2; HRMS (ESI) m/z calculated for C41H45N3O8S2Na [M+Na]+ 794.2546, 
found 794.2594. 
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N-Allyl-N-{2-[2-(1R*,2S*)-((6S*,4S*)-5-allyl-6-[1-(methylphenylsulfonyl)indol-3-yl]-
5-aza-spiro[2.4]hept-4-yl)-cyclopropyl]ethyl}-4-methylbenzenesulfonamide (1-153). A 
solution of 1-152a and 1-152b (480 mg, 0.622 mmol) was taken up in dry CH2Cl2 (6.5 mL) and 
partitioned between two microwave vials. To each vial was added Pd(PPh3)4 (35.6 mg, 0.031 
mmol), and each vial was heated in the microwave to 80 °C for 15 min. The reaction mixtures 
were combined and concentrated under reduced pressure and the residue was purified by MPLC 
(10% EtOAc/Hex) to afford 1-153a (190 mg, 0.28 mmol, 45%) and 1-153b (25.0 mg, 0.037 
mmol, 6%) as brown foams (7.5 : 1 d.r., 51% overall): 1-153a: IR (neat) 3068, 2924, 2856, 1597, 
1446, 1368, 1342, 1172, 1119, 1093, 992, 912, 813, 746 cm-1; 1H NMR (600 MHz, CDCl3) δ 
7.97 (d, J = 8.3 Hz, 1 H), 7.73 (d, J = 8.4 Hz, 3 H), 7.67 (d, J = 8.2 Hz, 2 H), 7.48 (s, 1 H), 7.28 
(t, J = 8.3 Hz, 1 H), 7.24 (d, J = 8.4 Hz, 2 H), 7.21-7.18 (m, 3 H), 5.75 (dddd, J = 6.6, 6.6, 10.3, 
16.9 Hz, 1 H),  5.64 (dddd, J = 6.4, 6.4, 10.1, 16.7 Hz, 1 H), 5.17 (dd, J = 1.3, 17.1 Hz, 1 H), 
5.13 (dd, J = 1.0, 10.1 Hz, 1 H), 4.92-4.88 (m, 2 H), 4.07 (t, J = 7.9 Hz, 1 H), 3.81, 3.77 (ddAB, J 
= 6.3, 15.7 Hz, 2 H), 3.31 (dd, J = 6.5, 15.1 Hz, 1 H), 3.26-3.13 (m, 3 H), 2.39 (s, 3 H), 2.33 (s, 3 
H), 2.05 (d, J = 9.2 Hz, 1 H), 1.97 (dd, J = 8.7, 12.2 Hz, 1 H), 1.88 (dd, J = 7.4, 12.2 Hz, 1 H), 
1.78 (dddd, J = 5.7, 10.4, 13.5, 15.7 Hz, 1 H),  1.24-1.19 (m, 1 H), 1.01 (ddd, J = 5.2, 5.2, 9.9 
Hz, 1 H), 0.49-0.40 (m, 4 H), 0.29 (ddd, J = 4.9, 5.7, 10.1 Hz, 1 H), 0.18-0.13 (m, 2 H); 13C 
NMR (150 MHz, CDCl3) δ 144.8, 143.2, 137.2, 136.0, 135.4, 134.3, 133.5, 130.0, 129.9, 129.8, 
127.2, 126.9, 125.7, 124.6, 123.9, 123.0, 120.9, 118.8, 117.1, 113.9, 69.7, 58.1, 53.6, 50.9, 47.4, 
42.8, 32.9, 24.9, 21.7, 21.6, 21.0, 13.7, 11.8, 9.4, 6.7; HRMS (EI+) m/z calculated for 
C39H46N3O4S2 (M•+) 684.2930, found 684.2919. 
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{1-[(13S*)-13-[1-(Methylphenylsulfonyl)indol-3-yl]-7-(4-methylphenylsulfonyl)-
(1S*,2S*,4R*)-7,12-diazatetracyclo[109.1.54.2](15-spiro[2.4]heptane)]cyclopropyl}hept-9-ene 
(1-154). To a solution of 1-153a (87.0 mg, 0.127 mmol) in dry CH2Cl2 (25 mL) was added 1-123 
(10.8 mg, 0.013 mmol, 10 mol%). The reaction vessel was purged under aspirator vacuum and 
refilled with ethylene gas (5 times) and kept under a balloon of ethylene while the reaction was 
heated to reflux for 4 h. The brown solution was cooled to room temperature and filtered through 
a pad of Celite/florisil (1:1 v/v) and concentrated. The crude product was purified by MPLC 
(20% EtOAc/Hex) to afford 1-154 (77.0 mg, 0.117 mmol, 92%) as a yellow foam: IR (neat) 
3056, 2924, 2859, 1597, 1446, 1639, 1341, 1212, 1160, 1120, 1093, 996, 813, 748 cm-1; 1H 
NMR (300 MHz, CDCl3) δ 7.94 (d, J = 8.2 Hz, 1 H), 7.77 (d, J = 7.8 Hz, 1 H), 7.71 (d, J = 8.7 
Hz, 2 H), 7.68 (d, J = 9.3 Hz, 2 H), 7.52 (s, 1 H), 7.31 (d, J = 8.2 Hz, 2 H), 7.27-7.24 (m, 1 H), 
7.19-7.14 (m, 3 H), 5.63-5.44 (m, 2 H), 4.11 (dd, J = 4.2, 11.7 Hz, 1 H), 3.95 (dd, J = 6.0, 10.4 
Hz, 1 H), 3.43 (d, J = 14.5 Hz, 1 H), 3.26 (d, J = 14.5 Hz, 1 H), 2.82-2.68 (m, 2 H), 2.46-2.40 
(m, 1 H), 2.42 (s, 3 H), 2.32 (s, 3 H), 2.15 (t, J = 11.5 Hz, 1 H), 1.76 (d, J = 9.5 Hz, 1 H), 1.63 
(dd, J = 6.0, 12.0 Hz, 1 H), 1.13 (ddd, J = 5.1, 5.1, 9.7 Hz, 1 H), 0.79-0.66 (m, 2 H), 0.58-0.50 
(m, 2 H), 0.43 (ddd, J = 6.2, 6.2, 10.0 Hz, 1 H), 0.30 (ddd, J = 4.9, 4.9, 10.2 Hz, 1 H), 0.24-0.13 
(m, 2 H); 13C NMR (75 MHz, CDCl3) δ 144.9, 143.4, 138.3, 136.0, 135.4, 135.2, 129.96, 129.89, 
129.81, 127.5, 126.9, 125.5, 125.0, 124.7, 123.8, 122.9, 120.9, 113.9, 77.7, 62.4, 57.8, 52.3, 47.6, 
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43.7, 36.9, 26.1, 23.6, 21.64, 21.61, 16.6, 14.9, 10.8, 9.1; HRMS (ESI) m/z calculated for 
C37H42N3O4S2 [M+H]+ 656.2617, found 656.2609. 
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1-155a 1-155b  
(9R*, 10R*)-{1-[(13S*)-13-[1-(Methylphenylsulfonyl)indol-3-yl]-7-(4-methylphenyl 
sulfonyl)-(1S*,2S*,4R*)-7,12-diazatetracyclo[109.1.54.2](15-spiro[2.4]heptane)]cyclopropyl} 
heptane-9,10-diol (1-155a) and (9S*, 10S*)-{1-[(13S*)-13-[1-(Methylphenylsulfonyl)indol-3-
yl]-7-(4-methylphenylsulfonyl)-(1S*,2S*,4R*)-7,12-diazatetracyclo[109.1.54.2](15-spiro[2.4] 
heptane)]cyclopropyl}heptane-9,10-diol (1-155b). To a stirred solution of 1-154 (120 mg, 
0.183 mmol) in THF (3.6 mL) and H2O (0.9 mL) was added N-methylmorpholine N-oxide (29.7 
mg, 0.220 mmol) at room temperature and the reaction was treated with a solution of OsO4 in 
toluene (55.4 µL of 0.33 M solution, 0.018 mmol). The pale yellow slurry was stirred for 36 h at 
which point the reaction mixture was quenched with sat. aq. Na2S2O3 (5 mL) and stirred for 30 
min. The biphasic mixture was diluted with EtOAc (5 mL) and the aqueous phase was extracted 
with EtOAc (3 x 5 mL). The combined organic layers were dried (MgSO4), filtered, 
concentrated, and the crude diols were subjected to MPLC purification (40% EtOAc/Hex) to 
afford 1-155b (33.0 mg, 0.048 mmol, 26%) and 1-155a (57.0 mg, 0.082 mmol, 45%) as yellow 
foams: 1-155a: IR (neat) 3492, 3060, 2993, 2924, 2862, 1591, 1446, 1365, 1328, 1265, 1155, 
1171, 1119, 1090, 1018, 989, 812, 733 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.95 (d, J = 8.3 Hz), 
7.76 (d, J = 8.3 Hz, 2 H), 7.68 (d, J = 6.6 Hz, 1 H), 7.65 (d, J = 8.2 Hz, 2 H), 7.61 (s, 1 H), 7.34 
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(d, J = 8.2 Hz, 2 H), 7.28 (t, J = 7.9 Hz, 1 H), 7.20 (d, J = 8.3 Hz, 2 H), 7.18 (t, J = 7.9 Hz, 1 H), 
3.98 (t, J = 7.4 Hz, 1 H), 3.57 (bs, 1 H), 3.53 (bs, 1 H), 3.49-3.35 (bm, 2 H), 3.06 (bs, 1 H), 2.85 
(bs, 1 H), 2.82 (dd, J = 4.4, 13.1 Hz, 1 H), 2.65 (bs, 1 H), 2.45 (s, 3 H), 2.32 (s, 3 H), 2.19 (bs, 1 
H), 2.05 (d, J = 9.3 Hz), 1.97 (bs, 1 H), 1.27-1.10 (m, 1 H), 1.17-1.11 (m, 2 H), 0.82-0.80 (m, 1 
H), 0.59 (dddd, J = 4.8, 4.8, 9.4, 13.5 Hz, 1 H), 0.56-0.50 (m, 2 H), 0.35-0.27 (m, 3 H); 13C 
NMR (150 MHz, CDCl3) δ 144.9, 144.1, 135.9, 135.3, 132.9, 129.98, 129.96, 129.1, 127.8, 
126.9, 125.3, 125.0, 124.6, 123.2, 120.4, 114.1, 74.9, 73.8, 67.9, 63.5, 61.2, 53.1, 51.7, 42.3, 
33.6, 29.8, 24.5, 21.7, 13.8, 10.4, 9.3; HRMS (EI+) m/z calculated for C37H43N3O6S2 (M•+) 
689.2593, found 689.2577. 1-155b: IR (neat) 3524, 3063, 2991, 2954, 2919, 1917, 1597, 1447, 
1366, 1338, 1160, 1119, 1091, 990, 909, 814, 726 cm-1; 1H NMR (600 MHz, CDCl3) mix of 
conformational isomers δ 7.95 (d, J = 8.4 Hz), 7.93 (d, J = 8.3 Hz), 7.78 (d, J = 8.3 Hz), 7.77 
(d,J = 8.3 Hz), 7.69 (s), 7.68 (d, J = 8.2 Hz), 7.66 (d, J = 8.0 Hz), 7.64 (s), 7.3 (d, J = 8.0 Hz), 
7.29 (t, J = 7.3 Hz), 7.25 (t, J = 7.4 Hz), 7.22 (t, J = 7.3 Hz), 7.18 (d, J = 8.3 Hz), 7.16 (t, J = 7.7 
Hz), 4.36 (bs), 4.21 (bs), 4.14 (dd, J = 5.6, 10.5 Hz), 4.05 (dd, J = 6.5, 9.8 Hz), 3.69-3.61 (m), 
3.56 (ddd, J = 3.4, 3.4, 6.4 Hz), 3.50 (dd, J = 10.9, 13.1 Hz), 3.27 (bdd, J = 4.2, 14.3 Hz), 3.09 
(dd, J = 4.9, 13.6 Hz), 2.94 (bt, J = 10.1 Hz), 2.86-2.77 (m), 2.67 (dd, J = 3.9, 14.2 Hz), 5.60 
(ddd, J = 5.2, 11.0, 11.0 Hz), 2.50 (dd, J = 4.2, 13.0 Hz), 2.43 (s), 2.31 (s), 2.27 (t, J = 11.3 Hz), 
2.22 (t, J = 11.6 Hz), 2.05 (d, J = 9.8 Hz), 1.73 (d, J = 9.7 Hz), 1.57-1.54 (m), 1.17 (ddd, J = 5.3, 
10.1 Hz), 0.99 (ddd, J = 4.8, 4.8, 9.5 Hz), 0.97-0.75 (m), 0.57 (ddd, J = 4.4, 5.5, 9.8 Hz), 0.55-
0.43 (m), 0.40 (ddd, J = 4.6, 4.6, 8.9 Hz), 0.36 (dddd, J = 3.9, 3.9, 8.8, 8.8 Hz); 13C NMR (150 
MHz, CDCl3) mix of conformational isomers δ 145.0. 144.8, 143.9, 143.8, 135.8, 135.5, 135.3, 
135.2, 133.8, 129.97, 129.93, 129.90, 129.87, 127.6, 127.5, 127.1, 127.0, 125.0, 124.8, 124.7, 
124.1, 123.3, 122.8, 119.9, 119.7, 114.1, 114.0, 75.9, 67.6, 66.0, 63.0, 62.4, 56.3, 52.8, 51.9, 
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49.2, 34.2, 33.8, 29.8, 27.4, 25.5, 21.71, 21.68, 16.1, 15.2, 14.6, 14.34, 14.27, 11.0; HRMS (ESI) 
m/z calculated for C37H44N3O6S2 [M+H]+ 690.2672, found 690.2681. 
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2-151  
 (R)-4-Benzyl-3-((2R,3S)-2-isopropyl-3-(triisopropylsilyloxy)butanoyl)oxazolidin-2-
one (2-151). To a solution of 2-147 (2.29 g, 8.76 mmol) in dry CH2Cl2 (23 mL) at 0 °C was 
added Bu2BOTf (2.42 mL, 9.63 mmol) followed by NEt3 (1.49 mL, 10.5 mmol). The reaction 
mixture was stirred for 15 min and was cooled to –78 °C, and freshly distilled acetaldehyde (1.10 
mL, 19.3 mmol) was added dropwise. The reaction mixture was stirred at –78 °C for 20 min and 
allowed to warm to 0 °C over 1 h at which point pH 7 phosphate buffer (5 mL) and MeOH (5 
mL) was added. A solution of H2O2 (15 mL, 2:1 v/v H2O2/MeOH) was introduced and the 
biphasic mixture was stirred for 45 min. The volatiles were removed under reduced pressure and 
the resulting aqueous phase was extracted with EtOAc (3 x 15 mL). The combined organic layers 
were dried (MgSO4), filtered and concetreated. The crude material was purified by 
chromatography on SiO2 (4:1 Hex/EtOAc) to afford 2-149 as a pale yellow oil. 
 To a solution of 2-149 (200 mg, 0.65 mmol) in dry CH2Cl2 (2 mL) was added 2,6-lutidine 
(154 µL, 1.31 mmol) followed by TIPSOTf (272 µL, 0.982 mmol) and the solution was allowed 
to stir for 1 h. The reaction mixture was quenched upon the addition of sat. aq. NH4Cl (5 mL) 
and the aqueous phase was extracted with EtOAc (3 x 5 mL). The combined organic layers were 
dried (MgSO4), filtered, concentrated and the crude product was purified by MPLC (95:5 
Hex/Et2O) to afford 2-151 (298 mg, 0.645 mmol, 99%) as a yellow oil: 1H NMR (300 MHz, 
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CDCl3) δ 7.34-7.21 (m, 5 H), 4.69-4.62 (m, 1 H), 4.35-4.23 (m, 2 H), 4.07 (dd, J = 2.2, 9.1 Hz, 1 
H), 4.02 (app q, J = 8.6 Hz, 1 H), 3.42 (dd, J = 3.1, 13.1 Hz, 1 H), 2.62 (dd, J = 10.6, 13.1 Hz, 1 
H), 2.11-1.99 (m, 1 H), 1.31 (d, J = 6.0 Hz, 3 H), 1.03 (s, 6 H), 1.02 (s, 18 H), 0.99 (d, J = 2.6 
Hz, 3 H), 0.96 (d, J = 2.5 Hz, 3 H); 13C NMR (75 MHz, CDCl3) δ 175.0, 153.4, 136.0, 129.6, 
129.1, 127.3, 69.4, 65.5, 56.2, 54.5, 38.1, 29.2, 21.1, 20.4, 18.9, 18.3, 18.2, 12.8. 
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2-172  
(2R,3S)-Ethyl 2-isopropyl-3-(methoxymethoxy)butanoate (2-172). To a solution of 
MOMCl, prepared according to a literature procedure,135
 
 was added a solution of 2-167 (5.00 g, 
28.7 mmol) in toluene (20 mL) followed by i-Pr2NEt (38.1 mL, 230 mmol) dropwise via an 
addition funnel. The cloudy reaction mixture was stirred overnight and became a yellow slurry. 
After 48 h the reaction mixture was cooled to 0 °C and was carefully quenched with sat. aq. 
NaHCO3, diluted with H2O, and the aqueous phase was extracted with EtOAc (3 x 50 mL). The 
combined organic layers were washed with brine, dried (MgSO4), concentrated and the crude 
product was purified by chromatography on SiO2 (4:1 Hex:EtOAc) to afford 2-172 (5.38 g, 24.6 
mmol, 86%) as a yellow oil and a 6:1 ratio of diastereomers by 1H NMR spectroscopy: 1H NMR 
(600 MHz, CDCl3) δ 4.67 (q, J = 6.9 Hz, 2 H), 4.18-4.12 (m, 2 H), 3.96 (dd, J = 6.4, 7.5 Hz, 1 
H), 3.38 (s, 2 H), 2.42 (t, J = 7.6 Hz, 1 H), 2.09 (sextet, J = 6.9 Hz, 1 H), 1.28-1.26 (m, 1 H), 
1.26 (t, J = 7.1 Hz, 3 H), 1.23 (d, J = 6.3 Hz, 3 H), 0.95 (d, J = 6.9 Hz, 3 H), 0.93 (d, J = 6.7 Hz, 
3 H).  
 142 
O OO
H
2-173  
(2R,3S)-2-Isopropyl-3-(methoxymethoxy)butanal (2-173). A solution of 2-172 (250 
mg, 1.14 mmol) in dry CH2Cl2 (10 mL) was cooled to –78 °C and DIBAL-H (1.14 mL, 1.14 
mmol, 1 M in hexane) was introduced dropwise and the colorless solution was stirred for 1 h and 
additional DIBAL-H (2.2 mL, 2.28 mmol, 1 M in hexane) was introduced. The reaction mixture 
was allowed to warm to room temperature and was stirred for 30 min, and carefully quenched 
with sat. aq. Rochelle's salt solution (10 mL). The colorless slurry was stirred for 30 min until it 
cleared, and the aqueous phase was extracted with CH2Cl2 (3 x 10 mL). The combined organic 
layers were dried (MgSO4), concentrated under reduced pressure, and purified by MPLC (4:1 
Hex/EtOAc) to afford the alcohol (195 mg, 1.11 mmol, 96%) as a thin pale yellow oil. 
To a solution of the alcohol (155 mg, 0.88 mmol) in CH2Cl2 (8 mL) was added 4A 
powdered molecular seives (155 mg) followed by NMO (212 mg, 1.76 mmol). The colorless 
slurry was cooled to 0 °C and TPAP (16 mg, 0.09 mmol) was added. The black slurry was stirred 
for 2 h at room temperature and the reaction mixture was filtered thorugh SiO2 washed with 4:1 
Hex/EtOAc and concentrated. The resulting yellow oil, 2-173 (148 mg, 0.849 mmol, 97%), was 
used without purification as a 6:1 mixture of diastereomers by 1H NMR spectroscopy: 1H NMR 
(600 MHz, CDCl3) δ 9.80 (d, J = 3.7, 1 H), 4.70 (d, J = 7.0 Hz, 1 H), 4.65 (d, J = 7.0 Hz, 1 H), 
4.09 (t, J = 6.4 Hz, 1 H), 3.38 (s, 3 H), 2.37 (ddd, J = 3.7, 6.5, 7.7 Hz, 1 H), 2.16 (sextet, J = 6.8 
Hz, 1 H), 1.24 (d, J = 6.5, 3 H), 1.02 (d, J = 6.9 Hz, 3 H), 0.96 (d, J = 6.8 Hz, 3 H). 
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2-176  
5-((2S,3R)-2-(Methoxymethoxy)-4-methylpentan-3-yl)-3-methylfuran-2(5H)-one (2-
176). A solution of 2-175 (30 mg, 0.111 mmol) in toluene (10 mL), and treated with Grubbs 2nd 
generation metathesis catalyst (4.70 mg, 0.006 mmol), and the pink solution was heated to 80 °C. 
for 2 h, and more Grubbs 2nd (4.70 mg, 0.006 mmol) was added. After heating the reaction 
mixture for another 1 h at 80 °C, more catalyst (4.70 mg, 0.006 mmol) was added. After 1 h the 
reaction mixture was filtered through Celite and the product was purified by MPLC (4:1 
Hex:EtOAc) to afford 2-175 (22.0 mg, 0.091 mmol, 82%) as a dark oil and a 1.4:1 mixture of 
inseparable diastereomers by 1H NMR spectroscopy: 1H NMR (600 MHz, CDCl3) δ (major 
peaks)  7.23 (t, J = 1.5 Hz) 7.18 (t, J = 1.5 Hz), 5.18-5.17 (m), 5.15-5.13 (m), 4.64 (t, J = 6.8 
Hz), 4.61 (t, J = 6.6 Hz), 4.54 (d, J = 6.9 Hz), 4.01-3.97 (m), 3.87-3.82 (m), 3.35 (s), 3.33 (s), 
2.08-2.01 (m), 1.98-1.92 (m), 1.91 (ddd, J = 1.8, 1.8, 4.3 Hz), 1.71-1.68 (m), 1.68-1.65 (m), 1.25 
(d, J = 6.5 Hz), 1.13 (d, J = 6.6 Hz), 1.02 (d, J = 6.8 Hz), 0.99 (d, J = 7.1 Hz), 0.98 (d, J = 7.0 
Hz), 0.96 (d, J = 6.9 Hz). 
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2-178  
(3S,3aR,5S,6R,6aR)-6-Isopropyl-3,5-dimethyltetrahydrofuro[3,2-b]furan-2(5H)-one 
(2-178). To a solution of 2-177 (18.0 mg, 0.091 mmol) in toluene (1 mL) at room temperature 
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was added KOt-Bu (3 mg, 0.027 mmol). A brown precipitate developed, and the reaction 
mixture was stirred for 5 h at which point additional KOt-Bu (10 mg, 0.089 mmol) was added. 
The reaction became orange and was allowed to stir for 4 h before being quenched with sat. aq. 
NaHCO3, diluted with H2O (1 mL) and Et2O (1 mL), and the aqueous phase was extracted with 
Et2O (3 x 5 mL). The combined organic layers were dried (MgSO4), filtered, concentrated, and 
MPLC purification (9:1 Hex:EtOAc) of the crude material yielded 4 peaks (10 mg, 0.050 mmol, 
56%). The major peak was isolated and 1H NMR spectroscopy confirms 2-178: 1H NMR (600 
MHz, CDCl3) δ 4.88 (t, J = 4.0 Hz, 1 H), 4.63 (dd, J = 4.0, 5.6 Hz, 1 H), 4.42 (p, J = 6.9 Hz, 1 
H), 2.69 (ddd, J = 5.8, 7.3, 13.1 Hz, 1 H), 2.03-1.94 (m, 2 H), 1.30 (d, J = 7.3 Hz, 3 H), 1.13 (d, J 
= 6.7 Hz, 3 H), 1.11 (t, J = 6.1 Hz, 3 H), 0.96 (d, J = 6.2 Hz, 3 H). 
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2-182  
(S)-1-(2-(1,3-Dioxolan-2-yl)ethyl)-5-(hydroxymethyl)pyrrolidin-2-one (2-182). A 
solution of 2-180 (300 mg, 1.31 mmol), TBAI (48 mg, 0.13 mmol) and dioxolane 2-142 (313 
µL, 2.62 mmol) in dry DMF (20 mL) was cooled to –15 °C, and treated with KHMDS (1.6 mL, 
1.57 mmol, 1.0 M in THF) dropwise. The solution turned orange during course of addition and 
the reaction mixture was allowed to warm to room temperature after 30 min and was stirred 
overnight. The reaction mixture was quenched with sat. aq. NH4Cl (10 mL) and diluted with H2O 
(50 mL). The aqueous phase was extracted with CH2Cl2 (3 x 20 mL). The combined organic 
layers were washed with H2O (2 x 10 mL) and brine (2 x 10 mL), dried (MgSO4), filtered and 
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concentrated to an orange oil (2-181 and DMF). The crude material was used without further 
purification. 
To a solution of crude 2-181 in THF (10 mL) was added TBAF (1.44 mL, 1.44 mmol, 1 
M in THF) and the resulting solution was stirred for 45 min at room temperature. The reaction 
mixture was quenched with H2O (10 mL) and the aqueous layer was extracted with EtOAc (3 x 
10 mL). The combined organic layers were dried (MgSO4), filtered and concentrated. The crude 
product was purified by chromatography on SiO2 (7:3 EtOAc/MeOH followed by 1:1 
EtOAc/MeOH). The rich fractions were concentrated and the residue was dissolved in a minimal 
amount of CH2Cl2 and filtered through a cotton plug to provide 2-182 (94 mg, 0.436 mmol, 33% 
over 2 steps) as a colorless oil: 1H NMR (600 MHz, CDCl3) δ 4.96 (dd, J = 3.6, 5.5 Hz, 1 H), 
3.99-3.94 (m, 2 H), 3.89-3.81 (m, 3 H), 3.67 (dddd, J = 3.1, 3.1, 4.6, 7.7 Hz 1 H), 3.58 (bd, J = 
12.0 Hz, 1 H), 3.53-3.43 (m, 2 H), 2.82 (bs, 1 H), 2.49 (ddd, J = 7.1, 10.1, 17.1 Hz, 1 H), 2.30 
(ddd, J = 5.6, 10.3, 15.9 Hz, 1 H), 2.13-2.08 (m, 1 H), 2.06-2.01 (m, 1 H), 2.01-1.97 (m, 1 H), 
1.96-1.89 (m, 1 H),  
 
N
OH
O
O
2-183  
(S)-1-(2-(1,3-Dioxolan-2-yl)ethyl)-5-vinylpyrrolidin-2-one (2-183). To a solution of 
DMSO (90.0 µL, 1.25 mmol) in dry CH2Cl2 (5 mL) at –78 °C was added oxalyl chloride (54.9 
µL, 0.627 mmol) and the colorless solution was stirred for 40 min. To this mixture was added 2-
182 (90.0 mg, 0.418 mmol) in dry CH2Cl2 (2 mL) dropwise. The reaction mixture was stirred for 
2 h at –78 °C and the pale yellow slurry was treated with NEt3 (308 µL, 2.17 mmol) and the 
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slurry cleared to a pale yellow solution that was allowed to stir for 1 h at –78 °C before warming 
to room temperature. The reaction mixture was quenched with H2O (5 mL) and the aqueous 
phase was extracted with CH2Cl2 (3 x 10 mL), dried (MgSO4), and concentrated to afford the 
crude aldehyde, which was taken on to the next step without purification. 
To a slurry of KOtBu (147 mg, 1.31 mmol) in dry THF (1 mL) was added MePPh3Br 
(202 mg, 1.27 mmol) and a canary-yellow slurry developed immediately. To the reaction mixture 
was added a solution of crude aldehyde (90.0 mg, 0.422 mmol). The slurry became brown 
immediately and was stirred at room temperature for 30 min. The reaction mixture was quenched 
with sat. aq. NH4Cl (3 mL), and the aqueous phase was extracted with EtOAc (3 x 5 mL), dried 
(MgSO4), concentrated, and purified by MPLC (100% EtOAc) to yield 2-183 (16 mg, 0.076 
mmol, 18%) as an orange oil: 1H NMR (600 MHz, CDCl3) δ 5.65 (ddd, J = 8.5, 10.0, 17.0 Hz, 1 
H), 5.24 (d, J = 17.0 Hz, 1 H), 5.20 (ddd, J = 0.7, 0.7, 10.0 Hz, 1 H), 4.86 (t, J = 4.6 Hz, 1 H), 
4.07 (ddd, J = 5.8, 8.1, 8.1 Hz, 1 H), 3.96-3.91 (m, 2 H), 3.84-3.80 (m, 2 H), 3.72 (ddd, J = 7.4, 
7.4, 14.1 Hz, 1 H), 3.01 (ddd, J = 5.7, 8.3, 13.8 Hz, 1 H), 2.40 (ddd, J = 5.9, 9.5, 16.4 Hz, 1 H), 
2.32 (ddd, J = 7.2, 9.5, 16.7 Hz, 1 H), 2.24-2.18 (m, 1 H), 1.90-1.80 (m, 2 H), 1.73 (dddd, J = 
5.7, 7.0, 9.5, 12.8 Hz, 1 H); 13C NMR (150 MHz, CDCl3) δ 175.2, 137.9, 118.2, 102.9, 65.0, 
64.9, 61.5, 36.1, 31.6, 30.2, 25.7; HRMS (EI) m/z calculated for C11H17NO3 (M·+) 211.1208, 
found 211.1207. 
 
OPMB
2-196   
1-(4-Methoxyphenyl)methoxy-3-butyne (2-196). To a cooled solution of 3-butynol 
(4.86 mL, 64.2 mmol) in dry THF (110 ml) and dry DMF (20 mL) at 0 °C was added NaH (3.08 
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g, 77.04 mmol, 60% disp. in mineral oil) in a single portion. After bubbling had ceased, freshly 
prepared PMBI136 (19.11 g, 77.04 mmol) was introduced via an addition funnel and the reaction 
mixture was allowed to warm to room temperature. After 16 h sat. aq. NH4Cl (20 mL) was added 
and the biphasic mixture was diluted with H2O (50 mL) and extracted with Et2O (3 x 30 mL), 
The combined organic layers were washed with brine (3 x 25 mL), dried (MgSO4), filtered, 
concentrated in vacuo, and the product was purified by chromatography on SiO2 (10% 
EtOAc/Hex) to yield 2-196 (11.0 g, 57.8 mmol, 90%) as a yellow oil. Analytical data matched 
previously reported data for 2-196:137
 
 1H NMR (600 MHz, CDCl3) δ 7.27 (d, J = 8.6 Hz, 2 H), 
6.88 (d, J = 8.6 Hz, 2 H), 4.49 (s, 2 H), 3.81 (s, 3 H), 3.57 (t, J = 7.0 Hz, 2 H), 2.48 (dt, J = 2.6, 
7.0 Hz, 2 H), 1.99 (t, J = 2.6 H, 1 H); 13C NMR (150 MHz, CDCl3) δ 159.4, 130.2, 129.5, 113.9, 
81.5, 72.8, 69.4, 67.9, 55.4, 20.0. 
HO OPMB
2-197  
5-(4-Methoxy-benzyloxy)-2E-penten-1-ol (2-197). To a solution of 2-196 (10 g, 52.6 
mmol) in THF (140 mL) cooled to 0 °C was added n-BuLi (53.0 mL, 57.8 mmol, 1.09 M 
solution in hexanes). The reaction mixture was stirred for 15 min at 0 °C and paraformaldehyde 
(3.02 mL, 84.1 mmol) was added in a single porotion. The reaction mixture was stirred for 1 h 
and quenched with H2O (50 mL) and the aqueous phase was extracted with EtOAc (3 x 20 mL). 
The combined organic layers were dried (MgSO4), concentrated in vacuo, and the crude 
propargyl alcohol (6.98 g, 31.7 mmol, 60%) was carried on without further purification. 
To a stirred solution of the alcohol (6.72 g, 30.5 mmol) in dry THF (175 mL) cooled to 0 
°C was added Red-Al (32.2 mL, 107 mmol), dropwise. The reaction mixture was allowed to 
warm to room temperature, stirred for 4 h and carefully quenched with H2O (200 mL). The 
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aqueous phase was extracted with EtOAc (3 x 100 mL) and the combined organic layers were 
dried (MgSO4), filtered through Celite, and concentrated in vacuo. The crude yellow oil (3.78 g, 
99%, 10:1 pdt:sm by 1H NMR) was used without further purification, and analytical data 
matched the previously reported data for 2-197:2 1H NMR (600 MHz, CDCl3) δ 7.26 (d, J = 8.6 
Hz, 2 H), 6.88 (d, J = 8.6 Hz, 2 H), 5.72-5.70 (m, 2 H), 4.44, (s, 2 H), 4.09 (bm, 2 H), 3.81 (s, 3 
H), 3.49 (t, J = 6.7 Hz, 2 H), 2.36 (m, 2 H), 1.33 (bs, 1 H); 13C NMR (150 MHz, CDCl3) δ 159.3, 
131.0, 130.5, 129.5, 128.8, 113.9, 72.7, 69.4, 63.8, 55.4, 32.8. 
 
HO OPMB
O
2-198  
(2S, 3S)-5-(4-Methoxyphenyl)methoxy-2,3-epoxy-1-pentanol (2-198). (+)-
Diisopropyl-L-tartrate (5.18 mL, 24.4 mmol) was added to a solution of freshly distilled Ti(Oi-
Pr)4 (6.79 mL, 22.1 mmol) in dry CH2Cl2 (20 mL) at room temperature. The colorless solution 
was stirred for 30 min and the volatiles were removed in vacuo. The residue was placed under 
reduced pressure (~1 torr) for 1 h. The resulting pale yellow foam was redissolved in dry CH2Cl2 
(250 mL) and the resulting solution was cooled to –20 °C. To this mixture was added 4 Å 
molecular sieves (4 g) and 2-197 (4.30 g, 18.8 mmol). After 30 min a solution of t-BuOOH in 
toluene138 (14.4 mL, 56.3 mmol, 3.9 M) was added and the reaction was allowed to stir at –20 °C 
for 16 h. The reaction was quenched with sat. aq. Na2S2O3 (100 mL) and diluted with sat. aq. 
Rochelle’s salt (100 mL) and EtOAc (100 mL). The aqueous slurry was extracted with EtOAc (3 
x 50 mL), and the combined organic extracts were washed with brine (30 mL) and dried 
(MgSO4), filtered through a pad of Celite, and concentrated. The crude residue was purified by 
chromatography on SiO2 (50% EtOAc/Hex) to provide 2-198 (2.95 g, 12.4 mmol, 66%, 94% ee) 
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as colorless oil. Analytical data matches previously reported data for 2-198:139
 
 [α]D -26.0 (c 1.0, 
CHCl3) (lit. [α]D21 = -27.7 (c 0.9, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.25 (d, J = 7.9 Hz, 2 
H), 6.79 (d, J = 8.7 Hz, 2 H), 4.46 (d, J = 11.5 Hz, 1 H), 4.44 (d, J = 11.5 Hz, 1 H), 3.89 (ddd, J 
= 2.7, 5.5, 12.6 Hz, 1 H), 3.80 (s, 3 H), 3.61 (ddd, J = 4.4, 7.3, 11.8 Hz, 1 H), 3.59-3.56 (m, 2 H), 
3.09 (ddd, J = 2.3, 4.8, 6.8 Hz, 1 H), 2.97 (ddd, J = 2.5, 2.5, 4.7 Hz, 1 H), 1.92 (dddd, J = 4.8, 
6.1, 7.3, 12.1 Hz, 1 H), 1.85-1.78 (m, 2 H); 13C NMR (150 MHz, CDCl3) δ 159.3, 130.4, 129.4, 
113.9, 72.9, 66.6, 61.8, 58.5, 55.4, 53.8, 32.2. 
OPMBI
O
3-1  
(1S, 2R)-2-Iodomethyl-3-[2-(4-methoxy-benzyloxy)-ethyl]-oxirane (3-1). A well-
stirred solution of 4 (2.00 g, 8.39 mmol) in a mixture of THF/MeCN (120 mL, 30 mL) at room 
temperature was treated with imidazole (4.33 g, 63.0 mmol), PPh3 (6.60 g, 25.2 mmol) and I2 
(6.39 g, 25.2 mmol). After 5 min the reaction mixture was diluted with Et2O (200 mL) and 
washed with sat. aq. NaHCO3 (100 mL), sat. aq. NaHSO3 (25 mL, to remove remaining iodine), 
and brine (100 mL).  The combined organic extracts were dried (MgSO4), concentrated in vacuo, 
and passed through a pad of SiO2 (10% EtOAc/Hex) to provide of 3-1 (2.61 g, 7.49 mmol, 89%) 
as a colorless oil. Analytical data matched previously reported data for 3-1:139 1H NMR (600 
MHz, C6D6) δ 7.19 (d, J = 8.6 Hz, 2 H), 6.81 (d, J = 8.6 Hz, 2 H), 4.25 (d, J =16.1 Hz, 1 H), 4.23 
(d, J = 16.1 Hz, 1 H), 3.29 (s, 3 H), 3.31-3.23 (m, 1 H), 2.63-2.58 (m, 2 H), 2.50-2.47 (m, 1 H), 
1.56 (dddd, J = 5.3, 5.3, 7.6, 10.4 Hz, 1 H), 1.47 (dddd, J = 6.0, 6.0, 11.5, 11.5 Hz, 1 H); 13C 
NMR (150 MHz, C6D6) δ 160.4, 131.5, 130.0, 128.9, 128.7, 128.5, 114.7, 73.5, 73.5, 67.1, 64.5, 
60.5, 58.7, 55.4, 33.2, 14.0, 6.0. 
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OPMB
OH
2-199  
(3S)-5-(4-Methoxy-benzyloxy)-pent-1-en-3-ol (2-199). According to a literature 
procedure,3 a slurry of 3-1 (2.55 g, 7.32 mmol) and zinc dust (1.43 g, 22.0 mmol) in MeOH (95 
mL) was sonicated at room temperature for 90 min. The grey slurry was diluted with Et2O (100 
mL), filtered through Celite, and washed with 5% aq. HCl  (25 mL), sat. aq. NaHCO3 (25 mL), 
and brine (25 mL). The combined organic layers were dried (MgSO4), filtered, and concentrated 
in vacuo to afford 2-199 (1.22 g, 5.49 mmol, 75%) as a yellow oil that was used without further 
purification: 1H NMR δ 7.13 (d, J = 8.8 Hz, 2 H), 6.76 (d, J = 8.6 Hz, 2 H), 5.78 (ddd, J = 5.2, 
10.4, 15.7 Hz, 1 H), 5.31 (ddd, J = 1.7, 1.7, 17.1 Hz, 1 H), 5.00 (ddd, J = 1.7, 1.7, 10.5 Hz, 1 H), 
4.25 (bm, 1 H), 4.20 (d, J = 11.6 Hz, 1 H), 4.17 (d, J = 11.6 Hz, 1 H), 3.43 (ddd, J = 5.1, 6.1, 9.2 
Hz, 1 H), 3.32 (ddd, J = 5.0, 6.8, 9.2 Hz, 1 H), 3.28 (s, 3 H), 1.69-1.61 (m, 2 H); 13C NMR (150 
MHz, C6D6) δ 159.8, 141.7, 130.7, 129.5, 128.4, 128.1, 128.0, 114.1, 113.7, 73.0, 71.7, 68.1, 
54.8. 
 
H
O
OTBS
2-200  
3-(tert-Butyldimethylsilyloxy)propionaldehyde (2-200). To a stirred solution of DMSO 
(8.39 mL, 118 mmol) in dry CH2Cl2 (450 mL) at –78 °C was added oxalyl chloride (5.17 mL, 
59.1 mmol) at a dropwise rate and the colorless solution was stirred for 1 h until gas evolution 
subsided. 3-(tert-Butyldimethylsilyloxy)-propan-1-ol (8.25 mL, 7.50 g, 39.4 mmol) was added 
dropwise and the resulting colorless slurry was stirred at –78 °C for 30 min. Triethylamine (29.1 
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mL, 205 mmol) was introduced slowly and the reaction mixture was stirred at –78 °C for an 
additional 30 min before being allowed to warm to 0 °C over 30 min. H2O (200 mL) was added 
and the biphasic mixture was extracted with CH2Cl2 (3 x 100 mL). The combined organic layers 
were dried (MgSO4) and concentrated in vacuo to afford a cloudy yellow oil that was taken up in 
a minimal amount of CH2Cl2 and passed through a pad of silica gel (1:1 EtOAc/Hex) and 
concentrated to yield 2-200 (7.41 g, 7.42 mmol, 99% yield) as a pungent yellow oil: 1H NMR 
(600 MHz, CDCl3) δ 9.80 (t, J = 2.1 Hz, 1 H), 3.99 (t, J = 6.1 Hz, 2 H), 2.60 (dt, J = 2.1, 6.1 , 2 
H), 0.88 (s, 9 H), 0.06 (s, 6 H); 13C NMR (150 MHz, CDCl3) δ 202.1, 57.4, 46.6, 41.0, 25.8, 
18.2, –5.4. 
 
OH
OTBS
TMS 2-201  
(3S)-5-(tert-Butyldimethylsilyloxy)-1-(trimethylsilyl)pent-1-yn-3-ol (2-201). To an 
oven-dried 1 L RBF charged with TMS-acetylene (18.5 mL, 127 mmol) in dry toluene (147 mL) 
under an atmosphere of N2 at room temperature was added dropwise with EXTREME 
CAUTION (PYROPHORIC) neat ZnEt2 (13.7 mL, 10.4 mmol). The brown turbid solution was 
heated to reflux for 1 h under N2 during which time a grey precipitate formed. The reaction was 
allowed to cool to room temperature and (R)-binol (4.60 g, 15.9 mmol) was added in one portion 
followed by the slow addition of dry Et2O (620 mL). To the well-stirred slurry was added Ti(Oi-
Pr)4 (9.77 mL, 31.86 mmol) and the resulting orange slurry was stirred at room temperature for 1 
h before 2-200 (6.00 g, 31.9 mmol) was added in dry Et2O (20 mL). The reaction mixture was 
stirred vigorously for 20 h and was carefully quenched with brine (20 mL) and poured into a 2 L 
erlynmeyer flask containing brine (180 mL) and Rochelle's salt solution (200 mL, 1.0 M aq.), 
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and the biphasic mixture was stirred vigorously for 1 h. The aqueous phase was extracted with 
Et2O (4 x 100 mL) and the combined organic layers were dried (MgSO4), filtered, concentrated 
in vacuo, and the residue was purified by chromatography on SiO2 (10 % Et2O/Hex) to yield 2-
201 (7.01 g, 24.2 mmol, 76%) as a pale yellow oil: [α]D -16.4 (c 1.07, CHCl3); IR (neat) 3375, 
2952, 2925, 2855, 2171, 1470, 1248, 1088, 831, 773 cm-1; 1H NMR (600 MHz, CDCl3) δ 4.60 
(dd, J = 4.3, 6.4 Hz, 1 H), 4.05 (ddd, J = 3.8, 8.2, 10.2 Hz, 1 H), 3.83 (ddd, J = 4.3, 5.9, 10.2 Hz, 
1 H), 3.44 (bs, 1 H), 2.00 (dddd, J = 4.3, 4.3, 8.3, 14.2 Hz, 1 H), 1.85 (dddd, J = 3.8, 6.1, 6.1, 
14.2 Hz, 1 H), 0.90 (s, 9 H), 0.17 (s, 9 H), 0.09 (s, 3 H), 0.08 (s, 3 H); 13C NMR (150 MHz, 
CDCl3) δ 106.3, 89.4, 62.6, 61.3, 38.5, 26.0, 18.3, 0.06, –5.4, –5.4.  
 
OTBS
OTBS
3-2  
(3S)-3,5-Bis-(tert-butyldimethylsilyloxy)-pent-1-yne (3-2). A solution of 2-201 (6.9 g, 
24.1 mmol) in dry DMF (60 mL) and treated with imidazole (3.31 g, 48.16 mmol) and a solution 
of TBSCl (5.50 g, 36.12 mmol) in DMF (10 mL). The reaction mixture was stirred for 4 h and 
was quenched with H2O (50 mL) and diluted with Et2O (50 mL). The biphasic mixture was 
separated and the aqueous phase was extracted with Et2O (3 x 20 mL). The combined organic 
layers were washed with H2O (50 mL) and brine (3 x 100 mL). The organic layer was dried 
(MgSO4), filtered, concentrated, and the crude oil was used without further purification (9.80 g, 
24.5 mmol, 101%). 
To a stirred solution of 2-201 (1.00 g, 2.49 mmol) in MeOH (25 mL) was added K2CO3 
(1.13 g, 8.23 mmol) and the reaction mixture became cloudy within 15 min. After stirring for 1 h 
the reaction mixture was diluted with H2O (30 mL) and Et2O (30 mL). The aqueous phase was 
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extracted with Et2O (3 x 30 mL) and the combined organic layers were washed with brine, dried 
(MgSO4), filtered, and concentrated in vacuo to afford 3-2 as a yellow oil (716 mg, 2.17 mmol, 
87%) with a small amount of silane byproducts by 1H NMR analysis: IR (neat) 2952, 2925, 
2883, 1470, 1360, 1250, 1090, 831, 773 cm-1; 1H NMR (600 MHz, CDCl3) δ 4.56 (ddd, J = 2.1, 
5.9, 7.7 Hz, 1 H), 3.76-3.69 (m, 1 H), 2.38 (d, J = 2.2 Hz, 1 H), 1.93-1.82 (m, 2 H), 0.90 (s, 9 H), 
0.89 (s, 9 H), 0.14 (s, 3 H), 0.11 (s, 3 H), 0.04 (s, 3 H), 0.04 (s, 3 H); 13C NMR (150 MHz, 
CDCl3) δ 85.7, 72.2, 59.7, 59.0, 41.8, 26.1, 25.9, 25.8, 18.4, –2.8, –4.5, –5.0, –5.2. 
 
OTBS
OTBS
3-3  
(3S)-3,5-(bis-tert-Butyldimethysiloxy)-pent-1-ene (3-3). A solution of 3-2 (674 mg, 
2.16 mmol) in dry CH2Cl2 (7 mL) was treated with Cp2Zr(H)Cl (537 mg, 2.67 mmol). The 
yellow reaction mixture cleared after 15 min and TLC showed the starting material had been 
consumed (Rf = 0.1, 100% Hex, yellow stain in p-anisaldehyde stain; product stains blue).  The 
reaction mixture was quenched with H2O (5 mL), and the aqueous phase was extracted with Et2O 
(3 x 20 mL), and the combined organic extracts were dried (MgSO4), filtered through Celite, and 
concentrated in vacuo to afford a yellow solid. The residue was suspended in Et2O (10 mL) and 
filtered through a pad of Celite and concentrated to afford pure 3-3 (678 mg, 2.05 mmol, 99%) as 
a yellow oil: 1H NMR (600 MHz, CDCl3) δ 5.81 (ddd, J = 6.1, 10.4, 17.1 Hz, 1 H), 5.15 (ddd, J 
= 1.4, 1.4, 17.1 Hz, 1 H), 5.02 (ddd, J = 1.3, 1.8, 10.4 Hz, 1 H), 4.27 (app qt, J = 1.2, 6.0 Hz, 1 
H), 3.70-3.61 (m, 2 H), 1.75-1.62 (m, 2 H), 0.89 (s, 9 H), 0.89 (s, 9 H), 0.06 (s, 3 H), 0.04 (s, 3 
H), 0.04 (s, 3 H), 0.03 (s, 3 H). 
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OTBS
OH
2-206  
(3S)-3-(tert-Butyldimethysiloxy)-pent-1-en-5-ol (2-206). Method A from 3-3: A 
cooled (–30 °C) solution of 13 (100 mg, 0.302 mmol) in CH2Cl2 (5 mL) and MeOH (5mL) was 
cooled to –30 °C in a CO2/acetone bath and was treated with CSA (7.00 mg, 0.0302 mmol). The 
colorless solution was stirred at –30 °C for 5 h until the starting material was consumed by TLC 
analysis (Rf sm = 0.9, 30% Et2O/Hex). The reaction mixture was quenched with sat. aq. NaHCO3 
(10 mL), washed with EtOAc (3 x 10 mL), dried (MgSO4), concentrated and purified by 
chromatography on SiO2 (20% Et2O/Hex) to afford 3-4 (44.7 mg, 0.206 mmol, 68%) as a pale 
yellow oil. Analytical data matched previously reported data for 3-3:139 1H NMR (600 MHz, 
CDCl3) δ 5.85 (ddd, J = 5.8, 10.4, 17.2 Hz, 1 H), 5.23 (ddd, J = 1.5, 1.5, 17.2 Hz), 5.11 (ddd, J = 
1.5, 1.5, 10.4 Hz, 1 H), 4.42 (ddddd, J = 1.4, 1.4, 4.5, 6.0, 6.0 Hz, 1 H), 3.82 (ddd J = 3.8, 8.3, 
11.2 Hz, 1 H), 3.72 (app q, J = 5.0, 1 H), 2.42 (bs, 1 H), 1.86 (dddd, J = 4.4, 4.4, 8.3, 14.3 Hz, 1 
H), 1.72 (dddd, J = 3.8, 6.2, 6.2, 14.3 Hz, 1 H), 0.91 (s, 9 H), 0.09 (s, 3 H), 0.06 (s, 3 H); 13C 
NMR (150 MHz, CDCl3) δ 140.7, 114.6, 73.4, 60.3, 39.2, 26.0, 18.3, –4.3, –4.9. 
 
OH O
OtBu
2-202  
tert-Butyl 3-hydroxypent-4-enoate (2-202). Following a literature procedure,140 a cooled 
solution of i-Pr2NH (47.1 mL, 0.330 mol) at –78 °C in dry THF (600 mL) was treated with n-
BuLi (244 mL, 0.330 mol, 1.3 M in hexanes) over 20 min. The yellow solution was stirred at –78 
°C for 20 min, before t-BuOAc (40.9 mL, 0.300 mol) was added. The mixture was stirred for 1 h 
at –78 °C before freshly distilled acrolein (22.5 mL, 0.300 mol) in dry THF (150 mL) was 
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introduced to the reaction mixture by cannula. The reaction was stirred for 1 h and was quenched 
with sat. aq. NH4Cl (200 mL), extracted with Et2O (3 x 100 mL), dried (MgSO4) and 
concentrated to afford 2-202 (47.0 g, 91%) as an orange oil that was used without further 
purification. Analytical data matched previously reported data for 12:140 1H NMR (600 MHz, 
CDCl3) δ 5.87 (ddd, J = 5.5, 10.5, 17.2 Hz, 1 H), 5.30 (dm, J = 17.2 Hz, 1 H), 5.14 (dm, J = 10.5 
Hz, 1 H), 4.49 (bm, 1 H), 3.13 (bs, 1 H), 2.51 (dd J = 3.8, 16.2 Hz, 1 H), 2.43 (dd, J = 8.2, 16.5 
Hz, 1 H), 1.46 (s, 9 H). 
 
OAc O
OtBu
2-203  
(S)-tert-Butyl 3-(acetoxy)pent-4-enoate (2-203). Following a literature procedure,119,141
119
 a 
solution of 2-202 (7.3 g, 42.4 mmol) and vinyl acetate (7.89 mL, 84.8 mmol) in pentane (260 
mL) was added PS Amano lipase (3.3 g) and the slurry was heated to reflux for 45 h. The 
reaction slurry was filtered and concentrated in vacuo to afford a yellow oil that was purified by 
chromatography on SiO2 (10% Et2O/Hex) to provide 13 (4.00 g, 18.7 mmol, 44%) as a colorless 
oil followed by enantioenriched 2-204 (3.2 g, 18.6 mmol, 44%). Analytical data matched 
previously reported data for 2-203: ,141 1H NMR (600 MHz, CDCl3) δ 5.82 (ddd, J = 6.2, 10.5, 
17.1 Hz, 1 H), 5.60 (app q, J = 6.8 Hz, 1 H), 5.30 (dt, J = 1.1, 17.2 Hz, 1 H), 5.20 (dt, J = 1.3, 
10.5 Hz, 1 H), 2.60, (dd, J = 8.2, 15.3 Hz, 1 H), 2.52 (dd, J = 5.7, 15.3 Hz, 1 H), 2.06 (s, 3 H), 
1.44 (s, 9 H); 13C NMR (150 MHz, CDCl3) δ 169.8, 169.0, 135.1, 117.4, 81.1, 71.1, 40.7, 28.0, 
21.1. 
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TBSO O
OtBu
2-205  
(S)-tert-Butyl 3-(tert-butyldimethylsilyloxy)pent-4-enoate (2-205). Following a literature 
procedure,119 2-203 (14.0 g, 65.2 mmol) in MeOH (300 mL) was cooled to –30 °C and treated 
with K2CO3 (13.5 g, 98.0 mmol) and the slurry was stirred for 16 h at –30 °C. The mixture was 
quenched with sat. aq. NH4Cl (300 mL) and the aqueous phase was extracted with Et2O (3 x 50 
mL). The combined organic layers were washed with brine, dried (MgSO4), filtered and 
concentrated to afford the free alcohol (10.9 g, 63.3 mmol, 97%) as a yellow oil that was used in 
the next reaction without further purification. 
The crude oil (10.9 g, 63.3 mmol) was taken up in dry CH2Cl2 (290 mL) and to this solution 
was added imidazole (6.52 g, 94.9 mmol) and TBSCl (11.7 g, 75.9 mmol). The reaction mixture 
was stirred for 48 h, and additional portions of imidazole (6.52 g, 94.9 mmol) and TBSCl (11.7 
g, 75.9 mmol) were added. After 24 h the reaction was quenched with sat. aq. NH4Cl (300 mL) 
and the aqueous phase was extracted with Et2O (3 x 100 mL). The combined organic layers were 
dried (MgSO4), filtered and concentrated. The crude material was purified by chromatography on 
SiO2 (100% Hex, followed by 5% Et2O/Hex) to afford 2-205 (15.93 g, 55.6 mmol, 88%) as a 
pale yellow oil. Analytical data matched previously reported data for 14:119 1H NMR (600 MHz, 
CDCl3) δ 5.83 (ddd, J = 6.2, 10.3, 16.9 Hz, 1 H), 5.2 (dt, J = 1.2, 17.2 Hz, 1 H), 5.05 (dt, J = 1.0, 
10.4 Hz, 1 H), 4.53 (dddd J = 1.2, 1.2, 6.1, 7.4, 10.3 Hz, 1 H), 2.45 (dd, J = 7.4, 14.7 Hz, 1 H), 
2.34 (dd, J = 5.7, 14.7 Hz, 1 H), 1.44 (s, 9 H), 0.88 (s, 9 H), 0.07 (s, 3 H), 0.04 (s, 3 H); 13C 
NMR (150 MHz, CDCl3) δ 170.5, 140.6, 114.6, 80.6, 71.0, 44.9, 28.3, 26.0, 18.3, -4.2, -4.8. 
 
 
 157 
TBSO
OH
2-206  
(S)-3-(tert-Butyldimethylsilyloxy)pent-4-en-1-ol (2-206). Method B from 2-205: To a 
solution of 2-206 (8.70 g, 30.4 mmol) in dry toluene (175 mL) was cooled to –78 °C and treated 
with DIBAL-H (36.4 mL, 36.4 mmol, 1 M solution in hexanes). The mixture was stirred for 30 
min and was quenched at –78 °C with NH4Cl (20 mL, sat. aq.) dropwise. The reaction mixture 
was allowed to warm to room temperature and was treated with sat. aq. Rochelle’s salt solution 
(100 mL) and was stirred until the slurry cleared. The biphasic mixture was diluted with brine 
(100 mL) and more sat. aq. Rochelle's salt solution (100 mL), and the aqueous phase was 
extracted with EtOAc (3 x 100 mL). The combined organic layers were dried (MgSO4), filtered 
and concentrated to afford a colorless oil.  
The crude oil was taken up in MeOH (100 mL), cooled to 0 °C, and treated with NaBH4 
(1.26 g, 33.4 mmol). The reaction was stirred for 30 min and sat. aq. NH4Cl (150 mL) was 
added. The biphasic mixture was extracted with Et2O (3 x 50 mL), dried (MgSO4), filtered and 
concentrated. The crude material was purified by chromatography on SiO2 (20% Et2O/Hex) to 
afford 1 (5.7 g, 26.4 mmol, 87%) as a colorless oil. Analytical data matched previously reported 
data for 1:139 1H NMR (600 MHz, CDCl3) δ 5.85 (ddd, J = 5.8, 10.4, 17.1 Hz, 1 H), 5.21 (dt, J = 
1.6, 17.2 Hz, 1 H), 5.10 (dt, J = 1.2, 10.4 Hz, 1 H), 4.41 (dddd, J = 1.4, 1.4, 4.5, 5.9 Hz, 1 H), 
3.84-3.79 (m, 1 H), 3.73-3.69 (m, 1 H), 2.46 (t, J = 5.4 Hz, 1 H), 1.85 (dddd, J = 4.4, 4.4, 12.6, 
14.3 Hz, 1 H), 1.71 (dddd, J = 3.9, 6.2, 6.2, 14.3 Hz, 1 H), 0.90 (s, 9 H), 0.09 (s, 3 H), 0.06 (s, 3 
H); 13C NMR (150 MHz, CDCl3) δ 140.8, 114.6, 73.4, 60.3, 39.2, 26.0, 18.3, -4.3, -4.9. 
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2-188  
(3S)-3-(tert-Butyldimethysiloxy)-5-iodopent-1-ene (2-188). Following a literature 
procedure,118 to a stirred solution of PPh3 (16.4 g, 62.4 mmol), imidazole (10.7 g, 156 mmol) and 
I2 (15.8 g, 62.4 mmol) in dry THF (400 mL) and dry MeCN (100 mL) was added 2-206 (4.5 g, 
20.8 mmol) in dry THF (40 mL). After 15 min the reaction was quenched with NaHCO3 (200 
mL), and the organic phase was washed with sat. aq. NaHSO3 (100 mL), dried (MgSO4), filtered, 
concentrated in vacuo, and purified by chromatography on SiO2 (5% Et2O/Hex) to afford 2-188 
as a yellow oil (6.39 g, 19.6 mmol, 95% yield). Analytical data matched previously reported data 
for 2-188:118 1H NMR (600 MHz, CDCl3) δ 5.78 (ddd, J = 6.4, 10.4, 17.2 Hz, 1 H), 5.21 (ddd, J 
= 1.3, 1.6, 17.2 Hz, 1 H), 5.09 (ddd J = 1.2, 1.6, 10.4 Hz, 1 H), 4.19 (ddddd, J = 1.2, 1.2, 4.8, 6.0, 
7.3 Hz, 1 H), 3.24-3.17 (m, 2 H), 2.05-1.94 (m, 2 H), 0.90 (s, 9 H), 0.10 (s, 3 H), 0.05 (s, 3 H); 
13C NMR (150 MHz, CDCl3) δ 140.5, 115.0, 73.8, 41.8, 26.0, 2.8, -4.1, -4.6. 
 
N
H
O
O H
EtS
2-192  
(5S)-Pyrrolidin-2-one-5-carbothioic acid ethyl ester (2-192). A solution of (S)-
pyroglutamic acid (2-39) (20.0 g, 150 mmol) in a mixture of dry CH2Cl2 (300 mL) and dry DMF 
(160 mL) was cooled to 0 °C and treated with DMAP (1.85 g, 15.0 mmol) and EtSH (13.8 mL, 
180 mmol). To this colorless solution was added DCC (40.5 g, 180 mmol) in one batch and a 
colorless suspension developed quickly. The reaction was allowed to warm to room temperature 
over 16 h and a thick slurry developed, which was filtered through Celite washed with CH2Cl2 
(200 mL) and concentrated in vacuo. The crude material was taken up in EtOAc (200 mL) and 
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washed with brine (3 x 100 mL), dried (MgSO4), filtered, concentrated in vacuo, and the mixture 
was purified by chromatography on SiO2 (90% EtOAc/Hex followed by 100% EtOAc) to afford 
the rich fractions of 2-192 as a slurry (urea byproduct) that were suspended in a minimal amount 
of EtOAc and filtered through Celite to yield pure 2-192 (18.6 g, 107 mmol, 71%) as a yellow oil 
(stench): [α]D = -83.0 (c 1.0, CHCl3); IR (neat) 3227, 2933, 1679, 1417, 1265, 1231, 1084, 730, 
700 cm-1; 1H NMR (600 MHz, CDCl3) δ 6.78 (bs, 1 H), 4.28 (dd, J = 3.3, 8.3 Hz, 1 H), 2.90 (dq, 
J = 7.4, 12.6 Hz, 2 H), 2.53-2.41 (m, 2 H), 2.31 (ddd, J = 4.4, 9.4, 14.2 Hz, 1 H), 2.19 (ddd, J = 
4.4, 9.8, 13.4 Hz, 1 H), 1.26 (t, J = 7.4 Hz); 13C NMR (150 MHz, CDCl3) δ 201.2, 178.7, 62.6, 
28.9, 26.1, 23.4, 14.6; HRMS (EI) m/z calculated for C7H12NOS [M+H]+ 174.0589 found 
174.0589. 
 
 
N O
O H Boc
EtS
2-193  
(5S)-N-(tert-Butyloxycarbonyl)pyrrolidin-2-one-5-carbothioic acid ethyl ester (2-193). To a 
stirred solution of 2-192 (6.00 g, 34.6 mmol) in MeCN (34 mL) cooled to 0 °C was added Boc2O 
(8.28 mL, 35.0 mmol) followed by DMAP (470 mg, 3.46 mmol), and the reaction mixture 
developed a dark red color accompanied by gas evolution that ceased after 20 min. After stirring 
for 1 h at room temperature, the reaction mixture was quenched with sat. aq. NH4Cl (50 mL), 
diluted with H2O (50 mL) and EtOAc (100 mL). The organic layer was separated and washed 
with H2O (25 mL), brine (25 mL), dried (MgSO4), filtered, concentrated in vacuo, and the 
residue was purified by chromatography on SiO2 (30% EtOAc/Hex) to afford 2-193 (7.9 g, 28.7 
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mmol, 83% yield) as a colorless oil that solidified upon standing: mp 58.7 - 60.9 °C; [α]D -47.4 
(c 1.02, CHCl3); IR (neat) 2969, 2929, 1791, 1704, 1675, 1456, 1366, 1331, 1302, 1251, 1152, 
1022, 988, 837, 716 cm-1; 1H NMR (600 MHz, CDCl3) δ 4.71 (dd, J = 2.4, 9.7 Hz, 1 H), 2.95 (m, 
2 H), 2.66 (ddd, J = 10.3, 10.3, 17.7 Hz, 1 H), 2.48 (ddd J = 2.9, 9.5, 17.6 Hz, 1 H), 2.32 (dddd, J 
= 10.1, 10.1, 13.4, 20.0 Hz, 1 H), 2.03 (dddd, J = 2.6, 2.6, 9.72, 12.5 Hz, 1 H), 1.49 (s, 9 H), 1.28 
(t, J = 7.4 Hz, 3 H); 13C NMR (150 MHz, CDCl3) δ 199.4, 173.6, 149.1, 84.0, 65.5, 31.0, 28.0, 
23.4, 22.5, 14.8; HRMS (ESI) m/z calculated for C12H19NO4Na [M+Na]+ 296.0932 found 
296.0928. 
 
N OH
Boc
2-195  
(5S)-N-(tert-Butyloxylcarbonyl)-5-vinylpyrrolidin-2-one (2-195). To a solution of 2-
193 (3.90 g, 14.3 mmol) in acetone (30 mL) cooled to 0 °C was added Pd/C (0.64 g, 0.60 mmol), 
and Et3SiH (6.83 mL, 42.80 mmol) was added to the black slurry dropwise over 15 minutes. The 
reaction mixture was allowed to warm to room temperature, and vigorous gas evolution was 
observed. After 20 min the reaction mixture was filtered through Celite washed with 1:1 
EtOAc/Hex and the volatiles were removed in vacuo at 30 °C. The resulting pale yellow oil, 2-
194, was immediately used in the next step without further purification. 
In a separate flask, a colorless slurry of MePPh3Br (17.2 g, 47.1 mmol) in dry THF (70 
mL) was treated with KOt-Bu (4.80 g, 42.77 mmol) cooled with a water bath at room 
temperature. The resulting yellow slurry was stirred for 30 min and crude 2-194 in dry THF (35 
mL) was added dropwise via an addition funnel. After 30 min the reaction mixture was quenched 
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with sat. aq. NH4Cl (50 mL) and extracted with EtOAc (3 x 25mL). The combined organic layers 
were dried (MgSO4), filtered, concentrated, and the residue was purified by chromatography on 
SiO2 (70% EtOAc/Hex) to afford 2-194 (2.90 g, 13.7 mmol, 96% yield over 2 steps) as a light 
yellow oil: [α]D -24.3 (c 1.07, CHCl3); IR (neat) 2980, 2934, 1780, 1749, 1715, 1367, 1302, 
1285, 1254, 1148, 1019, 849 cm-1; 1H NMR (600 MHz, CDCl3) δ 5.84 (ddd, J = 6.1, 10.2, 16.6 
Hz, 1 H), 5.18 (dd, J = 1.3, 1.7 Hz), 5.16 (dd, J = 1.0, 4.2 Hz, 1 H), 4.63, 2.56 (ddd, J = 9.0, 10.9, 
17.5 Hz, 1 H), 2.42 (ddd, J = 2.9, 9.0, 17.5 Hz, 1 H), 2.21  (dddd, J = 8.8, 8.8, 11.0, 12.8 Hz, 1 
H), 1.80 (dddd, J = 2.6, 2.6, 8.9, 12.6 Hz, 1 H), 1.49 (s, 9 H); 13C NMR (150 MHz, CDCl3) δ 
174.5, 149.9, 136.8, 115.5, 83.0, 59.8, 31.2, 28.1, 24.4; HRMS (EI) m/z calculated for C11H17NO 
(M·+) 211.1208 found 211.1205. 
 
ON
H
OTBS
2-189  
(5S)-N-[(3S)-3-(tert-Butyldimethylsilyloxy)pent-4-enyl]-5-vinylpyrrolidin-2-one 
(189). To a stirred solution of 2-195 (7.0 g, 33.1 mmol) in dry CH2Cl2 (480 mL) was added TFA 
(12.4 mL, 166 mmol). The reaction mixture was stirred at room temperature for 1 h and sat. aq. 
NaHCO3 (400 mL) was added. The biphasic mixture was diluted with H2O (100 mL), and the 
aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic layers were dried 
(MgSO4) and concentrated in vacuo to afford 2-141 (3.51 g, 31.6 mmol, 95%) as a yellow oil: 1H 
NMR (600 MHz, CDCl3) δ 7.01 (bs, 1 H), 5.77 (ddd, J = 6.6, 10.2, 17.0 Hz, 1 H), 5.19 (ddd, J = 
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0.9, 0.9, 17.1 Hz, 1 H), 5.08 (ddd, J = 1.0, 1.0, 10.2 Hz, 1 H), 4.13 (m, 1 H), 2.35-2.23 (m, 3 H), 
1.82-1.75 (m, 1 H). 
To a mixture of 2-141 (2.00 g, 18.0 mmol) and 2-188 (6.46 g, 19.8 mmol) in toluene (300 
ml) and NaOH (sat. aq, 300 mL) in a 2 L RBF was added Bu4NHSO4 (5.29 g, 21.6 mmol) and 
the biphasic mixture was vigorously stirred with an overhead stirrer into an emulsion for 1 h. The 
biphasic mixture was diluted with H2O (300 mL) and extracted with EtOAc (3 x 200 mL), dried, 
filtered, concentrated, and the crude orange oil was purified by chromatography on SiO2 (50% 
EtOAc/Hex) to afford 2-189 (4.20 g, 13.6 mmol, 75%) as a light yellow oil and a : [α]D +40.3 (c 
0.63, CHCl3); IR (neat) 2954, 2929, 2856, 1689, 1413, 1249, 1085, 923, 833, 774 cm-1; 1H NMR 
(600 MHz, CDCl3) δ 5.78 (ddd, J = 5.9, 10.3, 17.0 Hz, 1 H), 5.64 (ddd, J = 8.5, 9.9, 17.0 Hz, 1 
H), 5.23 (d, J = 17.0, 1 H), 5.20 (d, J = 10.1, 1 H), 5.16 (ddd, J = 1.5, 1.5 17.1 Hz, 1 H), 5.02 
(ddd, J = 1.4, 1.4, 10.4 Hz, 1 H), 4.13 (dddd, J = 1.3, 1.3, 4.7, 11.9 Hz, 1 H), 4.02 (ddd, J = 5.6, 
8.2, 8.2 Hz, 1 H), 3.54 (ddd, J = 5.5, 11.0, 13.6 Hz, 1 H), 3.00 (ddd, J = 5.1, 10.7, 13.7 Hz, 1 H), 
2.40 (ddd, J = 6.1, 9.7, 16.6 Hz, 1 H), 2.31 (ddd, J = 6.8, 9.6, 13.2 Hz, 1 H), 2.20 (dddd, J = 6.0, 
7.7, 9.5, 13.0 Hz, 1 H), 1.76-1.60 (m, 3 H), 0.88 (s, 9 H), 0.04 (s, 3 H), 0.01 (s, 3 H) ); 13C NMR 
(150 MHz, CDCl3) δ 174.9, 141.2, 137.9, 118.1, 114.2, 72.1, 61.5, 37.8, 35.3, 30.3, 26.0, 18.3, -
4.2, -4.8. HRMS (EI) m/z calculated for C17H31NO2Si (M·+) 309.2124 found 309.2119. 
 
N O
TBSO
H
2-207  
(7S,9aS)-7-(tert-Butyldimethylsilyloxy)-1,2,5,6,7,9a-hexahydropyrrolo[1,2-a]azepin-
3-one (2-207). To a solution of 2-189 (2.85 g, 9.21 mmol) in dry CH2Cl2 (460 mL) was added 
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Grubbs 2nd generation catalyst (390 mg, 0.460 mmol, 5 mol %) and the resulting pink solution 
was heated to reflux for 5 h. The reaction was cooled to room temperature and the entire reaction 
volume was directly applied to a column of SiO2 (14" length, 3” diameter) and the system was 
eluted with 50% EtOAc/Hex then 100% EtOAc to afford 2-207 (2.37 g, 8.42 mmol, 91%) as an 
off-white solid and a 6:1 ratio of diastereomers. An analytical sample was purified by 
chromatography on SiO2 (50% EtOAc/Hex followed by 100% EtOAc) to afford 2-207 as a 
single diastereomer: mp 90.9 - 92.9 °C; [α]D –28.1 (c 0.27, CHCl3); IR (neat) 2954, 2928, 2885, 
2857, 1664, 1470, 1455, 1432, 1418, 1360, 1277, 1252, 1073, 1050, 861, 835, 774 cm-1; 1H 
NMR (600 MHz, CDCl3) δ 5.74 (dddd, J = 1.0, 3.4, 3.4, 12.1 Hz, 1 H), 5.47 (ddd, J = 2.4, 2.4, 
12.1 Hz, 1 H), 4.44 (dddd, J = 2.0, 3.6, 5.5, 8.9 Hz, 1 H), 4.26-4.19 (m, 2 H), 2.91 (ddd, J = 2.5, 
10.0, 10.0 Hz, 1 H), 2.34 (ddd, J = 6.6, 9.7, 16.4 Hz, 1 H), 2.34-2.21 (m, 2 H), 1.97-1.92 (m, 1 
H), 1.83-1.77 (m, 2 H), 0.89 (s, 9 H), 0.07 (s, 3 H), 0.07 (s, 3 H); 13C NMR (150 MHz, CDCl3) δ 
173.9, 138.1, 129.8, 71.3, 58.0, 38.9, 36.0, 30.2, 26.5, 25.9, 18.3, -4.5, -4.6. HRMS (ESI) m/z 
calculated for C15H27NO2SiNa [M+Na]+ 304.1709 found 304.1736. 
 
N O
HO
H
2-208  
(7S,9aS)-7-Hydroxy-1,2,5,6,7,9a-hexahydropyrrolo[1,2-a]azepin-3-one (2-208). To a 
solution of 2-207 (480 mg, 1.70 mmol) in MeOH (8 mL) was added p-TsOH (32.4 mg, 0.170 
mmol) and the pale yellow solution was stirred at rt for 4. The reaction mixture was treated with 
pyridine (0.2 mL) and the volatiles were removed in vacuo. The brown residue was purified by 
chromatography on SiO2 (100% EtOAc, then 10% MeOH in EtOAc) to afford 2-208 (279 mg, 
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1.67 mmol, 98%) as a green-brown hygroscopic solid and an inseparable mixture of 
diastereomers: IR (neat) 3296, 2949, 2925, 2853, 1643, 1421, 1317, 1261, 1052, 910 cm-1; Major 
diastereomer: 1H NMR (600 MHz, CDCl3) δ 5.82 (ddddd, J = 1.2, 2.7, 3.6, 6.0, 12.1 Hz, 1 H), 
5.55 (ddd, J = 2.3, 2.3, 12.1 Hz, 1 H), 4.47-4.45 (m, 1 H), 4.28-4.22 (m, 2 H), 2.93 (dddd, J = 
3.2, 9.6, 12.3, 13.6 Hz, 1 H), 2.44 (ddd, J = 6.9, 9.7, 16.5 Hz, 1 H), 2.35-2.23 (m, 2 H), 2.08 
(dddd, J = 1.2, 2.5, 3.7, 7.3 Hz, 1 H), 2.02 (d, J = 6.1 Hz, 1 H), 1.87-1.78 (m, 2 H); 13C NMR 
(150 MHz, CDCl3) δ 174.1, 136.4, 131.1, 70.5, 58.2, 38.6, 35.7, 30.1, 26.5; Minor diastereomer: 
1H NMR (600 MHz, CDCl3) δ (distinctive peaks) 5.73 (dm, J = 11.7 Hz, 1 H), 4.32 (dddd, J = 
2.4, 2.4, 2.4, 4.7, 1 H), 4.00 (ddd, J = 5.7, 9.9, 13.9 Hz, 1 H), 3.14 (dd, J = 5.3, 5.3, 13.9 Hz, 1 
H); 13C NMR (150 MHz, CDCl3) δ 174.7, 135.6, 131.7, 68.7, 58.0, 37.9, 35.1, 29.9, 26.8; HRMS 
(ESI) m/z calculated for C9H13NO2Na [M+Na]+ 190.0844, found 190.0829. 
 
N O
O
H
O
O
2-210  
(7S, 9aS)-7-[3-Oxobutyryloxy]-1,2,5,6,7,9a-hexahydropyrrolo[1,2-a]azepin-3-one (2-
210). A solution of 2-208 (30.0 mg, 0.179 mmol) and 2-209 (27.6 µL, 0.197 mmol) in xylenes (1 
mL) was heated to 130 °C for 10 min. The dark reaction mixture was allowed to cool to room 
temperature and was directly subjected to purification by chromatography on SiO2 (100% EtOAc 
followed by 10% MeOH/EtOAc) to afford 2-210 (24.0 mg, 0.096 mmol, 53%) as a bright yellow 
oil and a mixture of keto and enol tautomers (~10:1 by 1H NMR analysis): IR (neat) 3369, 2929, 
1740, 1699, 1607, 1408, 1362, 1302, 1253, 1170, 1151, 1046 cm–1; 1H NMR (600 MHz, CDCl3) 
δ 5.76 (ddd, J = 3.5, 3.5, 12.1 Hz, 1 H), 5.68 (ddd, J = 1.9, 1.9, 12.1 Hz, 1 H), 5.54-5.51 (m, 1 
 165 
H), 4.31-4.27 (m, 1 H), 4.22 (ddd, J = 3.7, 7.4, 11.0, 1 H), 3.47 (s, 2 H), 2.97 (ddd, J = 3.1, 8.9, 
12.4 Hz, 1 H), 2.44-2.39 (m, 1 H), 2.34 (dd, J = 5.6, 9.3 Hz, 1 H), 2.31-2.27 (m, 1 H), 2.61 (s, 3 
H), 2.11-2.06 (m, 1 H), 2.01-1.96 (m, 1 H), 1.85-1.79 (m, 1 H); 13C NMR (150 MHz, CDCl3) δ 
200.4, 174.1, 166.5, 133.9, 131.2, 72.5, 58.2, 50.1, 38.2, 31.9, 30.4, 30.0, 26.4, enol: 176.3, 
171.8, 133.2, 132.0, 89.8, 71.2, 58.1, 38.5, 32.1, 31.8, 30.1, 26.4, 21.4. 
 
N OHMe2N
O H
2-219  
(9R, 9aS)-N,N-Dimethyl-2-(2,3,5,6,9,9a-hexahydro-1H-pyrrolo[1,2-a]azepin-3-on-9-
yl)acetamide  (2-219). A microwave vial charged with 19 (106 mg, 0.634 mmol) and N,N-
dimethylacetamide dimethyl acetal (823 µL, 5.07 mmol) in diglyme (4 mL) was capped and 
heated in the microwave reactor to 180 °C for 15 min. The brown solution was directly applied 
to a column of SiO2 and chromatography (100 % CH2Cl2 then 5% MeOH/CH2Cl2) afforded 22 
(138 mg, 0.584 mmol, 92%) as a brown syrup and a mixture of inseparable diastereomers: Major 
diastereomer: 1H NMR (600 MHz, CDCl3) δ 5.71-5.66 (m, 2 H), 4.10 (ddd, J = 2.9, 7.0, 7.0 Hz, 
1 H), 3.64 (ddd, J = 5.2, 5.2, 11.6 Hz, 1 H), 3.45 (ddd, J = 5.9, 5.9, 12.3 Hz, 1 H), 3.17-3.13 (m, 
1 H), 2.99 (s, 3 H), 2.95 (s, 3 H), 2.42-2.33 (m, 6 H), 2.13-2.07 (m, 1 H), 1.71-1.65 (m, 1 H); 13C 
NMR (150 MHz, CDCl3) δ 174.9, 171.1, 132.3, 129.6, 61.2, 41.0, 39.1, 37.5, 35.8, 33.1, 31.0, 
27.6, 22.6. Minor diastereomer: 1H NMR (600 MHz, CDCl3) δ (distinctive peaks) 5.84 (dddd, J 
= 2.5, 6.0, 6.0, 11.4 Hz, 1 H), 5.48-5.46 (m, 1 H), 3.91 (ddd, J = 3.2, 7.5, 10.6 Hz, 1 H), 3.72 
(ddd, J = 6.7, 6.7, 9.9 Hz, 1 H), 3.13-3.09 (m, 1 H), 2.48-2.42 (m, 1 H); HRMS (ESI) m/z 
calculated for C13H20N2O2Na [M+Na]+ 259.1422, found 259.1421. 
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N
O
O
O
I
H
H
H
2-220  
(2R,3R,4R,6aS)-4-Iodooctahydro-3-oxa-6a-azacyclopenta[e]azulene-2,7-dione (2-
220). A stirred solution of 2-219 (273 mg, 1.16 mmol) in THF (3 mL) and pH 5.5 phosphate 
buffer (3 mL) was treated with I2 (880 mg, 3.47 mmol). The flask was wrapped with with 
aluminum foil and stirred for 1 h at room temperature. The reaction mixture was quenched with 
sat. aq. Na2S2O3 (3 mL) and stirred for 5 min. The mixture was partitioned between EtOAc (15 
mL) and H2O (15 mL), and the aqueous phase was extracted with CH2Cl2 (3 x 15 mL). The 
combined organic layers were dried (MgSO4), filtered, concentrated and the crude reside was 
purified by chromatography on SiO2 (100% CH2Cl2 followed by 10% MeOH/CH2Cl2) to afford 
2-220 (383 mg, 1.14 mmol, 98%) as a light yellow solid as a 6:1 inseparable mixture of 
diastereomers by 1H NMR spectroscopy: mp 183.7 - 184.7 °C (decomp.); [α]D –11.7 (c 1.5, 
CH2Cl2); Major diastereomer: 1H NMR (600 MHz, CDCl3) δ 5.14 (dd, J = 4.2, 9.0 Hz, 1 H), 
4.61-4.59 (m, 2 H), 4.26 (ddd, J = 3.8, 5.7, 14.4 Hz, 1 H), 3.16-3.08 (m, 2 H), 2.56 (dd, J = 9.8, 
17.8 Hz, 1 H), 2.52 (dd, J = 10.8, 17.6 Hz, 1 H), 2.41-2.29 (m, 3 H), 2.03 (dddd, J = 2.8, 5.8, 8.0, 
10.0 Hz, 1 H), 1,82 (dddd, J = 1.7, 3.8, 9.9, 15.6 Hz, 1 H), 1.65-1.61 (m, 1 H); 13C NMR (150 
MHz, CDCl3) δ 175.7, 173.7, 85.4, 55.5, 44.6, 42.2, 30.7, 29.7, 29.4, 27.8, 24.5. Minor 
diastereomer: 1H NMR (600 MHz, CDCl3) δ (distinctive peaks) 4.80 (app t, J = 6.1 Hz, 1 H), 
4.07 (ddd, J = 4.8, 9.5, 14.3 Hz, 1 H), 3.02-2.97 (m, 1 H), 2,84-2.79 (m, 1 H), 2.11-2.07 (m, 1 
H); 13C NMR (150 MHz, CDCl3) δ 174.7, 173.9, 85.9, 56.4, 43.8, 43.6, 34.9, 30.2, 28.7, 24.8, 
24.6. HRMS (EI) m/z calculated for C11H14NO3I (M·+) 335.0018, found 335.0011. 
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2-221  
(8S, 9R, 9aS)-1,2,5,6,7,8,9,9a-octahydrodihydrofuro[3,2-c]pyrrolo[1,2-a]azepine-3,11 
-dione (2-221). To 2-220 (180 mg, 0.254 mmol) suspended in dry toluene (4 mL) was added 
with n-Bu3SnH (180 uL, 0.645 mmol) and the system was degassed (freeze, pump, thaw x 3) and 
heated to 80 °C using an oil bath. Through the reflux condensor was added 1 mL of a stock 
solution of AIBN (57.3 mg, 0.349 mmol) in dry toluene (2 mL) and the system was heated to 
reflux for 1 h, cooled to 80 °C and the remainder of the AIBN solution was added over 1 h. The 
reaction mixture was heated to reflux for another 1 h allowed to cool to room temperature, and 
directly applied to a column of SiO2 impregnated with 10% w/w KF (s) and eluted with 5% 
MeOH/DCM to afford a yellow syrup (109 mg, 0.521 mmol, 97%). MPLC purification (5% 
MeOH/EA) provided 2-221 as a light yellow solid and a single diastereomer: [α]D –21.0 (c = 0.3, 
CHCl3); IR (neat) 3470, 2929, 2858, 1761, 1670, 1427, 1372, 1280, 1185, 1078, 992 cm-1; 1H 
NMR (600 MHz, CDCl3) δ 4.86 (ddd, J = 4.4, 4.4, 8.9 Hz, 1 H), 4.28 (ddd, J = 3.9, 5.7, 13.8 Hz, 
1 H), 3.95-3.93 (m, 1 H), 3.03 (dddd, J = 1.9, 9.2, 10.8, 10.8 Hz, 1 H), 2.72 (ddd, J = 3.2, 10.2, 
13.4 Hz, 1 H), 2.50 (d, J = 10.7 Hz, 1 H), 2.42-2.32 (m, 3 H), 2.17 (ddd, J = 4.9, 8.4, 14.5 Hz, 1 
H), 1.91 (dddd, J = 1.0, 3.8, 10.4, 15.4 Hz, 1 H), 1.73-1.68 (m, 2 H), 1.57 (dddd, J = 3.7, 10.7, 
10.7, 19.3 Hz, 1 H); 13C NMR (150 MHz, CDCl3) δ 175.7, 175.3, 81.0, 56.6, 44.8, 43.9, 31.9, 
29.5, 27.8, 24.8, 21.3; HRMS (ESI) m/z calculated for C11H15NO3Na [M+Na]+ 232.0950, found 
232.0936. 
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8-epi-stemoamide 
(2-222)
8
 
(8S, 9R, 9aS, 10S)-10-Methyl-1,2,5,6,7,8,9,9a-octahydrodihydrofuro[3,2-c]pyr rolo 
[1,2-a]azepine-3,11-dione (2-222). To a cooled solution of 2-221 (40.0 mg, 0.191 mmol) in dry 
THF (2 mL) at –78 °C was added a feshly prepared solution of LiHMDS in THF (0.286 µL, 
0.286 mmol, 1.0 M) and the colorless solution was kept at –78 °C for 2 h. MeI (54.0 µL, 0.860 
mmol) was added and the solution was stirred for 4 h and the reaction mixture was quenched 
with sat. aq. NH4Cl (2 mL). The biphasic system was allowed to warm to room temperature and 
the aqueous phase was extracted with EtOAc (3 x 5 mL). The combined organic extracts were 
dried (MgSO4), filtered, concentrated, and MPLC purification (5% MeOH/EtOAc) provided 2-
222 (20.0 mg, 0.090 mmol, 47%) as a colorless solid: [α]D –60.0 (c = 0.10, CHCl3); IR (neat) 
2958, 2929, 2858, 1740, 1687, 1448, 1422, 1330, 1278, 1188, 1074, 991 cm-1; 1H NMR (600 
MHz, CDCl3) δ 4.81 (ddd, J = 3.7, 3.7, 9.5 Hz, 1 H), 4.31 (dddd, J = 0.9, 4.5, 4.5, 13.9 Hz, 1 H), 
3.96 (dm, 9.3 Hz, 1 H), 2.64 (ddd, J = 1.6, 10.4, 10.4 Hz, 1 H), 2.64-2.61 (m, 1 H), 2.56 (ddddd, 
J = 7.0, 7.0, 10.3, 14.1, 14.1 Hz, 1 H), 2.49-2.43 (m, 1 H), 2.40-2.34 (m, 2 H), 2.24 (ddddd J = 
1.0, 1.0, 4.0, 8.0, 14.3 Hz, 1 H), 1.88-1.82 (m, 2 H),  1.72-1.67 (dddd, J = 3.7, 7.7, 7.7, 11.9 Hz, 
1 H), 1.45 (dddd, J = 3.6, 11.6, 11.6, 15.0, 1 H), 1.40 (d, J = 7.0 Hz, 3 H); 13C NMR (150 MHz, 
CDCl3) δ 178.6, 175.6, 79.2, 57.3, 52.1, 43.8, 34.3, 32.2, 29.3, 24.0, 21.6, 18.2; HRMS (EI) m/z 
calculated for C12H17NO3 (M·+) 223.1208, found 223.1201. 
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2-223  
(2R,3S,6aS)-3a,6,8,9,9a,9b-Hexahydro-1H-3-oxa-6a-azacyclopenta[e]azulene-2,7-
dione (2-223). A stirred solution of 2-220 (40.0 mg, 0.119 mmol) in toluene (1 mL) was treated 
with DBU (44.6 µL, 0.298 mmol) and the reaction mixture was heated to 80 °C for 4 h. The 
volatiles were removed in vacuo and the reside was purified by chromatography on SiO2 (5% 
MeOH/CH2Cl2) to provide 2-223 (22.0 mg, 0.106 mmol, 89%) contaminated with grease as a 
colorless crystalline solid and a mixture of diastereomers: [α]D +95.5 (c = 0.31, CHCl3); IR 
(neat) 2917, 2850, 1770, 1684, 1661, 1448, 1428, 1377, 1319, 1271, 1234, 1167, 979, 916, 740 
cm-1; 1H NMR (600 MHz, CDCl3) δ 5.75 (dddd, J = 1.7, 3.3, 5.1, 12.8 Hz, 1 H), 5.65 (bdd, J = 
1.2, 12.7 Hz, 1 H), 5.17 (ddd, J = 1.6, 3.7, 7.5 Hz, 1 H), 4.62 (dddd, J = 1.5, 1.5, 5.5, 18.7 Hz, 1 
H), 4.05-4.01 (m, 1 H), 3.62 (bdd, J = 1.4, 18.7 Hz, 1 H), 3.04-2.99 (m, 1 H), 2.54 (dd, J = 12.1, 
16.8 Hz, 1 H), 2.44, (dd, J = 7.9, 16.7 Hz, 1 H), 2.42-2.33 (m, 4 H), 1.78-1.75 (m, 1 H); 13C 
NMR (150 MHz, CDCl3) δ 175.0, 174.9, 126.8, 126.3, 79.2, 55.6, 45.7, 42.2, 29.4, 27.5, 24.5; 
HRMS (ESI) m/z calculated for C11H13NO3Na [M+Na]+ 230.0793, found 230.0782. 
 
N
O
O
O
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2-224  
(1S, 8S, 9R, 9aS)-1-Ethyl-1,2,5,8,9,9a-hexahydrodihydrofuro[3,2-c]pyr rolo[1,2a]azepine 
-3,11-dione (2-224). To a stirred suspension of 2-223 (41.0 mg, 0.199 mmol) in dry THF (2 mL) 
cooled to –78 °C was added freshly prepared LiHMDS (515 µL, 0.258 mmol, 0.5 M in 
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THF/Hex) and the brown solution that developed was allowed to warm to 0 °C after 15 min, then 
cooled to –78 °C after 5 min. The solution was treated with EtI (158 µL, 1.98 mmol) and the 
mixture was allowed to passively warm to room temperature over 5 h. To the brown reaction 
mixture was added SiO2 (~0.5 g) and the slurry was directly applied to a column of SiO2 and was 
eluted with 5% MeOH/CH2Cl2 followed by 10% MeOH/EA to afford 2-224 (24.0 mg, 0.102 
mmol, 52%) as a brown gum: IR (neat) 3262, 2954, 2929, 2856, 1697, 1404, 1250, 1169, 1084, 
926, 834, 775cm-1; 1H NMR (600 MHz, CDCl3) δ 5.87-5.86 (m, 2 H), 5.07 (ddd, J = 1.4, 2.9, 8.2 
Hz, 1 H), 4.24 (d, J = 16.2 Hz, 1 H), 4.07 (ddd, J = 2.1, 4.6, 9.1 Hz, 1 H), 3.95-3.92 (dm, 1 H), 
2.73 (ddd, J = 2.1, 8.2, 8.2, 1 H), 2.62 (ddd, J = 5.4, 5.4, 8.1 Hz, 1 H), 2.52 (ddd, J = 7.4, 10.3, 
17.2 Hz, 1 H), 2.43-2.38 (m, 1 H), 2.32 (dddd, J = 7.3, 9.0, 10.6, 13.2 Hz, 1 H), 1.95 (ddd, J = 
2.4, 7.4, 14.9 Hz, 1 H), 1.78 (dddd, J = 5.6, 5.6, 13.4, 15.2 Hz, 1 H), 1.72 (dddd, J = 5.9, 7.4, 7.4, 
13.2 Hz, 1 H), 1.05 (t, J = 7.4 Hz, 3 H). 
 
N OH
HO
EtO
2-230a  
Ethyl (S)-2-((9R,9aS,Z)-3-oxo-2,3,5,6,9,9a-hexahydro-1H-pyr rolo[1,2-a]azepin-9-yl) 
butanoate (2-230a). To a  flask charged with 2-208 (73.0 mg, 0.437 mmol) was added degassed 
o-DCB (3.6 mL), triethyl orthobutyrate (524 µL, 2.19 mmol) and HCl in dioxane (11.0 µL, 0.437 
mmol, 0.1 equiv). The reaction mixture was heated in oil bath to 130 °C for 36 h at which point 
the reaction mixture was transferred to a microwave vial and was twice heated to 200 °C for 1 h 
in the microwave reactor. The reaction mixture was directly applied to a column of SiO2 and 
purified (5% MeOH/CH2Cl2) to afford 2-230a and 2-230b (49.0 mg, 0.184 mmol, 42%), which 
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existed as a 2.5:1 mixture by 1H NMR spectroscopy that were separated by MPLC (100% 
EtOAc): [α]D –27.2 (c 0.33, CHCl3); 1H NMR (600 MHz, CDCl3) δ 5.53 (dddd, J = 2.6, 5.6, 8.6, 
11.2 Hz, 1 H), 5.25 (ddd, J = 2.5, 5.4, 11.4, 1 H), 4.21-4.11 (m, 2 H), 4.01 (ddd, J = 5.8, 5.8, 8.9 
Hz, 1 H) 3.86 (ddd, J = 2.6, 7.4, 14.0 Hz, 1 H), 3.18 (ddd, J = 5.7, 10.6, 14.2 Hz, 1 H), 3.14-3.11 
(m, 1 H), 2.56-2.49 (m, 1 H), 2.41-2.29 (m, 4 H), 1.94 (dddd, J = 2.3, 6.5, 8.7, 12.3 Hz, 1 H), 
1.70-1.62 (m, 3 H), 1.27 (t, J = 7.1 Hz, 3 H), 0.92 (t, J = 7.4 Hz, 3 H); 13C NMR (150 MHz, 
CDCl3) δ 174.9, 174.8, 130.4, 126.3, 60.8, 60.7, 48.5, 41.5, 37.6, 31.0, 28.9, 23.7, 21.9, 14.4, 
11.8; HRMS (ESI) m/z calculated for C15N23N2O3Na [M+Na]+ 288.1576, found 288.1565. 
 
O
O
O
2-232  
Trineopentyl orthobutyrate (2-232). A solution of triethyl orthobutyrate (2.38 mL, 9.93 
mmol) and neopentyl alcohol (3.54 g, 39.7 mmol) was treated with HCl/dioxane (124 µL, 0.500 
mmol) and heated to 95 °C in an uncapped flask in an oil bath overnight. Orthoester 2-232 was 
isolated by distillation under reduced pressure (105 °C at 2 Torr) as a colorless oil (2.11 g, 6.67 
mmol, 67%): 1H NMR (600 MHz, CDCl3) δ 3.14 (s, 6 H), 1.68-1.66 (m, 2 H), 1.45-1.39 (m, 2 
H), 0.91 (s, 27 H), 0.90 (t, J = 7.4 Hz, 3 H); 13C NMR (150 MHz, CDCl3) δ 114.0, 71.5, 32.5, 
31.9, 27.1, 16.9, 14.5. 
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2-238  
4,4-Dimethylcyclohex-2-enol (2-238). To a flask containing LiAlH4 (20.3 mL, 20.3 
mmol, 1 M in Et2O) in dry THF (200 mL) cooled to 0 °C was added 4,4-dimethyl-2-cyclohexen-
1-one (10.6 mL, 78.1 mmol) in dry THF (700 mL) by addition funnel. The reaction was allowed 
to warm to room temperature and was stirred for 2 h. The reaction mixture was carefully poured 
into a separatory funnel containing Et2O (200 mL) and brine (200 mL). The aqueous phase was 
extracted with Et2O (3 x 100 mL) and the combined organic layers were dried (MgSO4), filtered 
and concentrated to afford 2-238 (9.42 g, 74.6 mmol, 96%) as a yellow oil. Analytical data 
matched previously reported data for 2-238:142
 
 1H NMR (600 MHz, CDCl3) δ 5.59 (dd, J = 3.0, 
10.0 Hz, 1 H), 5.52 (d, J = 10.0 Hz, 1 H), 4.14 (bm, 1 H), 1.94-1.89 (m, 1 H), 1.65-1.55 (m, 2 H), 
1.44-1.40 (m, 1 H), 1.37 (d, J = 6.4 Hz, 1 H), 1.01 (s, 3 H), 0.97 (s, 3 H); 13C NMR (150 MHz, 
CDCl3) δ 140.7, 127.5, 66.0, 33.7, 32.0, 30.4, 29.2, 29.2.  
 
 
NH
O
OTr
3-4  
(5S)-5-(Trityloxymethyl)-2-pyrrolidinone (3-4). Following a literature procedure,143 to 
a solution of (S)-(+)-5-(hydroxymethyl)-2-pyrrolidinone (2.30 g, 19.4 mmol) in dry CH2Cl2 (200 
mL) was added DMAP (355 mg, 2.91 mmol) and NEt3 (4.12 mL, 29.1 mmol), and the solution 
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was cooled to 0 °C. Trityl chloride (8.10 g, 29.1 mmol) was added in a single portion and the 
reaction mixture was allowed to warm to room temperature overnight. The reaction mixture was 
poured into sat. aq. NaHCO3 (200 mL) and the biphasic system was extracted with CH2Cl2 (3 x 
50 mL). The combined organic layers were dried (MgSO4), filtered, concentrated, and the yellow 
syrup was purified by chromatography on SiO2 (100% CH2Cl2 then 5% MeOH/CH2Cl2) to afford 
3-4 (6.58 g, 18.4 mmol, 95% yield) as a colorless foamy solid. Analytical data matched 
previously reported data for 3-4: 1H NMR (600 MHz, CDCl3) δ 7.40-7.39 (m, 6 H), 7.32-7.29 
(m, 6 H), 7.27-7.24 (m, 3 H), 5.85 (bs, 1 H), 3.86 (dddd, J = 3.9, 5.8, 8.1, 8.1 Hz, 1 H), 3.21 (dd, 
J = 3.9, 9.3 Hz, 1 H), 2.99 (dd, J = 8.1, 9.3 Hz, 1 H), 2.32 (app t, J = 8.0 Hz, 2 H), 2.14 (dddd, J 
= 7.8, 7.8, 13.0, 15.4 Hz, 1 H), 1.66 (dddd, J = 5.8, 8.3, 8.3, 13.0 Hz, 1 H). 
 
N
O
TrO
O
2-240  
(5S)-1-Crotonoyl-5-(trityloxymethyl)-2-pyrrolidinone (2-240). According to a 
literature procedure,143 to a stirred solution of 3-4 (2.00 g, 5.59 mmol) in dry THF (50 mL) at –
78 °C was added n-BuLi (5.59 mL, 6.71 mmol, l.2 M in hexanes) and the mixture was stirred for 
30 minutes at –78 °C and trans-crotonoyl chloride (774 µL, 7.27 mmol) was added dropwise. 
After 40 min, the reaction was warmed to 0 °C and quenched with sat. aq. NH4Cl (50 mL), 
diluted with H2O (20 mL), and extracted with EtOAc (3 x 25 mL). The combined organic 
extracts were dried (MgSO4), filtered, concentrated and purified by chromatography on SiO2 
(20% EtOAc/Hex) to afford 2-240 (4.47 g, 10.5 mmol, 85% yield) as a colorless foam. 
Analytical data matched previously reported data for 2-240:143 1H NMR (600 MHz, CDCl3) δ 
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7.36-7.26 (m, 13 H), 7.22 (app tt, J = 1.2, 7.1 Hz, 3 H), 7.10 (dq, J = 7.0, 15.3 Hz, 1 H), 4.55-
4.52 (m, 1 H), 5.82 (dd, J = 3.9, 9.8 Hz, 1 H), 3.13 (dd, J = 2.7, 9.8 Hz, 1 H), 2.97 (ddd, J = 10.0, 
11.0, 17.9 Hz, 1 H), 2.50 (ddd, J = 1.8, 10.0, 11.8 Hz, 1 H), 2.12-2.05 (m, 1 H), 1.98 (dd, J = 1.7, 
6.9 Hz, 3 H); 13C NMR (150 MHz, CDCl3) δ 176.6, 165.9, 145.8, 143.8, 128.6, 128.1, 127.2, 
124.1, 87.1, 64.3, 56.9, 33.6, 21.3, 18.7. 
 
N
O O
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3-5  
(5S)-1-{(3S)-3-[Dimethyl(phenyl)silyl]butanoyl}-5-(triphenylmethoxymethyl) 
pyrrolidin-2-one (3-5). According to a literature procedure,124 a solution of neat ZnEt2 (180 µL, 
1.76 mmol) in dry THF (5 mL) cooled to –78 °C was added a feshly prepared solution of 
PhMe2SiLi (1.60 mL, 1.88 mmol, 1.17 M in THF). The cooled reaction mixture was stirred for 
30 min and 2-240 (500 mg, 1.175 mmol) was added in a single portion. The reaction was stirred 
for 1 h at –78 °C and was allowed to warm to 0 °C. The reaction mixture was carefully quenched 
with H2O (10 mL) and diluted with sat. aq. Rochelle's salt solution (5 mL). The biphasic system 
was stirred 30 min and the aqueous phase was extracted with EtOAc (3 x 10 mL). The combined 
organic layers were dried (MgSO4), filtered and purified by chromatography on SiO2 (10% 
EtOAc/Hex) to afford 3-5 (531 mg, 0.945 mmol, 80%, >20:1 d.r.) as a colorless foam. Analytical 
data matches previously reported data for 3-5:4 1H NMR (600 MHz, CDCl3) δ 7.58-7.56 (m, 2 
H), 7.39-7.34 (m, 9 H), 7.27-7.20 (m, 9 H), 4.48-4.45 (m, 1 H), 3.51 (dd, J = 4.0, 9.8), 3.19 (dd, 
J = 2.7, 9.8 Hz, 1 H), 2,98 (dd, J = 3.2, 16.2 Hz, 1 H), 2.94 (dd, J = 9.8, 11.3 Hz, 1 H), 2.78 (dd, 
J = 11.4, 16.2 Hz, 1 H), 2.45 (ddd, J = 1.7, 9.9, 17.8 Hz, 1 H), 2.06 (dddd, J = 9.7, 11.2, 12.9, 
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19.1 Hz, 1 H), 1.96 (dddd, J = 1.4, 1.4, 9.7, 12.7 Hz, 1 H), 1.58 (ddddd, J = 3.3, 7.3, 7.3, 7.3, 
18.6 Hz, 1 H), 0.94 (d, J = 7.3 Hz, 3 H), 0.38 (s, 3 H), 0.36 (s, 3 H). 
 
EtO
O Si
Ph
2-241  
(3S)-3-Dimethyl(phenyl)silyl butyric acid ethyl ester (2-241). To a cooled solution of 
EtOH (1.08 mL, 16.4 mmoll) in THF (25 mL) at 0 °C was added n-BuLi (10.7 mL, 11.7 mmol, 
1.1 M in hexanes). After 30 min the solution was warmed to room temperature for 30 min, then 
cooled to 0 °C for 15 min. A solution of 3-5 (1.32 g, 2.34 mmol) in THF (10 mL) was added and 
the reaction mixture was allowed to warm to room temperature over 1 h and was quenched with 
sat. aq. NH4Cl (10 mL). The biphasic mixture was diluted with H2O (10 mL) and Et2O (10 mL) 
and the aqueous phase was extracted with Et2O (3 x 10 mL). The combined organic layers were 
dried (MgSO4), filtered, and purification of the crude residue by chromatography on SiO2 (10% 
Et2O/Hex) gave 2-241 (525 mg, 2.10 mmol, 89%) as a yellow, sweet-smelling oil. Analytical 
data matches previously reported data for 17:124 1H NMR (600 MHz, CDCl3) δ 7.5-7.48 (m, 2 
H), 7.37-7.34 (m, 3 H), 4.08 (q, J = 7.1 Hz, 2 H), 2.37 (dd, J = 4.0, 15.2 Hz, 1 H), 2.04 (dd, J = 
11.3, 15.2 Hz, 1 H), 1.44 (ddddd, J = 4.0, 7.4, 7.4, 7.4, 14.9 Hz, 1 H), 1.23 (t, J = 7.1 Hz, 3 H), 
0.97 (d, J = 7.4 Hz, 3 H), 0.28 (s, 3 H), 0.28 (s, 3 H); 13C NMR (150 MHz, CDCl3) δ 174.1, 
137.4, 134.0, 129.2, 127.9, 60.3, 37.0, 16.6, 14.6, 14.4, –4.9, –5.2. 
 
Si
Ph
N
2-243  
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(S)-3-(Dimethyl(phenyl)silyl)butanenitrile (2-243). To a solution of 2-242 (158 mg, 
0.765 mmol) in THF (2.4 mL) was added 28% NH4OH in H2O (2.39 mL, 19.1 mmol) followed 
by I2 (213 mg, 0.842 mmol). The flask was wrapped in foil and the solution was stirred for 2 h. 
The reaction mixture was quenched by addition of sat. aq. Na2S2O3 (2 mL), and the aqueous 
phase was extracted with Et2O (3 x 5 mL). The combined organic layers were dried (MgSO4), 
filtered, and concentrated to afford crude oil that was purified by chromatography on SiO2 (10% 
Et2O/Hex) to afford 2-243 (148 mg, 0.728 mmol, 95%) as a colorless oil: IR (neat) 3070, 2955, 
2870, 2240, 1746, 1632, 1456, 1427, 1251, 1110, 832, 812, 773, 734, 699 cm-1; 1H NMR (600 
MHz, CDCl3) δ 7.48-7.47 (m, 2 H), 7.41-7.35 (m, 3 H), 2.39 (dd, J = 4.3, 16.9 Hz, 1 H), 2.08 
(dd, J = 10.4, 16.9 Hz, 1 H), 1.27-1.22 (m, 1 H), 1.16 (d, J = 7.2 Hz, 3 H), 0.34 (s, 6 H); 13C 
NMR (150 MHz, CDCl3) δ 136.0, 133.9, 129.8, 128.2, 120.0, 2.06, 17.4, 14.6, –4.8, –5.5. 
 
HO
O Si
Ph
2-244  
(3S)-3-Dimethyl(phenyl)silyl butyric acid (2-244). A solution of 2-241 (936 mg, 3.73 
mmol) in THF (10.5 mL) and MeOH (10.5 mL) at room temperature treated with 2M NaOH 
(3.73 mL, 7.47 mmol) and the reaction mixture was heated to 60 °C for 3 h. The solution was 
allowed to cool to room temperature and was diluted with sat. aq. NH4Cl (10 mL) and acidified 
with 1N HCl to pH 2. The hazy solution was extracted with EtOAc (3 x 25 mL), and the 
combined organic layers were dried (MgSO4), filtered, concentrated and purified by 
chromatography on SiO2 (100% Hex followed by 20% EtOAc/Hex then 50% EtOAc/Hex) to 
afford 2-244 (831 mg, 3.73 mmol. 99%) as a yellow oil. Analytical data matches previously 
reported data for 18:144 1H NMR (600 MHz, CDCl3) δ 11.1 (bs, 1 H), 7.50-7.49 (m, 2 H), 7.37-
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7.35 (m, 3 H), 2.43 (dd, J = 3.8, 15.5 Hz, 1 H), 2.07 (dd, J = 11.4, 15.5 Hz, 1 H), 1.45-1.39 
(ddddd, J = 3.8, 7.4, 7.4, 7.4, 14.7 Hz, 1 H), 1.01 (d, J = 7.3 Hz, 3 H), 0.30 (s, 3 H), 0.29 (s, 3 H); 
13C NMR (150 MHz, CDCl3) δ 180.3, 137.1, 134.0, 129.3, 127.9, 36.7, 16.4, 14.5, –4.9, –5.3. 
 
O
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Ph
O
2-247  
(S)-3-(Dimethyl(phenyl)silyl)-(1-(4-methyl-2,6,7-trioxabicyclo[2.2.2]octan-1-yl) 
propane (40). To a stirred solution of 2-244 (130 mg, 0.585 mmol) in dry CH2Cl2 (2 mL) was 
added DMAP (21.4 mg, 0.175 mmol) followed by DCC (132 mg, 0.643 mmol) and 3-methyl-3-
oxetanemethanol (2-245) (65.0 µL, 0.643 mmol). The resulting slurry was stirred at room 
temperature for 3 h, and filtered through a plug of Celite and diluted with H2O (2 mL). The 
aqueous phase was extracted with EtOAc (3 x 1 mL) and the combined organic extracts were 
dried (MgSO4), filtered, concentrated, and the residue was purified by chromatography on SiO2 
(10% EtOAc/Hex) to afford 2-246 (179 mg, 0.584 mmol, 99%) as a colorless oil: 1H NMR (600 
MHz, CDCl3) δ 7.50-7.49 (m, 2 H), 7.37-7.36 (m, 3 H), 5.50 (d, J = 6.0 Hz, 2 H), 4.37 (d, J = 6.0 
Hz, 2 H), 4.12 (d, J = 11.1 Hz, 1 H), 4.09 (d, J = 11.1 Hz, 1 H), 2.43 (dd, J = 3.9, 15.3 Hz, 1 H), 
2.09 (dd, J = 11.4, 15.3 Hz, 1 H), 1.48-1.42 (m, 1 H), 1.32 (s, 3 H), 0.98 (d, J = 7.3 Hz, 3 H), 
0.29 (s, 6 H). 
A solution of 2-246 (170 mg, 0.557 mmol) in dry CH2Cl2 (550 µL) was cooled to 0 °C and 
treated with BF3·OEt2 (17.5 µL, 0.14 mmol). The reaction mixture was allowed to warm to room 
temperature and was stirred overnight. The reaction mixture was quenched with NEt3 (79.0 µL, 
0.555 mmol) and diluted with Et2O (1 mL). The cloudy mixture was filtered through a plug of 
SiO2 and was concentrated. The resulting residue was purified by chromatography on SiO2 (20% 
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EtOAc/Hex) to afford 2-247 (132 mg, 0.431 mmol, 78%) as a colorless oil that solidified upon 
standing: 1H NMR (600 MHz, CDCl3) δ 7.50-7.48 (m, 2 H), 7.33-7.31 (m, 3 H), 3.86-3.82 (m, 6 
H), 1.84 (dd, J = 3.2, 14.5 Hz, 1 H), 1.51 (dd, J = 11.0, 14.5 Hz, 1 H), 1.30-1.24 (m, 1 H), 1.01 
(d, J = 7.3 Hz, 3 H), 0.77 (s, 3 H), 0.25 (s, 3 H), 0.24 (s, 3 H); 13C NMR (150 MHz, CDCl3) δ 
138.4, 124.1, 128.8, 1277, 109.9, 72.6, 38.3, 30.4, 14.9, 14.7, 14.2, 4.7, 4.9; HRMS (EI) m/z 
calculated for C17H26O3Si (M·+) 306.1651, found 306.1642. 
 
N
O Si
Ph
2-248  
(3S)-3-Dimethylphenylsilanyl-N,N-dimethyl butyramide (2-248). To a stirred solution 
of 2-244 (231 mg, 1.04 mmol) in dry CH2Cl2 (10 mL) was added i-Pr2NEt (381 uL, 2.29 mmol), 
EDC·HCl (177 mg, 1.14 mmol), HOBt (154 mg, 1.14 mmol), and Me2NH·HCl (94.0 mg, 1.14 
mmol). The clear solution became cloudy after 15 min and the slurry was stirred overnight at 
room temperature. The slurry was filtered through a plug of cotton and diluted with H2O (10 mL) 
and EtOAc (10 mL). The aqueous layer was extracted with EtOAc (3 x 10 mL), and the 
combined organic extracts were dried (MgSO4), filtered and concentrated. The crude oil was 
purified by chromatography on SiO2 (50% EtOAc/Hex) to provide 2-248 (220 mg, 0.882 mmol, 
85%) as a colorless oil: [α]D –8.5 (c 1.0, CHCl3); IR (neat) 3068, 2952, 2866, 1641, 1393, 1248, 
1111, 982, 814, 767, 734, 700 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.51-7.49 (m, 2 H), 7.36-7.33 
(m, 3 H), 2.90 (s, 3 H), 2.88 (s, 3 H), 2.32 (dd, J = 3.6, 15.1 Hz, 1 H), 2.08 (dd, J = 11.1, 15.1 
Hz, 1 H), 1.54-1.47 (m, 1 H), 0.98 (d, J = 7.3 Hz, 3 H), 0.29 (s, 3 H), 0.29 (s, 3 H). 13C (150 
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MHz, CDCl3) δ 173.1, 137.9, 134.1, 129.1, 127.9, 37.4, 35.6, 35.3, 16.3, 14.8, –4.6, –5.2; HRMS 
(EI) m/z calculated for C14H23NOSi (M·+) 249.1549, found 249.1538. 
 
N
S Si
Ph
2-251  
(S)-3-(Dimethyl(phenyl)silyl)-N,N-dimethylbutanethioamide (2-251). To a stirred 
solution of 2-248 (96.0 mg, 0.385 mmol) in dry THF (1 mL) was added Lawesson's reagent (110 
mg, 0.270 mmol) and the slurry was stirred at room temperature for 24 h. An additional portion 
of Lawesson’s reagent (110 mg, 0.270 mmol) was added and afer 48 h the reaction mixture was 
quenched with sat. aq. NH4Cl (1 mL) and diluted with H2O (5 mL). The aqueous phase was 
extracted with EtOAc (3 x 5 mL) and the combined organic extracts were dried (MgSO4), 
filtered, and concentrated. The resulting residue was purified by chromatography on SiO2 (20% 
EtOAc/hex) to afford 2-251 (70 mg, 0.26 mmol, 69%) as a pale yellow oil: IR (neat) 3067, 2952, 
2866, 1512, 1389, 1276, 1260, 1111, 1046, 980, 812, 765, 700 cm-1; 1H NMR (600 MHz, 
CDCl3) δ 7.52-7.50 (m, 2 H), 7.37-7.34 (m, 3 H), 3,43 (s, 3 H), 3.09 (s, 3 H), 2.78 (dd, J = 3,3, 
13.9 Hz, 1 H), 2.67 (dd, J = 11.7, 13.9 Hz, 1 H), 1.63-1.57 (m, 1 H), 1.04 (d, J = 7.3 Hz, 3 H), 
0.32 (s, 3 H), 0.32 (s, 3 H); 13C NMR (150 MHz, CDCl3) δ 204.7, 137.6, 134.1, 129.3, 128.0, 
44.9, 44.8, 41.7, 20.3, 13.8, 4.6, 5.4; HRMS (EI) m/z calculated for C14H23NSiS (M·+) 265.1321, 
found 265.1317. 
 
2-252
N
SMe SiMe2Ph
BF4
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(S)-3-(Dimethyl(phenyl)silyl)-N,N-dimethylbutanethiomethylimidolium 
tetrafluoroborate (2-252). To a solution of 2-252 (64.0 mg, 0.241 mmol) in dry CH2Cl2 (1 mL) 
at room temperature was added Me3O·BF4 (37.1 mg, 0.241 mmol). The slurry was stirred 
overnight and cleared to a pale orange solution. The volatiles were removed in vacuo to provide 
2-252 (76.0 mg, 0.207 mmol, 86%) as an orange oil: [α]D +105.5 (c 0.83, CHCl3); IR (neat) 
2965, 2873, 1596, 1427, 1261, 1048, 1034, 834, 812, 779, 738, 702 cm-1; 1H NMR (600 MHz, 
CDCl3) δ 7.54-7.53 (m, 2 H), 7.41-7.40 (m, 3 H), 3.51 (s, 3 H), 3.47 (s, 3 H), 2.99 (dd, J = 2.8, 
15.2 Hz, 1 H), 2.85 (dd, J = 12.6, 15.0 Hz, 1 H), 2.43 (s, 3 H), 1.22-1.56 (m, 1 H), 1.05 (d, J = 
7.3 Hz, 3 H), 0.41 (s, 6 H); 13C NMR (150 MHz, CDCl3) δ 196.2, 135.3, 134.1, 130.2, 128.5, 
46.2, 45.6, 34.9, 21.2, 17.0, 13.4, 5.0, 6.3; HRMS (EI) m/z calculated for C15H26NSiS (M-BF4-) 
280.1555, found 280.1555. 
 
N OH
O
O
2-253  
(7S,9aS)-7-Butyryloxy-1,2,5,6,7,9a-hexahydropyrrolo[1,2-a]azepin-3-one (2-253). To 
a solution of 2-208 (1.23 g, 7.37 mmol) in dry CH2Cl2 (25 mL) was added DMAP (90 mg, 0.74 
mmol), butyric acid (744 µL, 8.11 mmol) and EDC·HCl (1.55 g, 8.11 mmol). The reaction 
mixture was stirred overnight at room temperature and was filtered through a plug of Celite. The 
volatiles were removed under reduced pressure and the residue was purified by chromatography 
on SiO2 (100% EtOAc) to afford 2-253 (1.61 g, 6.8 mmol, 92%) as a pale yellow oil and a 6:1 
inseparable mixture of diastereomers by 1H NMR spectroscopy: [α]D –48.0 (c 0.55, CHCl3); IR 
(neat) 2964, 2935, 2876, 1727, 1681, 1419, 1252, 1173, 1085, 1001, 971 cm-1; 1H NMR (600 
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MHz, CDCl3) δ 5.72 (dt, J = 2.9, 12.0 Hz, 1 H), 5.64 (dt, J = 2.1, 12.1 Hz, 1 H), 5.50-5.48 (m, 1 
H), 4.30 (ddddd, J = 2.3, 2.3, 4.6, 7.8, 7.8), 4.21 (ddd, J = 3.4, 7.2, 14.2 Hz, 1 H), 2.98 (ddd, J = 
2.8, 9.3, 13.2 Hz, 1 H), 2.43 (ddd, J = 6.9, 10.0, 16.5 Hz, 1 H), 2.36-2.26 (m, 4 H), 2.09-2.04 (m, 
1 H), 1.92 (dddd, J = 3.4, 9.1, 9.1 14.1 Hz, 1 H), 1.84-1.79 (m, 1 H), 1.64 (sextet, J = 7.4 Hz, 2 
H), 0.93 (t, J = 7.4 Hz, 3 H); 13C NMR (150 MHz, CDCl3) δ 174.0, 173.0, 133.1, 132.2, 71.5, 
58.1, 38.5, 36.4, 32.1, 30.1, 26.5, 18.6, 13.8; HRMS (EI) m/z calculated for C13H19NO3Na 
[M+Na]+ 260.1263, found 260.1269. 
 
 
N OH
MeO H
O N OH
MeO H
O
2-255a 2-255b
+
 
Methyl (S)-2-((9R,9aS,Z)-3-oxo-2,3,5,6,9,9a-hexahydro-1H-pyr rolo[1,2-a]azepin-9-
yl) butanoate (2-255a) and Methyl (R)-2-((9R,9aS,Z)-3-oxo-2,3,5,6,9,9a-hexahydro-1H-
pyr rolo[1,2-a]azepin-9-yl)butanoate (2-255b). To a cooled solution of TIPSCl (1.38 mL, 6.32 
mmol) in dry HMPA (6.0 mL) and dry THF (16.2 mL) was added a freshly prepared solution of 
LiHMDS (5.47 mL, 5.47 mmol, 1.0 M in THF) and the solution was stirred at –78 °C for 15 min. 
To this mixture was added 2-253 (500 mg, 2.11 mmol) in dry THF (4.2 mL). The homogeneous 
reaction mixture turned a dark color and became a deep brown over 2 h at –78 °C. The reaction 
mixture was allowed to warm to 0 °C and was quenched upon addition of cold (~–30 °C) Et2O 
(20 mL). The solution was allowed to warm to room temperature and the organic solution was 
washed with H2O (5 x 20 mL), brine (20 mL) and dried (MgSO4. The volatiles were removed 
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under reduced pressure to afford a brown oil that was used without further purification. 1H NMR 
analysis confirmed complete conversion to a single silyl ketene acetal isomer. 
The brown oil was taken up in dry, degassed xylenes (16 mL) and the solution was 
heated to reflux for 3 h. The resulting yellow solution was allowed to warm to room temperature 
and the volatiles were removed under reduced pressure to afford a brown oil that was used 
without further purification. 
A solution of the brown oil (829 mg, 2.11 mmol, theoretical) in THF (15.2 mL) was 
treated with a solution of TBAF (2.52 mL, 2.53 mmol, 1 M in THF). The brown solution became 
dark brown immediately upon addition and the reaction mixture was stirred for 2 h at room 
temperature. The solution was diluted with EtOAc (40 mL) and H2O (25 mL) followed by 1N 
HCl (25 mL). The organic layer was extracted 3 x 20 mL H2O, and the aqueous layers were 
back-extracted with EtOAc (3 x 20 mL) and the combined organic layers were washed with 
brine (30 mL), filtered, dried (MgSO4) and concentrated to a brown oil that solidified in vacuo.  
This residue was taken up in benzene (30 mL) and MeOH (7 mL) and the solution was 
treated with TMSdiazomethane (1.26 mL, 2.53 mmol, 2 M in hexanes) and gas evolution was 
observed immediately. After 20 min the reaction mixture was concentrated under reduced 
pressure and the residue was purified by MPLC (90% EtOAc/Hex) to provide 2-255a and 2-
255b (269 mg, 1.07 mmol, 51%) as an amber oil and a 6:1 ratio of diastereomers by 1H NMR 
spectroscopy: [α]D –28.8 (c 0.54, CH2Cl2); IR (neat) 2964, 2878, 1732, 1683, 1457, 1422, 1274, 
1166, 1077, 987 cm-1; 1H NMR (600 MHz, CDCl3) δ 5.54 (dddd, J = 2.3, 2.3, 5.3, 8.6 Hz, 1 H), 
5.24 (ddd, J = 2.3, 5.0, 11.2 Hz, 1 H), 4.02 (ddd, J = 6.0, 6.0, 9.1 Hz, 1 H), 3.84 (ddd, J = 3.0, 
7.4, 14.1 Hz, 1 H), 3.70 (s, 3 H), 3.18 (ddd, J = 5.7, 10.6, 14.2 Hz, 1 H), 3.14-3.10 (m, 1 H), 
2.56-2.49 (m, 1 H), 2.42 (ddd, J = 5.0, 9.7, 9.7 Hz, 1 H), 2.39-2.30 (m, 3 H), 1.95 (ddddd, J = 
 183 
2.4, 6.7, 8.7, 8.7, 12.0 Hz, 1 H), 1.71-1.63 (m, 3 H), 0.91 (t, J = 7.4 Hz, 3 H); 13C NMR (150 
MHz, CDCl3) δ 175.3, 174.8, 130.5, 126.3, 60.7, 51.8, 18.5, 41.6, 37.7, 31.0, 28.8, 23.8, 21.9, 
11.8; HRMS (ESI) m/z calculated for C14H21NO3Na [M+Na]+ 274.1419, found 274.1409. 
 
N OH
O
O
PhMe2Si
2-262  
(7S,9aS)-7-([3S]-3-Dimethyl(phenyl)silylbutyryloxy-1,2,5,6,7,9a-hexahydropyrrolo[1,2-
a]azepin-3-one (2-262). A solution of 2-208 (520 mg, 3.11 mmol) in dry CH2Cl2 (7.5 mL) was 
treated with DMAP (38.0 mg, 0.311 mmol) and EDC-HCl (715 mg, 3.73 mmol). To this solution 
was added 2-244 (705 mg, 3.17 mmol) in dry CH2Cl2 (2 x 1 mL) and the yellow reaction mixture 
was stirred overnight at room temperature. The reaction mixture was diluted with sat. aq. NH4Cl 
(10 mL) and H2O (10 mL) and CH2Cl2 (10 mL). The aqueous layer was extracted with CH2Cl2 (3 
x 5 mL), and the combined organic layers were dried (MgSO4), filtered, concentrated and the 
crude residue was purified by chromatography on SiO2 (80% EtOAc/Hex) to afford 2-262 (1.08 
g, 2.90 mmol, 93% yield) as a colorless oil and a 6:1 ratio of inseparable diastereomers by 1H 
NMR spectroscopy that becomes orange upon storage: [α]D –41.9 (c 0.21, CHCl3); IR (neat) 
2954, 2870, 1726, 1686, 1426, 1250, 1205, 1111, 999, 813, 732, 700 cm-1; 1H NMR (600 MHz, 
CDCl3) δ 7.49-7.48 (m, 2 H), 7.37-7.35 (m, 3 H), 5.65 (ddd, J = 2.4, 2.4,12.2 Hz, 1 H), 5.61 
(ddd, J = 1.8, 1.8 Hz, 12.2 Hz, 1 H), 5.47-5.45 (m, 1 H), 4.8 (dddd, J = 2.3, 4.4, 7.9, 10.3 Hz, 1 
H), 4.21 (ddd, J = 3.1, 7.1, 10.3 Hz, 1 H), 2.97 (ddd, J = 2.3, 9.7, 13.1 Hz, 1 H), 2.45-2.40 (m, 1 
H), 2.39 (dd, J = 3.9, 15.3 Hz, 1 H), 2.35-2.31 (m, 1 H), 2.30-2.24 (m, 1 H), 2.05 (dd, J = 11.5, 
15.3 Hz, 1 H), 2.06-2.01 (m, 1 H), 1.90-1.84 (m, 1 H), 1.84-1.78 (m, 1 H), 1.43 (ddddd, J = 4.0, 
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7.4, 7.4, 7.4, 14.8 Hz, 1 H), 0.96 (d, J = 7.3 Hz, 3 H), 0.28 (s, 3 H), 0.27 (s, 3 H); 13C NMR (150 
MHz, CDCl3) δ 174.0, 173.3, 137.3, 134.1, 132.7, 132.3, 129.3, 127.9, 71.9, 58.1, 38.6, 37.0, 
32.3, 30.1, 26.4, 16.7, 14.6, -4.8, -5.2. 
 
N OH
HO H
3-6  
(9R,9aS)-9-((S)-1-Hydroxybutan-2-yl)hexahydro-1H-pyrrolo[1,2-a]azepin-3(2H)-one 
(3-6). A solution of 2-255a,b (125 mg, 0.497 mmol) in MeOH (5.0 mL) was treated with Pd/C 
(52.9 mg, 0.050 mmol) and the system was purged with H2 and stirred under balloon pressure for 
2 h. The black slurry was filtered through Celite, washed with CH2Cl2 and concentrated to afford 
the crude product as a yellow film (126 mg, 0.497 mmol, 99%). 
To a solution of the crude hydrogenation product (126 mg, 0.497 mmol) in dry THF (3 
mL) at 0 °C was added a solution of LiBH4 (1.24 mL, 2.49 mmol, 2.0 M in THF) and the 
colorless reaction mixture was allowed to warm to room temperature overnight. An additional 
amount of LiBH4 (1.24 mL, 2.49 mmol, 2 M in THF) was added and the reaction mixture was 
stirred for a total of 48 h. The turbid mixture was carefully quenched with sat. aq. NH4Cl (3 mL) 
and diluted with H2O (3 mL) and EtOAc (5 mL). The aqueous phase was extracted with EtOAc 
(3 x 5 mL), and the combined organic layers were dried (MgSO4), filtered, concentrated, and 
purified by MPLC (5 % MeOH/EtOAc) to afford 3-6 (65.0 mg, 0.288 mmol, 58%) as a yellow 
oil and a single diastereomer along with mixed fractions (15.0 mg, 0.067 mmol, 13%): [α]D –195 
(c 0.22, CHCl3); IR (neat) 3379, 2927, 2876, 1655, 1458, 1434, 1422, 1320, 1281, 1159, 1033 
cm-1; 1H NMR (600 MHz, CDCl3) δ 3.99 (ddd, J = 3.0, 3.0, 13.7 Hz, 1 H), 3.91 (ddd, J = 6.0, 
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6.0, 10.2 Hz, 1 H), 3.73 (dd, J = 3.9, 11.1 Hz, 1 H), 3.70 (dd, J = 4.7, 11.0 Hz, 1 H), 2.65 (ddd, J 
= 1.8, 12.5, 14.1 Hz, 1 H), 2.38-2.29 (m, 2 H), 2.00 (ddd, J = 6.0, 8.2, 8.2 Hz, 1 H), 1.94 (dddd, J 
= 2.2, 6.1, 8.1, 12.6, 1 H), 1.87-1.83 (bm, 1 H), 1.70-1.61 (m, 2 H), 1.58-1.50 (m, 2 H), 1.46-1.34 
(m, 3 H), 1.27-1.24 (m, 2 H), 0.93 (t, J = 7.3 Hz, 3 H); 13C NMR (150 MHz, CDCl3) δ 174.7, 
62.1, 60.7, 43.6, 42.2, 40.7, 31.0, 29.9, 29.1, 24.4, 22.0, 21.5, 11.7; HRMS (EI) m/z calculated 
for C13H23NO2 (M·+) 225.1729, found 225.1724. 
 
N OH
H
O
H
2-267  
(S)-2-(9R, 9aS)-oxooctahydro-1H-pyrrolo[1,2-a]azepin-9-yl)butanal (2-267). To a 
stirred solution of crude 3-6 (77 mg, 0.34 mmol, theoretical) in dry CH2Cl2 (3.5 mL) at room 
temperature was added Dess-Martin reagent (147 mg, 0.343 mmol). The slurry was stirred for 3 
h and sat. aq. NaHCO3 (1 mL) was added followed by sat. aq. Na2S2O3 (1 mL) and diluted with 
EtOAc (3 mL). The aqueous layer was extracted with EtOAc (3 x 1 mL) and the combined 
organic layers were dried (MgSO4), filtered and concentrated. MPLC purification (100% EtOAc) 
of the residue provided 2-262 (27.0 mg, 0.121 mmol, 35% from 2-255a,b) as an orange oil and a 
single diastereomer by 1H NMR spectroscopy that is unstable upon storage overnight: [α]D –
100.4 (c 0.27, CHCl3); IR (neat) 3018, 2963, 2929, 2877, 1717, 1681, 1458, 1423, 1278 cm-1; 1H 
NMR (600 MHz, CDCl3) δ 9.56 (d, J = 3.5 Hz, 1 H), 4.03 (ddd, J = 3.9, 3.9, 13.9, 1 H), 3.89 
(ddd, J = 5.8, 5.8, 10.1, 1 H), 2.64 (ddd, J = 1.7, 12.4, 14.1 Hz, 1 H), 2.38-2.39 (m, 2 H), 2.25-
2.21 (m, 2 H), 1.91 (dddd, J = 3.3, 6.4, 6.4, 12.6 Hz, 1 H), 1.87-1.82 (m, 1 H), 1.73-1.69 (m, 2 
H), 1.66-1.56 (m, 2 H), 1.46-1.38 (m, 1 H), 1.37-1.34 (m, 2 H), 1.34-1.28 (m, 1 H), 0.89 (t, J = 
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7.5 Hz); 13C NMR (150 MHz, CDCl3) δ 204.1, 174.5, 59.9, 55.4, 41.7, 40.8, 30.8, 29.6, 29.1, 
25.6, 21.9, 20.8, 11.3. 
 
N OH
H
O
O
H
Sessilifoliamide C 
(2-227)  
(9R,9aS)-9-((S)-1-((R)-4-methyl-5-oxo-2,5-dihydrofuran-2-yl)propyl)hexahydro-1H-
pyrrolo[1,2-a]azepin-3(2H)-one; Sessilifoliamide C (2-227).  
To a solution of 2-262 (57 mg, 0.255 mmol) in dry THF (3.7 mL) at –78 °C was added 
vinylMgBr (1.02 mL, 1.02 mmol, 1 M in THF). The resulting yellow solution was stirred at –78 
°C overnight. To the pale yellow slurry was added acryloyl chloride (165 µL, 1.53 mmol) and 
NEt3 (362 µL, 2.55 mmol) and the reaction mixture was allowed to warm to room temperature 
and homogeneity was achieved. The reaction mixture was stirred for 2 h and was quenched by 
the addition of sat. aq. NaHCO3 (10 mL) and the biphasic mixture was diluted with EtOAc (5 
mL). The aqueous phase was extracted with EtOAc (3 x 10 mL) and the combined organic layers 
were washed with brine (20 mL), dried (MgSO4), filtered, and concentrated to afford a yellow 
oil that was purified by MPLC (4:1 EtOAc/Hex) to provide 2-269a and 2-269b (48.0 mg, 0.150 
mmol, 59%) as an orange film and a 2:1 mixture of diastereomers by 1H NMR spectroscopy: 1H 
NMR (600 MHz, CDCl3) δ (distinctive peaks) 6.14 (t, J = 1.0 Hz), 6.11 (t, J = 3.4 Hz), 5.89 
(ddd, J = 5.8, 10.3, 16.9 Hz), 5.84 (ddd, J = 5.8, 10.9, 16.5 Hz), 5.66-5.64 (m), 5.64-5.63 (m), 
5.61 (t, J = 1.5 Hz), 5.27 (t, J = 1.4 Hz), 5.25 (ddd, J = 1.2, 1.2, 4.4 Hz), 5.23 (bs), 5.21 (ddd, J = 
1.3, 1.3, 8.1 Hz), 4.01 (bd, J = 13.7 Hz), 3.91-3.86 (m), 2.67-2.56 (m), 2.37-2.31 (m), 1.97 (s), 
1.97 (s), 2.04-1.91 (m), 1.97 (s), 1.97 (s), 1.87-1.81 (m), 1.71-1.66 (m), 1.64-1.58 (m), 1.52-1.31 
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(m), 1.26-1.20 (m), 1.15-1.07 (m), 1.01 (t, J = 7.4 Hz), 0.98 (t, J = 7.4 Hz); 13C NMR (150 MHz, 
CDCl3) δ (major diastereomer) 174.5, 166.4, 136.4, 135.2, 125.9, 116.5, 75.6, 60.6, 44.5, 42.1, 
40.8, 30.9, 29.7, 29.0, 23.6, 21.9, 21.0, 18.5, 12.2, (minor diastereomer) 174.5, 166.6, 136.5, 
134.7, 125.8, 117.4, 75.5, 60.4, 47.3, 42.7, 40.6, 31.1, 29.1, 26.1, 22.8, 20.8, 13.7. 
A solution of 2-264a and 2-264b (17 mg, 0.053 mmol) and 2-95 (5.3 mg, 0.005 mmol) in 
dry CH2Cl2 (10 mL) was heated to reflux overnight. An additional batch of 2-95 was added (5.3 
mg, 0.005 mmol) and the reaction mixture was heated for 4 h. A third batch of 2-95 was added 
(5.3 mg, 0.005 mmol) and the reaction mixture was heated to reflux for an additional 3 h. The 
brown solution was allowed to cool to room temperature and was directly subjected to MPLC 
purification (100% EtOAc) to afford 2-227 and epi-2-227 (13 mg, 0.045 mmol, 84%), which 
could be separated by MPLC (100% EtOAc). Analytical data for the slower-eluting major 
diastereomer matches the reported isolation data for sessilifoliamide C:121 2-227: [α]D –84.6 (c 
0.25, CHCl3), –43.4 (c 0.5, EtOH); IR (neat) 2928, 2877, 1749, 1676, 1449, 1422, 1323, 1282, 
1091, 923, 729 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.03 (t, J = 1.5 Hz, 1 H), 5.17 (bq, J = 2.0 
Hz, 1 H), 4.03 (ddd, J = 3.3, 3.3, 13.8 Hz, 1 H), 3.92 (ddd, J = 5.9, 5.9, 10.1 Hz, 1 H), 2.66 (ddd, 
J = 1.7, 12.4, 12.4 Hz, 1 H), 2.43-2.33 (m, 2 H), 2.20 (ddd, J = 5.8, 8.3, 8.3 Hz, 1 H), 1.98-1.92 
(m, 1 H), 1.95 (t, J = 1.7 Hz, 3 H), 1.90-1.86 (bm, 1 H), 1.75-1.65 (m, 4 H), 1.49-1.41 (m, 1 H), 
1.40-1.31 (m, 3 H), 1.19 (sept, J = 7.3 Hz, 1 H), 0.84 (t, J = 7.5 Hz, 3 H); 13C NMR (150 MHz, 
CDCl3) δ 174.6, 174.5, 148.2, 130.5, 82.3, 60.9, 44.2, 43.3, 40.7, 31.0, 29.5, 29.0, 24.6, 22.1, 
19.1, 13.5, 10.9; HRMS (EI) m/z calculated for C17H25NO3 (M·+) 291.1834, found 291.1836. 
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APPENDIX A 
TARGETING MITOCHONDRIA 
The following review article co-authored by A. T. Hoye is reproduced without 
alteration.145
 
 Primary authorship is indicated for each section. 
A.1 INTRODUCTION 
 (P. Wipf, V. Kagan and M. Fink, authors)  
Reactive oxygen species (ROS) and 
reactive nitrogen species (RNS) are closely linked 
to degenerative diseases such as Alzheimer’s 
disease, Parkinson’s, neuronal death including 
ischemic and hemorrhagic stroke, acute and 
chronic degenerative cardiac myocyte death, and 
cancer. As a byproduct of oxidative phosphorylation, a steady stream of reactive species emerge 
from our cellular energy plants, the mitochondria. ROS and RNS potentially cause damage to all 
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cellular components. Structure alteration, biomolecule fragmentation, and oxidation of side 
chains are trade-offs of cellular energy production. ROS and RNS escape results in the activation 
of cytosolic stress pathways, DNA damage, and the upregulation of JNK, p38, and p53. 
Incomplete scavenging of ROS and RNS particularly affects the mitochondrial lipid cardiolipin 
(CL), triggers the release of mitochondrial cytochrome c, and activates the intrinsic death 
pathway.  
Due to the active redox environment and the excess of NADH and ATP at the inner 
mitochondrial membrane, a broad range of agents including electron acceptors, electron donors, 
and hydride acceptors can be used to influence the biochemical pathways. The key to therapeutic 
value is to enrich selective redox modulators at the target sites. 
Our approach is based on conjugating nitroxides to segments of natural products with 
relatively high affinity for mitochondrial membranes. For example, a modified gramicidin S 
segment was successfully used for this purpose and proven to be effective in preventing 
superoxide production in cells and CL oxidation in mitochondria and in protecting cells against a 
range of pro-apoptotic triggers such as actinomycin D, radiation, and staurosporine. More 
importantly, these mitochondriatargeted nitroxide/gramicidin conjugates were able to protect 
against apoptosis in vivo by preventing CL oxidation induced by intestinal hemorrhagic shock. 
Optimization of nitroxide carriers could lead to a new generation of effective antiapoptotic 
agents acting at an early mitochondrial stage.  
Alternative chemistry-based approaches to targeting mitochondria include the use of 
proteins and peptides, as well as the attachment of payloads to lipophilic cationic compounds, 
sulfonylureas, anthracyclines, and other agents with proven or hypothetical affinities for 
mitochondria. Manganese superoxide dismutase (MnSOD), SS tetrapeptides with 2’,6’-
 190 
dimethyltyrosine (Dmt) residues, rhodamine, triphenylphosphonium salts, nonopioid analgesics, 
adriamycin, and diverse electron-rich aromatics and stilbenes were used to influence 
mitochondrial biochemistry and the biology of aging.  
Some general structural principles for effective therapeutic agents are now emerging. 
Among these are the presence of basic or positively charged functional groups, hydrophobic 
substructures, and, most promising for future selective strategies, classes of compounds that are 
actively shuttled into mitochondria, bind to mitochondria-specific proteins, or show preferential 
affinity to mitochondria-specific lipids. 
In 1956, Harman proposed the “free radical theory” of aging and associated degenerative 
diseases.146 According to this hypothesis, “...the reaction of active free radicals, normally 
produced in the organisms, with cellular constituents initiates the changes associated with 
aging.” Consequences of these biochemical alterations are an up-regulation of p53 and the 
activation of cytosolic stress signaling pathways. Ultimately, both life span and life quality are 
severely negatively affected. While some controversy regarding the generality of the Harman 
theory continues, experimental evidence for the link between reactive oxygen species (ROS) and 
the biology of aging is steadily solidifying.147 In particular, mitochondrial metabolism and the 
oxidative phosphorylation cascade are emerging as key factors in the generation of ROS 
associated with a large number of disease states, including atherosclerosis, Alzheimer’s disease, 
Parkinson’s, neuronal death including ischemic and hemorrhagic stroke, acute and chronic 
degenerative cardiac myocyte death, and cancer.148,149
With a notable exception of NADPH oxidase in activated inflammatory cells, the lion’s 
share, possibly up to 90%
  
147 of intracellular ROS are generated in mitochondria during the 
controlled oxidation of NADH and FADH with molecular oxygen coupled with the 
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phosphorylation of ADP to give ATP in a multienzyme complex embedded in the mitochondrial 
membrane (Figure 1). In addition to superoxide radical anion (O2-•), major reactive species 
generated in this process include H2O2 and HO•. Furthermore, ROS collectively include both 
oxygen radicals and nonradical oxidizing species such as 1O2, O3, and ROOR; a large variety of 
these reactive molecules are produced in vivo, even though the specific reaction mechanisms 
involved in their generation remain still unclear.150,151 Upon reaction with nitric oxide (NO·), 
O2–• also participate in the formation of reactive nitrogen species (RNS), such as ONOO-. 
Several efficient enzymatic processes are continuously operational to quench ROS and RNS, 
including superoxide dismutase (SOD) and superoxide reductase (SOR),152 catalase,153 
peroxiredoxin (Prx),154 glutathione peroxidase (GP), and thioredoxin/thioredoxin reductase 
(Trx/TrxR) (Figure 2).155 However, if, as a result of aging or pathological processes, the 
production of ROS and RNS exceeds the scavenging capacity of endogenous systems, then both 
mitochondrial and extramitochondrial cellular components, including proteins, nucleic acids, and 
lipids, can be damaged. Under these circumstances, an external chemical intervention might be 
beneficial. Pharmaceuticals that provide ROS and RNS scavenging systems are most effective if 
they address the problem at its source, in the inner mitochondrial membrane.156
In the past ten years, the search for new protective remedies against damage caused by excessive 
free radical formation in mitochondria has accelerated. Similar to our body’s own natural 
defenses against ROS, research has been primarily focused on molecules combining antioxidant 
utilities with recycling capacities.
 This Account 
summarizes some of the current strategies used to target antioxidants to mitochondria, including 
peptide and nonpeptide delivery systems.  
157 Large doses of antioxidants proved ineffective at preventing 
oxidative damage in animal disease models, presumably because the antioxidants and proteins 
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such as manganese superoxide dismutase (MnSOD) cannot penetrate cell membranes effectively 
and therefore do not reach the relevant sites of ROS and RNS generation. One solution to this 
general problem is to attach a molecule with antioxidant properties onto a vehicle that can 
penetrate both the cellular and outer mitochondrial membranes and thereby deliver the “payload” 
to a site where it can scavenge ROS and ameliorate oxidative damage (Figure 3). Since the 
mitochondrial membrane spans across a negative potential, most agents have a positively 
charged moiety that takes advantage of electrostatic forces in locating its target. 
 
 
FIGURE 1. Schematic model for generation of reactive oxygen species (ROS) and 
reactive nitrogen species (RNS) during the oxidative phosphorylation in the mitochondrial 
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membrane. The formation of superoxide radical anion initiates a cascade process that can induce 
programmed cell death (apoptosis). 
 
O2•-
SOD
H2O2
Catalase
H2O +  O2
Trx(SH)2 +  H2O2
Prx
TrxS2  +  H2O
GSH +  H2O2
GP
GSSG  +  H2O  
FIGURE 2. Antioxidant scavenging reactions that eliminate ROS. SOD = superoxide dismutase, 
Prx = peroxiredoxin, GP = glutathione peroxidase, Trx = thioredoxin, GSH = glutathione. 
A.2 PROTEINS, PEPTIDES, AND PEPTIDE MIMETICS AS MITOCHONDRIAL 
TARGETING SYSTEMS 
 (J. Davoren, A. Hoye and P. Wipf, authors) 
A.2.1 Proteins 
For polypeptide strands to be properly recognized and imported into mitochondria, precursor 
proteins that are synthesized in the cytosol require specific sequence information that is 
recognized by an import pathway.158  While precursor proteins are prone to misfolding and 
aggregation, cytosolic chaperone proteins maintain them in an import-competent form.159 The 
processed protein is then bound by translocases of the outer and inner membranes (TOM and 
TIM), which transport the target across the lipid bilayers.160   
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Protein import and recognition is generally directed by an N-terminal or, less frequently, 
a C-terminal signal sequence consisting of about 20–30 amino acid residues, which are cleaved 
by mitochondrial processing peptidase (MPP) either during import or once inside the 
mitochondrial matrix. Comparison of known presequences reveals that they do not share a 
common primary structure. In these cases, however, a common secondary structure as well as 
certain basic (arginine), hydrophobic (alanine, leucine), and polar residues (serine) might be 
present. Alternatively, proteins such as cytochrome c and superoxide dismutases are imported 
with minimal processing since they contain the necessary recognition elements as part of their 
primary sequence.161,162 The N-terminal regions are postulated to fold into amphiphilic 
helices.163 It is proposed that this amphiphilicity in combination with localized positive charges 
emanating from basic residues are the two main features required for successful protein import. 
Electrostatic interactions are thought to occur between the positive charges found on the helix 
and the negative charges of the TOM receptors.164 then, in an electrophoretic event, the 
presequence follows the very large membrane potential (typically 150-180 mV) and is pulled 
across the inner membrane.165
A.2.2 Manganese superoxide dismutase (MnSOD). 
 
Superoxide dismutases (SOD) are responsible for catalyzing the dismutation of 
superoxide into oxygen and hydrogen peroxide and are therefore an important part of the 
antioxidant defense in most cells exposed to oxygen.166 Several families of SOD are known, and 
the activities of each family depend on a redox-active metal cofactor such as manganese, iron, 
copper, or nickel. A single metal cofactor will catalyze a single electron oxidation and reduction 
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of two separate superoxide anions to give oxygen and hydrogen peroxide, respectively. These 
reactions are self-contained and do not require an external source of redox equivalents. 
A generic mechanism for the catalytic breakdown of superoxide anion is: 
 
The family of manganese superoxide dismutases (MnSOD)167 consists of dimers or 
tetramers of approximately 21 kDa subunits and contains considerable sequence homology and 
well conserved protein folds across various phyla.168 Dimeric forms of MnSOD are typical of 
bacteria, while in eukaryotes the tetramer is most commonly observed. At the active site of the 
enzyme, a single manganese atom catalyzes the disproportionation of superoxide and is 
coordinated in a trigonal bipyramidal geometry to three histidine residues, one aspartate, and a 
solvent water molecule (Figure 4).169
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FIGURE 4. Structure of the active site of human superoxide dismutase 2. His74, His26, His163, 
and Asp159 provide a tight complex for manganese(III). 
 
In the case of eukaryotic MnSOD (SOD2), the polypeptide is initially encoded by a 
nuclear gene as a precursor polypeptide containing the requisite mitochondrial targeting 
sequence at its N-terminus. The mechanism by which SOD obtain their manganese cofactors is 
still unknown; however, the manganese- containing form of SOD typically resides in the matrix 
of the mitochondrion. Enzymatically inactive mutant forms of Saccharomyces cerevisiae SOD2 
lacking the mitochondrial targeting sequence [denoted as SOD2P] were found to accumulate in 
the cytosol rather than the mitochondria.170
166
 Their inactivity was attributed to a manganese 
deficiency, and further investigations suggested that SOD2P required mitochondrial localization 
in order to efficiently acquire manganese. Therefore it is proposed that as the SOD2 polypeptide 
precursor enters mitochondria, manganese is inserted into the polypeptide, and the complex then 
assembles into the quaternary enzyme structure.   
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MnSOD plays an essential role in oxidative stress protection, and the assembly of this 
tetrameric peptide into the active manganese-containing enzyme is critical for survival. For 
example, in neonatal mice, the loss of MnSOD is lethal,171 while its modification in fruit flies 
leads to a severely reduced adult life span.172  In contrast, due to its role as a negative modulator 
of apoptosis, inhibition of MnSOD in cancer cells is considered to be a promising target for 
anticancer therapies.173 The MnSOD gene is known to be induced by tumor necrosis factor alpha 
(TNFR) and provides protection against TNF-induce apoptosis.174
173
 As such, even small amounts 
of this enzyme are considered crucial for tumor cell resistance to inflammatory stimuli, ionizing 
radiations, and commonly employed anticancer drugs.  
A.2.3 Peptides and Peptide Mimetics.  
Several cell-permeable mitochondrial targeting peptides with attached antioxidants have been 
conceived and tested, including SS peptides,175 which feature a 2,6-dimethyltyrosine (Dmt) 
payload, as wellas the XJB peptide mimetics,176
 
 which deliver a 4-amino-TEMPO (4-AT), a 
stable nitroxide radical. 
A.2.3.1  SS tetrapeptides.  
The SS tetrapeptides represent a series of mitochondria-targeting antioxidant peptides 
that feature a common structural motif of alternating aromatic and basic residues (Figure 5).175 
Prior to the discovery of their antioxidant properties, these tetrapeptides were already 
extensively studied due to their high affinity and selectivity to the µ-opioid receptor, and they 
were found to be surprisingly potent andlong-acting analgesics.177 
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The antioxidant properties of SS-02 and SS-31 are likely to originate from their 
dimethyltyrosine (Dmt) residues.178 More specifically, tetrapeptides SS-31 and SS-02 were 
found to be equally effective in scavenging H2O2 and inhibiting linoleic acid oxidation in vitro. 
This result indicates that the specific location of the Dmt residue in the sequence of the 
antioxidant peptide is inconsequential. The basic residues provide for localization in the inner 
mitochondrial membrane, and the Dmt phenol moieties of SS-02 and SS-31 are likely 
responsible for chemically reducing reactive oxygen species and peroxide bonds. Tetrapeptide 
SS-20, where Dmt is substituted with a phenylalanine residue, was devised as a control and, in 
agreement with the hypothesis, demonstrated no ROS scavenging ability. 
 
FIGURE 5. Structures of active and control SS peptides. 
 
Despite the net positive charge of these small peptides at physiological pH values, their 
amino acid sequence allows them  to freely penetrate cells in an energy-independent 
nonsaturable passive manner.179 A fluorescent SS-peptide analogue (Dmt-DArg-PheantDap-
NH2; ant = β-anthraniloyl-L-α,β-diaminopropionic acid), SS-19, was prepared to study 
mitochondrial and cellular uptake in living cells. Confocal images showed that the pattern of 
localization of the fluorescent analogue was similar to that of Mitotracker TMRM, a fluorescent 
dye that is readily taken up by mitochondria. To ensure that uptake was not an artifact caused by 
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the presence of the fluorophore, these aromatic cationic peptides were further studied by 
incubating [3H]SS-03 with mouse liver mitochondria. The uptake of [3H]SS-03 reached 
maximal levels within 2 min and reflected a 100-fold concentration in mitochondria. 
In consideration of their positive net charge, these peptides were expected to pass through 
the inner membrane of the mitochondria (IMM) into the matrix; however, pretreatment with the 
mitochondrial uncoupler carbonylcyanide-p-trifluoromethoxyphenylhydrazone (FCCP) only 
decreased SS-19 or [3H]SS-03 uptake by about 20%. This finding suggests that the bulk of the 
peptide was localized in the IMM, while only 20% was delivered to the matrix in a potential-
driven manner. 
tert-Butyl hydroperoxide (tBHP) is a membrane permeable oxidant known to induce 
apoptosis in treated cells.180 Apoptosis induced by t-BHP is triggered by a phenomenon called 
the mitochondrial permeability transition (MPT),181 which delivers an increase in the 
permeability of the mitochondrial membranes to small molecules of less than 1500 Da molecular 
weight. In a series of in vitro studies, the peptides SS-02 and SS-31 were demonstrated to be 
effective antioxidants, which inhibited triggering of the MTP and partially ameliorated apoptosis 
of t-BHP-treated cells.182
Reperfusion injury following ischemia or hemorrhagic shock is thought to include ROS 
production and mitochondrial permeability transition.
  
183 Once blood loss occurs, if intravascular 
volume expansion successfully restores arterial blood pressure before hemostasis has been 
achieved, then paradoxically, resuscitation can actually promote bleeding and reduce the chances 
of survival.184
In an ex vivo reperfusion study on guinea pig heart, both SS-02 and SS-31 were able to 
 In animal models, the overexpression of SOD was associated with protection 
against reperfusion injury, while SOD knockout animals were more susceptible. 
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prevent myocardial stunning and significantly improve contractile force, albeit at drastically 
different doses (100 μM and 1 nM, respectively).175,185
185
 The discrepancy in activity must be 
attributed to the amino acid sequence alone, since both SS-02 and SS-31 were of similar 
efficiency as antioxidants in the nonenzymatic in vitro assay. SS-20, which lacks the scavenging 
Dmt moiety, was unable to prevent myocardial stunning when administered upon reperfusion. 
Furthermore in vivo testing of SS-02 was found to protect against myocardial stunning in rats,  
thus supporting the theory that ROS play a major role in reperfusion-induced myocardial 
stunning  Since mitochondria contain μ-type opiod receptors, further study on these SS 
tetrapeptides is required to determine whether it is the opiod receptor association of these 
peptides that mediates mitochondrial targeting and whether this event is the cause of cardiac 
protection at reperfusion.186
 
 
A.2.3.2  XJB Gramicidin S Analogs.  
XJB peptides and peptide mimetics are based on the sequence of the membrane-active 
gramicidin S (GS) antibiotics (Figure 6); their antioxidant properties stem from the attachment to 
the stable free radical, 4-amino-TEMPO (4-AT).187 Among the advantages of TEMPO is the 
ability to use electron spin resonance (ESR) to measure distribution of the spin label and detect 
oxidative stress in the local cellular environment.188
In addition to XJB-5-131, initial proof-of-principle experiments also used two different 
hemi-GS segments (Leu-D-Phe-Pro-Val-Orn and D-Phe-Pro-Val-Orn-Leu) in conjugation with 
4-AT (XJB-5-125 and XJB-7-75, respectively, Figure 7). Incubation of mouse embryonic cells 
with either XJB-5-125 or XJB-7-75 attenuated ActD-induced phosphatidylserine (PS) 
externalization in a dose-dependent manner at a concentration nearly 1000 times lower than 
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untargeted 4-AT. Hemi-GS-TEMPO derivatives almost completely inhibited superoxide 
production in ActDtreated mouse embryonic cells. The shortened peptide isostere sequence 
XJB-5-208 showed no antiapoptotic effects, and, in accordance with the functional hypothesis, 
control fragments with slightly altered sequences such as XJB-5-197 and XJB-5-194 also 
provided no protection.189
187
 Most subsequent follow up studies used the peptide isostere XJB-5-
131,  since the replacement of an amide bond with an alkene group often leads to an extended 
bioavailability, possibly due to increased resistance against protease action.190
 
   
 
FIGURE 6. Structures of the cyclodecapeptide antibiotic, microbial lipid targeting gramicidin S, 
and the designed XJB-5-131, which delivers the ROS scavenging unit 4-AT to mitochondrial 
membranes. 
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FIGURE 7. Structures of XJB-5-131 analogs. 
 
The levels of internalization of XJB-5-125, XJB-5-131, and XJB-5-208, as well as 
untethered 4-AT, after their incubation with mouse embryonic cells were tested using ESR 
spectroscopy and ESI-MS. XJB-5-125, XJB-5-131, and XJB-5-208 were readily detected in 
mitochondria, whereas the presence of free 4-AT was not observed. The biodistribution profile 
of non-antiapoptotic XJB-5-208 indicates that the simple accumulation of nitroxides in the 
mitochondria is not sufficient for preventing ActD-induced apoptosis. It was speculated that both 
the nitroxide functionality and the reverse turn (β-turn) of the targeting sequence are essential for 
the antiapoptotic properties of the hemi-GS-TEMPO derivatives.189 
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Since XJB-5-131 proved to be a novel and effective mitochondrial ROS and electron 
scavenger,191
184
 a follow up study was performed to assess its ability to prolong the survival of rats 
with lethal hemorrhagic shock.  Thirteen rats were bled over 60 min with a total blood loss of 
33.5 mL/kg or approximately 55% of total blood volume. Six were randomly assigned to receive 
XJB-5-131, and seven received only its vehicle, a 1:2 (vol/vol) mixture of DMSO and normal 
saline. All seven of the vehicle-treated (control) group died within 125 min, whereas animals 
treated with XJB-5-131 survived significantly longer. Three survived longer than 3 h and one 
survived for the whole postbleeding observation period. This study showed for the first time that 
acute administration of a single dose of a mitochondria-targeting ROS scavenger, XJB-5-131, 
can have a dramatic physiological effect in a whole animal model of critical illness. Furthermore, 
these studies suggest that treatment with XJB-5-131 might prolong the period of time that 
patients can survive after losing large quantities of blood, thereby allowing transport of otherwise 
mortally wounded individuals to locations where additional care can be provided. Further assays 
of these compounds to determine toxicity, half-life, distribution, metabolism, and physiological 
elimination are currently being pursued. 
A.3 NON-PEPTIDIC MITOCHONDRIAL TARGETING SPECIES 
 (A. Hoye, author) 
A.3.1 Lipophilic cationic compounds 
Mitochondria use ion channel pumps and oxidation pathways to maintain a constant 
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membrane potential of ca. -180 mV across their lipid bilayer. The magnitude of this potental is 
unprecedented in any other organelle; it is twice that of the plasma membrane of excitable cells 
and roughly six times higher than the plasma membrane of nonexcitable cells.192
The use of lipophilic cations as selective targeting agents has been explored to capitalize 
on this physiological phenomenon. Rhodamine 123 (1) and similar compounds containing 
cationic functionality in an otherwise nonpolar framework have the ability to traverse the 
mitochondrial lipid membrane by using the negative potential gradient of the organelle as an 
electrostatic driving force. According to the Nernst equation, this can result in a 100-500-fold 
increase in accumulation. Rhodamine 123 and related analogs have been used to assess the 
accumulation of this class of fluorescent dyes in mitochondria, and as a result of the success and 
reproducibility of their selective incorporation into mitochondria, practical rhodamine-based 
stains for mitochondrial assays have been developed and are routinely employed. 
 The unique 
nature of the mitochondrial membrane distinguishes it from its intracellular counterparts and 
offers a unique chemical opportunity for selectively targeting the mitochondrion. 
Rhodamine 123 has also been successfully used as a chaperone to direct tethered 
compounds into mitochondria. The anticancer drug cisplatin was selectively incorporated into 
the mitochondria of cancer cells using this method,193
192
 and similar approaches have been 
demonstrated with other small molecules. Arguably the most beneficial outcome of the 
rhodamine trials has been the discovery of the utility of the chaperone effect, which was further 
extended toward the development of lipophilic triphenylphosphonium (TPP) salts. The latter 
compound class includes the majority of the nonpeptidic mitochondrial targeting agents 
synthesized to date (Figure 8). ,193,194,195 
 205 
O NH2H2N
CO2Me
Rhodamine 123 (1)
R
Br
R
P
Br
EtOH, reflux
P
Br
PPh3
O
HO
Mito Vit E (2)
P
Br
(C7H14)
OH
O
O
MitoQ (3)
N
O
N
O
O (C4H8) PPh3
Br
O(C4H8)Ph3P
Br
Mn
JD- 29 (4)
Cl
 
FIGURE 8. Lipophilic cationic targeting agents. 
 
Given the similar uptake and selectivity profile of alkyl TPP compounds to that of the 
more structurally complex rhodamine analogues, a number of antioxidant-tethered lipophilic 
TPP cations have been synthesized.195,196 The common synthetic strategy for constructing this 
class of compounds proceeds via the displacement of the corresponding primary bromide using 
triphenylphosphine as outlined in Figure 8. Vitamin E has been shown to diminish the amount of 
ROS-associated mitochondrial damage by itself, but because the compound cannot effectively 
accumulate within mitochondria and due to health concerns related to higher dosages, only a 
limited effectiveness was observed without the use of the lipophilic cation transport tether. In 
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contrast, MitoVit E (2), named in reference to the tethered benzopyran moiety of vitamin E, is 
localized in energized mitochondria and protects isolated rat liver mitochondria from iron/ 
ascorbate- and tert-butylhydroperoxide-induced oxidative damage.197 MitoQ (3) is a related 
redox-active compound using ubiquinol as the active moiety, which selectively protects 
mitochondria against cardiac ischemia-reperfusion oxidative injury.198 Both 3 and the salen-
bound manganese compound JD-29 (4) were shown to exhibit MnSOD-like behavior and 
prevent mitochondrial oxidative damage.199
192
 MitoPBN, MitoCP, and Tempol-TPP (5-7) contain 
N-oxide moieties that scavenge ROS by mimicking SOD (Figure 9). ,195,200
195
, MitoPeroxidase (8) 
contains the glutathione peroxidase mimic ebselen to achieve its protective effects against 
Fe2+/H2O2-induced lipid peroxidation; it is part of a larger class of biologically significant 
organoselenium antioxidants. ,201
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FIGURE 9. Natural ROS scavenger mimic TPP lipophilic cations. 
 
Other lipophilic cations also show selectivity for mitochondria and are attractive 
candidates for potential therapeutic development. Flupirtine (9) is a nonopioid analgesic 
localized within mitochondria and protects against cell injury induced by N-methyl-D-aspartate 
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and against ischemic injury and prevents glutamate-induced increase of intracellular Ca2+ levels 
leading to apoptosis (Figure 10).202,203 MKT-077 (10) accumulates in mitochondria due to its 
cationic amino function and relatively nonpolar scaffold. However, instead of acting in a 
protective fashion, 10 displays selective toxicity to carcinoma mitochondria due to the increased 
mitochondrial membrane potential in cancer cells compared to normal cells.204,205
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FIGURE 10. Other lipophilic cation targeting agents. 
 
While lipophilic cations elicit protective effects toward mitochondrial injury, their 
dependence on the membrane potential in mitochondria also constitutes a major drawback. As 
increasing numbers of lipophilic cations enter the organelle, the potential gradient diminishes to 
the point where a rapid efflux of the inhibitor from the mitochondrion results in loss of activity 
until entry is regained. Therefore, unless inhibition is irreversible, uninterrupted activity of the 
lipophilic cation cannot occur. This deficiency poses a potential problem depending on the rates 
of influx and efflux of cationic species.193 
A.3.2 Sulfonylurea and related compounds 
Compounds 11–15 were observed to both activate and inhibit mitochondrial potassium ATP-
regulated ion channels (mitoKATP) (Figure 11). They bind with high affinity to sulfonylurea 
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receptors (SURs) in the plasma membrane across a number of cell types. A potassium channel 
structurally related to the SUR was detected in the inner membrane of mitochondria and 
identified as the target of these compounds, although the exact mechanism of action and 
specificity have not been elucidated.203,206 Potassium channel openers and inhibitors exhibit 
diverse activity ranging from vasodilation to hair growth, and recent evidence indicates that 
KATP channel openers could prove to be effective as pharmacological lead structures for the 
cardioprotection of tissues against ischemic necrosis and ultimately coronary artery disease, the 
main cause for fatalities in the industrialized world. 207
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FIGURE 11. Sulfonyl-urea and related mitochondrial targeting agents. 
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A.3.3 Anthracyclines 
Adriamycin (16) and daunomycin (17) belong to a class of anthracyclines that exhibit potent 
antitumor activity, presumably through direct binding to DNA in an intercalative fashion, that is, 
through insertion between stacked bases and charge interaction on the outer regions of the DNA 
helix (Figure 12). However, data has emerged that suggests these compounds interact, perhaps 
exclusively, with mitochondria by the disruption of major mitochondrial functions.208
208
 The 
cytotoxic side effects of anthracyclines have been attributed to the accumulation of these 
compounds in the mitochondrial lipid membrane and subsequent redox activity of the quinone 
moiety, resulting in damage of membranebound proteins and enzymes. The mitochondrial 
specificity of these compounds is noteworthy and has been correlated to their high affinity 
toward binding an inner mitochondrial membrane-specific phospholipid, cardiolipin. The 
glycosidic amino function in 16 and 17 was critical for the observed activity and differentiates 
them from related anthracycline analogues.  
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FIGURE 12. Mitochondrial-targeting anthracyclines Adriamycin and Daunomycin. 
 
 210 
A.3.4 Other structural classes 
 Several other structural classes have been shown to target mitochondria selectively, but more 
detailed investigations are required before their utility can be established. For example, 
resveratrol (18) and its analogues 19 and 20 selectively initiate the apoptotic mitochondrial 
pathway in cancer cell lines while leaving normal cells untouched; however, their precise 
mechanism of action is not fully understood (Figure 13).209
The mitochondrial targeting ability of porphyrin-based antitumor compounds such as 
verteporfin (21, Visudyne, Novartis AG) was postulated to derive from the enrichment of these 
compounds within mitochondria. Apparently, this accumulation is due to an interaction with 
mitochondrial-specific benzodiazepine receptors. The porphyrin moiety serves as a 
photosensitizer and induces the apoptotic pathways in tumor cell lines.
 
210
210
 BMD188 (22) is a 
cyclic hydroxamic acid derivative that has shown potent activity against prostate cancer, an 
effect that is hypothesized to be the result of an interaction with mitochondria. A number of other 
structurally diverse compounds, including curcumin (23), the steroid betulinic acid (24), and the 
retinoid CD437 (25) have also been shown to induce mitochondrial apoptosis through an 
opening of the mitochondrial transition permeability pore.  
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FIGURE 12. Other structural mitochondria targeting small molecules. 
A.4 CONCLUSIONS  
(P. Wipf, V. Kagan and M. Fink, authors) 
Due to the high concentration of mitochondria in heart tissue, it is not surprising that a 
major goal in cardioprotection is a decrease in the burst of mitochondrial ROS formation that 
characterizes postischemic reperfusion. Other important areas for therapeutic intervention based 
on controlling the mitochondrial pathway for apoptosis include neurodegeneration, diabetes, 
cancer, and antiviral diseases.211 
 212 
Accordingly, mitochondrial targeting of ROS scavengers or compounds that interfere 
with the unique biochemistry in mitochondria is emerging as a novel and highly relevant 
approach in drug discovery for the treatment of degenerative diseases and acute conditions 
derived from surging ROS and RNS. No pharmaceutical agents specifically designed to deliver a 
therapeutic compound to mitochondria have yet reached the market, but it is likely that a 
significant number of essential nutrients, including ascorbic acid, selenium, vitamins E and Q10, 
carotenoids, etc., fulfill at least part of their function by controlling the surge of reactive 
byproducts of the oxidative phosphorylation process and ATP generation in mitochondria. Since 
age-related conditions are rapidly becoming a major source of a declining quality of life in a 
graying population, we can only hope that the near future will show the emergence of a new 
class of effective therapies that involve mitochondrial survival strategies. This is an exciting 
development for synthetic chemists who are being challenged with the discovery of innovative 
approaches to deliver functional small organic compounds as well as larger biomolecules across 
cell membranes to specific intracellular targets.212
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APPENDIX B 
SELECTED 1H AND 13C NMR SPECTRA FOR COMPOUNDS 2-189, 2-208, 2-221, 2-222,  
2-255a,b, 3-6, 2-267, and 2-227 
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